0001558370-22-011757.txt : 20220803 0001558370-22-011757.hdr.sgml : 20220803 20220803073053 ACCESSION NUMBER: 0001558370-22-011757 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 76 CONFORMED PERIOD OF REPORT: 20220630 FILED AS OF DATE: 20220803 DATE AS OF CHANGE: 20220803 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aclaris Therapeutics, Inc. CENTRAL INDEX KEY: 0001557746 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 460571712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37581 FILM NUMBER: 221130929 BUSINESS ADDRESS: STREET 1: 640 LEE ROAD STREET 2: SUITE 200 CITY: WAYNE STATE: PA ZIP: 19087 BUSINESS PHONE: 484-324-7933 MAIL ADDRESS: STREET 1: 640 LEE ROAD STREET 2: SUITE 200 CITY: WAYNE STATE: PA ZIP: 19087 10-Q 1 acrs-20220630x10q.htm 10-Q
0.310.340.620.9065990031539684056372312352163136659900315396840563723123521631360.310.340.620.90000066667580http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent61228446000001557746--12-312022Q2false61228446666675800001557746us-gaap:AdditionalPaidInCapitalMemberacrs:AtMarketOfferingMember2022-04-012022-06-300001557746us-gaap:AdditionalPaidInCapitalMemberacrs:FollowOnPublicOfferingMember2021-04-012021-06-300001557746us-gaap:AdditionalPaidInCapitalMemberacrs:FollowOnPublicOfferingMember2021-01-012021-03-310001557746us-gaap:CommonStockMemberacrs:AtMarketOfferingMember2022-04-012022-06-300001557746us-gaap:CommonStockMemberacrs:FollowOnPublicOfferingMember2021-04-012021-06-300001557746us-gaap:CommonStockMemberacrs:FollowOnPublicOfferingMember2021-01-012021-03-310001557746us-gaap:CommonStockMember2022-04-012022-06-300001557746us-gaap:CommonStockMember2022-01-012022-03-310001557746us-gaap:CommonStockMember2021-04-012021-06-300001557746us-gaap:CommonStockMember2021-01-012021-03-310001557746us-gaap:RetainedEarningsMember2022-06-300001557746us-gaap:AdditionalPaidInCapitalMember2022-06-300001557746us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001557746us-gaap:RetainedEarningsMember2022-03-310001557746us-gaap:AdditionalPaidInCapitalMember2022-03-310001557746us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-3100015577462022-03-310001557746us-gaap:RetainedEarningsMember2021-12-310001557746us-gaap:AdditionalPaidInCapitalMember2021-12-310001557746us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001557746us-gaap:RetainedEarningsMember2021-06-300001557746us-gaap:AdditionalPaidInCapitalMember2021-06-300001557746us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001557746us-gaap:RetainedEarningsMember2021-03-310001557746us-gaap:AdditionalPaidInCapitalMember2021-03-310001557746us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-3100015577462021-03-310001557746us-gaap:RetainedEarningsMember2020-12-310001557746us-gaap:AdditionalPaidInCapitalMember2020-12-310001557746us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001557746acrs:SiliconValleyBankSecuritiesLlcAndCantorFitzgeraldAndCo.Memberacrs:AtMarketOfferingMember2022-04-300001557746acrs:June2021PublicOfferingMember2021-06-300001557746acrs:January2021PublicOfferingMember2021-01-3100015577462021-01-012021-12-310001557746acrs:EquityCompensation2017InducementPlanMember2022-06-300001557746acrs:EquityCompensationPlan2012Member2012-01-012015-09-140001557746acrs:EquityCompensationPlan2012Member2022-06-300001557746acrs:EquityIncentivePlan2015Member2015-09-300001557746acrs:EquityIncentivePlan2015Member2022-01-012022-01-010001557746acrs:EquityCompensationPlan2012Member2022-01-012022-06-300001557746us-gaap:RestrictedStockUnitsRSUMember2022-06-300001557746us-gaap:RestrictedStockUnitsRSUMember2021-12-310001557746us-gaap:RestrictedStockUnitsRSUMemberacrs:EquityIncentivePlan2015Member2022-06-300001557746us-gaap:RestrictedStockUnitsRSUMemberacrs:EquityCompensation2017InducementPlanMember2022-06-300001557746acrs:AtMarketOfferingMember2022-01-012022-06-300001557746acrs:FollowOnPublicOfferingMember2021-01-012021-06-300001557746us-gaap:RoyaltyMemberacrs:AssetPurchaseAgreementEncompassingWorldwideRightsToOxymetazolineHydrochlorideCreamPlusIntellectualPropertyMember2022-04-012022-06-300001557746us-gaap:IntersegmentEliminationMemberacrs:ContractResearchSegmentMember2022-04-012022-06-300001557746acrs:OtherRevenueMember2022-04-012022-06-300001557746acrs:LaboratoryResearchRevenueMember2022-04-012022-06-300001557746us-gaap:RoyaltyMemberacrs:AssetPurchaseAgreementEncompassingWorldwideRightsToOxymetazolineHydrochlorideCreamPlusIntellectualPropertyMember2022-01-012022-06-300001557746us-gaap:IntersegmentEliminationMemberacrs:ContractResearchSegmentMember2022-01-012022-06-300001557746acrs:OtherRevenueMember2022-01-012022-06-300001557746acrs:LaboratoryResearchRevenueMember2022-01-012022-06-300001557746us-gaap:RoyaltyMemberacrs:AssetPurchaseAgreementEncompassingWorldwideRightsToOxymetazolineHydrochlorideCreamPlusIntellectualPropertyMember2021-04-012021-06-300001557746us-gaap:IntersegmentEliminationMemberacrs:ContractResearchSegmentMember2021-04-012021-06-300001557746acrs:OtherRevenueMember2021-04-012021-06-300001557746acrs:LaboratoryResearchRevenueMember2021-04-012021-06-300001557746us-gaap:RoyaltyMemberacrs:AssetPurchaseAgreementEncompassingWorldwideRightsToOxymetazolineHydrochlorideCreamPlusIntellectualPropertyMember2021-01-012021-06-300001557746us-gaap:IntersegmentEliminationMemberacrs:ContractResearchSegmentMember2021-01-012021-06-300001557746acrs:OtherRevenueMember2021-01-012021-06-300001557746acrs:LaboratoryResearchRevenueMember2021-01-012021-06-300001557746acrs:SiliconValleyBankMemberacrs:TermLoanFacilityMember2021-07-012021-07-310001557746us-gaap:LeaseholdImprovementsMember2022-06-300001557746us-gaap:FurnitureAndFixturesMember2022-06-300001557746us-gaap:ComputerEquipmentMember2022-06-300001557746acrs:LaboratoryEquipmentMember2022-06-300001557746us-gaap:LeaseholdImprovementsMember2021-12-310001557746us-gaap:FurnitureAndFixturesMember2021-12-310001557746us-gaap:ComputerEquipmentMember2021-12-310001557746acrs:LaboratoryEquipmentMember2021-12-310001557746acrs:SiliconValleyBankSecuritiesLlcAndCantorFitzgeraldAndCo.Memberacrs:AtMarketOfferingMember2022-04-012022-04-3000015577462019-02-280001557746us-gaap:RetainedEarningsMember2022-04-012022-06-300001557746us-gaap:RetainedEarningsMember2022-01-012022-03-310001557746us-gaap:RetainedEarningsMember2021-04-012021-06-300001557746us-gaap:RetainedEarningsMember2021-01-012021-03-310001557746us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001557746us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001557746us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001557746us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001557746acrs:RosiAndFulcherVs.AclarisTherapeuticsInc.Membersrt:ExecutiveOfficerMember2020-01-242020-01-240001557746acrs:RosiAndFulcherVs.AclarisTherapeuticsInc.Member2022-06-300001557746acrs:SiliconValleyBankMemberacrs:TermLoanFacilityMember2021-07-310001557746acrs:TermLoanFacilityMember2020-03-310001557746us-gaap:InProcessResearchAndDevelopmentMember2022-06-300001557746us-gaap:InProcessResearchAndDevelopmentMember2021-12-310001557746us-gaap:OtherIntangibleAssetsMember2022-01-012022-06-300001557746us-gaap:OtherIntangibleAssetsMember2022-06-300001557746acrs:OperatingLeasesMember2022-06-300001557746us-gaap:OtherIntangibleAssetsMember2021-12-310001557746acrs:OperatingLeasesMember2021-12-310001557746us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-06-300001557746acrs:EmployeeConsultantsAndDirectorsStockOptionsMember2022-01-012022-06-300001557746us-gaap:CorporateNonSegmentMember2022-04-012022-06-300001557746acrs:ContractResearchSegmentMember2022-04-012022-06-300001557746us-gaap:CorporateNonSegmentMember2022-01-012022-06-300001557746acrs:ContractResearchSegmentMember2022-01-012022-06-300001557746us-gaap:CorporateNonSegmentMember2021-04-012021-06-300001557746acrs:ContractResearchSegmentMember2021-04-012021-06-300001557746us-gaap:CorporateNonSegmentMember2021-01-012021-06-300001557746acrs:ContractResearchSegmentMember2021-01-012021-06-300001557746us-gaap:CommonStockMember2022-06-300001557746us-gaap:CommonStockMember2022-03-310001557746us-gaap:CommonStockMember2021-12-310001557746us-gaap:CommonStockMember2021-06-300001557746us-gaap:CommonStockMember2021-03-310001557746us-gaap:CommonStockMember2020-12-310001557746us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001557746us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001557746acrs:SiliconValleyBankMember2021-01-3100015577462021-06-3000015577462020-12-310001557746acrs:DermatologyTherapeuticsSegmentMember2022-04-012022-06-300001557746acrs:DermatologyTherapeuticsSegmentMember2022-01-012022-06-300001557746acrs:ConfluenceMember2022-01-012022-06-300001557746acrs:DermatologyTherapeuticsSegmentMember2021-04-012021-06-300001557746acrs:DermatologyTherapeuticsSegmentMember2021-01-012021-06-300001557746us-gaap:FixedIncomeSecuritiesMember2022-06-300001557746us-gaap:FixedIncomeSecuritiesMember2021-12-310001557746us-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-06-300001557746us-gaap:CorporateDebtSecuritiesMember2022-06-300001557746us-gaap:AssetBackedSecuritiesMember2021-12-310001557746acrs:ForeignGovernmentAgenciesDebtSecuritiesMember2021-12-310001557746us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001557746us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001557746us-gaap:FairValueMeasurementsRecurringMember2022-06-300001557746us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001557746us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001557746us-gaap:FairValueMeasurementsRecurringMember2021-12-310001557746us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-06-300001557746acrs:EmployeeConsultantsAndDirectorsStockOptionsMember2022-01-012022-06-300001557746us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-06-300001557746acrs:EmployeeConsultantsAndDirectorsStockOptionsMember2021-01-012021-06-300001557746us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-06-300001557746us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-06-300001557746us-gaap:CostOfSalesMember2022-01-012022-06-300001557746us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-310001557746us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-03-310001557746us-gaap:CostOfSalesMember2022-01-012022-03-310001557746us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-06-300001557746us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-06-300001557746us-gaap:CostOfSalesMember2021-01-012021-06-300001557746us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-03-310001557746us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-03-310001557746us-gaap:CostOfSalesMember2021-01-012021-03-310001557746acrs:AtMarketOfferingMember2022-04-012022-06-300001557746acrs:FollowOnPublicOfferingMember2021-04-012021-06-300001557746acrs:FollowOnPublicOfferingMember2021-01-012021-03-310001557746us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001557746us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-3100015577462022-01-012022-03-310001557746us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001557746us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-3100015577462021-01-012021-03-3100015577462022-07-290001557746acrs:EquityIncentivePlan2015Member2022-06-300001557746srt:MinimumMember2022-01-012022-06-300001557746srt:MaximumMember2022-01-012022-06-300001557746acrs:June2021PublicOfferingMember2021-06-012021-06-300001557746acrs:January2021PublicOfferingMember2021-01-012021-01-3100015577462022-04-012022-06-3000015577462021-04-012021-06-300001557746acrs:SiliconValleyBankMember2020-03-3100015577462021-01-012021-06-300001557746us-gaap:AssetBackedSecuritiesMember2022-06-300001557746us-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-12-310001557746us-gaap:CorporateDebtSecuritiesMember2021-12-310001557746acrs:AgreementAndPlanOfMergerMember2022-06-300001557746acrs:AssetPurchaseAgreementEncompassingWorldwideRightsToOxymetazolineHydrochlorideCreamPlusIntellectualPropertyMember2022-06-3000015577462020-12-012020-12-310001557746acrs:AgreementAndPlanOfMergerMember2022-01-012022-06-300001557746acrs:AssetPurchaseAgreementEncompassingWorldwideRightsToOxymetazolineHydrochlorideCreamPlusIntellectualPropertyMember2019-10-012019-10-3100015577462022-06-3000015577462021-12-3100015577462022-01-012022-06-30iso4217:USDutr:sqftacrs:Votexbrli:purexbrli:sharesiso4217:USDxbrli:sharesacrs:itemacrs:segment

7

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark one)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2022

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                      

Commission File Number 001-37581

Aclaris Therapeutics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction of
Incorporation or Organization)

46-0571712
(I.R.S. Employer
Identification No.)

640 Lee Road, Suite 200
Wayne, PA
(Address of principal executive offices)

19087
(Zip Code)

Registrant’s telephone number, including area code: (484324-7933

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class:

 

Trading Symbol(s)

Name of Each Exchange on which Registered

Common Stock, $0.00001 par value

 

ACRS

The Nasdaq Stock Market, LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Securities Exchange Act of 1934:

Large accelerated filer  

Accelerated filer  

Non-accelerated filer  

Smaller reporting company  

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934).   Yes  No 

The number of outstanding shares of the registrant’s common stock, par value $0.00001 per share, as of the close of business on July 29, 2022 was 66,671,750.

ACLARIS THERAPEUTICS, INC.

INDEX TO FORM 10-Q

    

PAGE

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

2

Unaudited Condensed Consolidated Balance Sheets as of June 30, 2022 and December 31, 2021

2

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2022 and 2021

3

Unaudited Condensed Consolidated Statements of Stockholders’ Equity for the three and six months ended June 30, 2022 and 2021

4

Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2022 and 2021

5

Notes to Unaudited Condensed Consolidated Financial Statements

6

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

19

Item 3. Quantitative and Qualitative Disclosures about Market Risk

34

Item 4. Controls and Procedures

35

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

36

Item 1A. Risk Factors

36

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

36

Item 6. Exhibits

36

Signatures

38

Part I. FINANCIAL INFORMATION

Item 1. Financial Statements

ACLARIS THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands, except share and per share data)

    

June 30, 

December 31, 

    

2022

    

2021

Assets

Current assets:

Cash and cash equivalents

$

68,264

$

27,349

Short-term marketable securities

 

180,339

 

164,065

Accounts receivable, net

637

623

Prepaid expenses and other current assets

 

10,114

 

12,995

Total current assets

 

259,354

 

205,032

Marketable securities

 

7,221

 

34,242

Property and equipment, net

 

1,276

 

1,335

Intangible assets

7,011

7,048

Other assets

 

3,114

 

3,554

Total assets

$

277,976

$

251,211

Liabilities and Stockholders’ Equity

Current liabilities:

Accounts payable

$

5,703

$

9,985

Accrued expenses

 

7,571

 

10,051

Current portion of lease liabilities

741

693

Discontinued operations

2,202

2,202

Total current liabilities

 

16,217

 

22,931

Other liabilities

1,840

 

2,172

Contingent consideration

23,800

28,400

Deferred tax liability

 

367

 

367

Total liabilities

 

42,224

 

53,870

Commitments and contingencies (Note 16)

Stockholders’ Equity:

Preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued or outstanding at June 30, 2022 and December 31, 2021

Common stock, $0.00001 par value; 100,000,000 shares authorized at June 30, 2022 and December 31, 2021; 66,667,580 and 61,228,446 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively

 

1

 

1

Additional paid‑in capital

 

871,805

 

792,971

Accumulated other comprehensive loss

 

(1,326)

 

(224)

Accumulated deficit

 

(634,728)

 

(595,407)

Total stockholders’ equity

 

235,752

 

197,341

Total liabilities and stockholders’ equity

$

277,976

$

251,211

The accompanying notes are an integral part of these condensed consolidated financial statements.

2

ACLARIS THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

(In thousands, except share and per share data)

Three Months Ended

Six Months Ended

June 30, 

June 30, 

    

2022

    

2021

    

2022

    

2021

Revenues:

Contract research

$

1,218

$

1,606

$

2,439

$

3,141

Other revenue

310

218

542

460

Total revenue

1,528

1,824

2,981

3,601

Costs and expenses:

Cost of revenue

1,068

1,263

2,223

2,465

Research and development

 

18,779

7,897

 

33,085

 

15,735

General and administrative

 

6,075

5,870

 

12,174

 

10,697

Revaluation of contingent consideration

(3,400)

4,800

(4,600)

21,239

Total costs and expenses

 

22,522

 

19,830

 

42,882

 

50,136

Loss from operations

 

(20,994)

 

(18,006)

 

(39,901)

 

(46,535)

Other income (expense), net

 

462

 

(155)

 

580

 

(380)

Net loss

$

(20,532)

$

(18,161)

$

(39,321)

$

(46,915)

Net loss per share, basic and diluted

$

(0.31)

$

(0.34)

$

(0.62)

$

(0.90)

Weighted average common shares outstanding, basic and diluted

 

65,990,031

 

53,968,405

 

63,723,123

 

52,163,136

Other comprehensive loss:

Unrealized gain (loss) on marketable securities, net of tax of $0

$

(354)

$

25

$

(1,101)

$

(10)

Foreign currency translation adjustment

(69)

(80)

Total other comprehensive loss

 

(354)

 

(44)

 

(1,101)

 

(90)

Comprehensive loss

$

(20,886)

$

(18,205)

$

(40,422)

$

(47,005)

The accompanying notes are an integral part of these condensed consolidated financial statements.

3

ACLARIS THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF

STOCKHOLDERS’ EQUITY

(Unaudited)

(In thousands, except share data)

Accumulated

Common Stock

Additional

Other

Total

Par

Paidin

Comprehensive

Accumulated

Stockholders’

  

  Shares 

  

Value

  

Capital

  

Loss

  

Deficit

  

Equity

Balance at December 31, 2021

61,228,446

$

1

$

792,971

$

(224)

$

(595,407)

$

197,341

Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units

509,037

49

49

Unrealized loss on marketable securities

(748)

(748)

Stock-based compensation expense

2,346

2,346

Net loss

(18,789)

(18,789)

Balance at March 31, 2022

61,737,483

$

1

$

795,366

$

(972)

$

(614,196)

$

180,199

Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units

91,388

88

88

Issuance of common stock under at-the-market sales agreement, net of offering costs of $2,341

4,838,709

72,659

72,659

Unrealized loss on marketable securities

(354)

(354)

Stock-based compensation expense

3,692

3,692

Net loss

(20,532)

(20,532)

Balance at June 30, 2022

66,667,580

$

1

$

871,805

$

(1,326)

$

(634,728)

$

235,752

Accumulated

Common Stock

Additional

Other

Total

Par

Paidin

Comprehensive

Accumulated

Stockholders’

  

  Shares 

  

Value

  

Capital

  

Income (Loss)

  

Deficit

  

Equity

Balance at December 31, 2020

45,109,314

$

$

542,286

$

(94)

$

(504,542)

$

37,650

Issuance of common stock in connection with exercise of stock options and warrants and vesting of restricted stock units

666,144

(2,579)

(2,579)

Issuance of common stock in connection with public offering, net of offering costs of $7,011

6,306,271

103,348

103,348

Unrealized loss on marketable securities

(35)

(35)

Foreign currency translation adjustment

(11)

(11)

Stock-based compensation expense

2,675

2,675

Net loss

(28,754)

(28,754)

Balance at March 31, 2021

52,081,729

$

$

645,730

$

(140)

$

(533,296)

$

112,294

Issuance of common stock in connection with vesting of restricted stock units

1,024,666

1,041

1,041

Issuance of common stock in connection with public offering, net of offering costs of $8,899

8,098,592

1

134,851

134,852

Unrealized gain on marketable securities

25

25

Foreign currency translation adjustment

(69)

(69)

Stock-based compensation expense

3,833

3,833

Net loss

(18,161)

(18,161)

Balance at June 30, 2021

61,204,987

$

1

$

785,455

$

(184)

$

(551,457)

$

233,815

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

ACLARIS THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

Six Months Ended

June 30, 

    

2022

    

2021

Cash flows from operating activities:

    

    

    

    

Net loss

$

(39,321)

$

(46,915)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization

 

414

 

535

Stock-based compensation expense

 

6,038

 

6,507

Revaluation of contingent consideration

(4,600)

21,239

Changes in operating assets and liabilities:

Accounts receivable

(14)

(167)

Prepaid expenses and other assets

 

1,309

 

(5,223)

Accounts payable

 

(4,283)

 

(1,290)

Accrued expenses

 

(178)

 

861

Net cash used in operating activities

 

(40,635)

 

(24,453)

Cash flows from investing activities:

Purchases of property and equipment

 

(350)

 

(52)

Purchases of marketable securities

 

(85,096)

 

(147,289)

Proceeds from sales and maturities of marketable securities

 

94,155

 

26,557

Net cash provided by (used in) investing activities

 

8,709

 

(120,784)

Cash flows from financing activities:

Proceeds from issuance of common stock in connection with public offerings, net of issuance costs

238,200

Proceeds from issuance of common stock under the at-the-market sales agreement, net of issuance costs

72,744

Payments of employee withholding taxes related to restricted stock unit award vesting

(23)

(3,038)

Proceeds from exercise of employee stock options and the issuance of stock

120

1,459

Net cash provided by financing activities

 

72,841

 

236,621

Net increase in cash and cash equivalents

 

40,915

 

91,384

Cash and cash equivalents at beginning of period

 

27,349

 

22,063

Cash and cash equivalents at end of period

$

68,264

$

113,447

Supplemental disclosure of non-cash investing and financing activities:

Additions to property and equipment included in accounts payable

$

72

$

37

Offering costs included in accounts payable

$

$

28

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

ACLARIS THERAPEUTICS, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Organization and Nature of Business

Overview

Aclaris Therapeutics, Inc. was incorporated under the laws of the State of Delaware in 2012. In 2015,  Aclaris Therapeutics International Limited (“ATIL”) was established under the laws of the United Kingdom as a wholly-owned subsidiary of Aclaris Therapeutics, Inc. In 2017, Confluence Life Sciences, Inc. (now known as Aclaris Life Sciences, Inc.) (“Confluence”) was acquired by Aclaris Therapeutics, Inc. and became a wholly-owned subsidiary thereof.  Aclaris Therapeutics, Inc., ATIL and Confluence are referred to collectively as the “Company.”  The Company is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases.  In addition to developing its novel drug candidates, the Company is pursuing strategic alternatives, including identifying and consummating transactions with third-party partners, to further develop, obtain marketing approval for and/or commercialize its novel drug candidates.  

Liquidity

The Company’s condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities in the ordinary course of business.  As of June 30, 2022, the Company had cash, cash equivalents and marketable securities of $255.8 million and an accumulated deficit of $634.7 million.  Since inception, the Company has incurred net losses and negative cash flows from its operations.  Prior to the acquisition of Confluence, the Company had never generated revenue.  There can be no assurance that profitable operations will ever be achieved, and, if achieved, will be sustained on a continuing basis. In addition, development activities, including clinical and preclinical testing of the Company’s drug candidates, will require significant additional financing.  The future viability of the Company is dependent on its ability to successfully develop its drug candidates and to generate revenue from identifying and consummating transactions with third-party partners to further develop, obtain marketing approval for and/or commercialize its development assets or to raise additional capital to finance its operations.  The Company will require additional capital to complete the clinical development of zunsemetinib (ATI-450), ATI-1777 and ATI-2138, to develop its preclinical compounds, and to support its discovery efforts.  

Additional funds may not be available on a timely basis, on commercially acceptable terms, or at all, and such funds, if raised, may not be sufficient to enable the Company to continue to implement its long-term business strategy.  The Company’s ability to raise additional capital may be adversely impacted by the potential worsening of global economic conditions, including inflationary pressure, and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the COVID-19 pandemic and geopolitical tensions.  If the Company is unable to raise sufficient additional capital or generate revenue from transactions with potential third-party partners for the development and/or commercialization of its drug candidates, it may need to substantially curtail planned operations. The Company’s failure to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies.  

The Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that its condensed consolidated financial statements are issued.  As of the report date, the Company does not believe that substantial doubt exists about its ability to continue as a going concern.  The Company believes its existing cash, cash equivalents and marketable securities are sufficient to fund its operating and capital expenditure requirements for a period greater than 12 months from the date of issuance of these condensed consolidated financial statements.

6

2. Summary of Significant Accounting Policies

Unaudited Interim Financial Information

The accompanying condensed consolidated balance sheet as of June 30, 2022, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2022 and 2021, the condensed consolidated statement of stockholders’ equity for the three and six months ended June 30, 2022 and 2021, and the condensed consolidated statements of cash flows for the six months ended June 30, 2022 and 2021 are unaudited.  The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual financial statements contained in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 24, 2022 and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company’s financial position as of June 30, 2022, the results of its operations and comprehensive loss for the three and six months ended June 30, 2022 and 2021, its changes in stockholders’ equity for the three and six months ended June 30, 2022 and 2021 and its cash flows for the six months ended June 30, 2022 and 2021.  The condensed consolidated balance sheet data as of December 31, 2021 was derived from audited financial statements but does not include all disclosures required by generally accepted accounting principles in the United States (“GAAP”).  The financial data and other information disclosed in these notes related to the three and six months ended June 30, 2022 and 2021 are unaudited. The results for the three and six months ended June 30, 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2022, any other interim periods, or any future year or period.  The unaudited interim financial statements of the Company included herein have been prepared, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K filed with the SEC on February 24, 2022.  

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in conformity with GAAP.  The condensed consolidated financial statements of the Company include the accounts of the operating parent company, Aclaris Therapeutics, Inc., and its wholly-owned subsidiaries, ATIL and Confluence.  All intercompany transactions have been eliminated.  Based upon the Company’s revenue, the Company believes that gross profit does not provide a meaningful measure of profitability and, therefore, has not included a line item for gross profit on the condensed consolidated statement of operations.  

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods.  Significant estimates and assumptions reflected in these financial statements include, but are not limited to, contingent consideration and the valuation of stock-based awards.  Estimates are periodically reviewed in light of changes in circumstances, facts and experience.  As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require an update to its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities.  Actual results could differ from the Company’s estimates.

Significant Accounting Policies

The Company’s significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K filed with the SEC on February 24, 2022.  Except as set forth below, there have been no changes to the Company’s significant accounting policies from those disclosed in the annual report.

7

Contingent Consideration

The Company initially recorded a contingent consideration liability at fair value on the date of acquisition related to future potential payments resulting from the acquisition of Confluence based upon significant unobservable inputs including the achievement of development, regulatory and commercial milestones, as well as estimated future sales levels and the discount rates applied to calculate the present value of the potential payments. Significant judgement was involved in determining the appropriateness of these assumptions.  These assumptions are considered Level 3 inputs.  Revaluation of the contingent consideration liability can result from changes to one or more of these assumptions.  The Company evaluates the fair value estimate of the contingent consideration liability on a quarterly basis with changes, if any, recorded as income or expense in the condensed consolidated statement of operations.

The fair value of contingent consideration is estimated using a probability-weighted expected payment model for regulatory milestone payments and a Monte Carlo simulation model for commercial milestone and royalty payments and then applying a risk-adjusted discount rate to calculate the present value of the potential payments.  Significant assumptions used in the Company’s estimates include the probability of achieving regulatory milestones and commencing commercialization, which are based on an asset’s current stage of development and a review of existing clinical data. Probability of success assumptions ranged between 10% and 40% at June 30, 2022.  Additionally, estimated future sales levels and the risk-adjusted discount rate applied to the potential payments are also significant assumptions used in calculating the fair value.  The discount rate ranged between 10.2% and 10.9% depending on the year of each potential payment.

3. Fair Value of Financial Assets and Liabilities

The following tables present information about the fair value measurements of the Company’s financial assets and liabilities which are measured at fair value on a recurring and non-recurring basis, and indicate the level of the fair value hierarchy utilized to determine such fair values:

June 30, 2022

(In thousands)

    

Level 1

    

Level 2

    

Level 3

    

Total

Assets:

    

    

    

    

    

    

    

    

Cash equivalents

$

63,838

$

$

$

63,838

Marketable securities

 

187,560

187,560

Total assets

$

63,838

$

187,560

$

$

251,398

Liabilities:

Contingent consideration

$

$

$

23,800

$

23,800

Total liabilities

$

$

$

23,800

$

23,800

December 31, 2021

(In thousands)

    

Level 1

    

Level 2

    

Level 3

    

Total

Assets:

    

    

    

    

    

    

    

    

Cash equivalents

$

21,678

$

$

$

21,678

Marketable securities

 

198,307

198,307

Total assets

$

21,678

$

198,307

$

$

219,985

Liabilities:

Contingent consideration

$

$

$

28,400

$

28,400

Total liabilities

$

$

$

28,400

$

28,400

As of June 30, 2022 and December 31, 2021, the Company’s cash equivalents consisted of a money market fund, which was valued based upon Level 1 inputs.  The Company’s marketable securities as of June 30, 2022 and December

8

31, 2021 consisted of commercial paper and corporate, asset-backed and U.S. government agency debt securities, which were all valued based upon Level 2 inputs.  Marketable securities as of December 31, 2021 also included foreign government agency debt securities which were all valued based upon Level 2 inputs.

In determining the fair value of its Level 2 investments, the Company relies on quoted prices for identical securities in markets that are not active. These quoted prices are obtained by the Company with the assistance of a third-party pricing service based on available trade, bid and other observable market data for identical securities.  The Company compares the quoted prices obtained from the third-party pricing service to other available independent pricing information to validate the reasonableness of the quoted prices provided.  The Company evaluates whether adjustments to third-party pricing are necessary and, historically, the Company has not made adjustments to quoted prices obtained from the third-party pricing service.  During the three and six months ended June 30, 2022 and 2021, there were no transfers into or out of Level 3.

A decrease in the fair value of the contingent consideration liability of $4.6 million during the six months ended June 30, 2022 was mainly due to higher discount rates, resulting from higher risk-free rates and wider credit spreads, being applied to potential payments relative to prior periods.  The overall decrease was partially offset by an increase in the contingent consideration liability as a result of the impact of the passage of time.

As of June 30, 2022 and December 31, 2021, the fair value of the Company’s available-for-sale marketable securities by type of security was as follows:

June 30, 2022

Gross

Gross

Amortized

Unrealized

Unrealized

Fair

(In thousands)

Cost

Gain

Loss

Value

Marketable securities:

Corporate debt securities

$

47,201

$

$

(398)

$

46,803

Commercial paper

56,053

56,053

Asset-backed debt securities(1)

28,423

(175)

28,248

U.S. government agency debt securities

57,211

(755)

56,456

Total marketable securities

$

188,888

$

$

(1,328)

$

187,560

(1) Included in Asset-backed debt securities is $7.2 million with maturity dates between one and five years.

December 31, 2021

Gross

Gross

Amortized

Unrealized

Unrealized

Fair

(In thousands)

Cost

Gain

Loss

Value

Marketable securities:

Corporate debt securities(1)

$

40,993

$

6

$

(50)

$

40,949

Commercial paper

71,837

71,837

Asset-backed debt securities

36,166

(43)

36,123

Foreign government agency debt securities

4,073

(13)

4,060

U.S. government agency debt securities(2)

45,465

(127)

45,338

Total marketable securities

$

198,534

$

6

$

(233)

$

198,307

(1) Included in Corporate debt securities is $9.2 million with maturity dates between one and five years.

(2) Included in US government agency debt securities is $25.0 million with maturity dates between one and five years.

9

4. Property and Equipment, Net

Property and equipment, net consisted of the following:

June 30, 

December 31, 

(In thousands)

2022

2021

Computer equipment

    

$

1,355

    

$

1,380

Lab equipment

1,879

1,605

Furniture and fixtures

620

620

Leasehold improvements

1,123

1,123

Property and equipment, gross

 

4,977

 

4,728

Accumulated depreciation

 

(3,701)

 

(3,393)

Property and equipment, net

$

1,276

$

1,335

Depreciation expense was $0.2 million for each of the three months ended June 30, 2022 and 2021, and $0.4 million for each of the six months ended June 30, 2022 and 2021.

5. Intangible Assets

Intangible assets consisted of the following:

Gross Cost

Accumulated Amortization

Remaining

June 30, 

December 31, 

June 30, 

December 31, 

(In thousands, except years)

   

Life (years)

   

2022

   

2021

   

2022

   

2021

Other intangible assets

5.1

$

751

$

751

$

369

$

332

In-process research and development

n/a

6,629

6,629

Total intangible assets

$

7,380

$

7,380

$

369

$

332

Amortization expense was $19 thousand for each of the three months ended June 30, 2022 and 2021, and $38 thousand for each of the six months ended June 30, 2022 and 2021.

As of June 30, 2022, estimated future amortization expense was as follows:

Year Ending

(In thousands)

    

December 31,

2022

$

37

2023

 

75

2024

 

75

2025

75

2026

75

Thereafter

45

Total

$

382

10

6. Accrued Expenses

Accrued expenses consisted of the following:

June 30, 

December 31, 

(In thousands)

    

2022

    

2021

Employee compensation expenses

$

2,885

$

4,389

Research and development expenses

2,771

1,278

Litigation settlements (see Note 16)

2,650

Other

 

1,915

 

1,734

Total accrued expenses

$

7,571

$

10,051

7. Debt

Loan and Security Agreement – Silicon Valley Bank

In March 2020, the Company entered into a Loan and Security Agreement with Silicon Valley Bank (“SVB”).  The Loan and Security Agreement provided for $11.0 million in term loans, of which the Company borrowed the entire amount on March 30, 2020.  In connection with the Loan and Security Agreement, the Company issued to SVB a warrant to purchase up to 460,251 shares of common stock (the “Warrant”) (see Note 8).  The proceeds of the Loan and Security Agreement were allocated to the term loan and Warrant using a relative fair value approach.  

In July 2021, the Company repaid in full the $11.0 million that was outstanding under the Loan and Security Agreement, together with all accrued and unpaid interest and fees as of the payoff date, for a total payment of $11.7 million.

8. Stockholders’ Equity

Preferred Stock

As of June 30, 2022 and December 31, 2021, the Company’s amended and restated certificate of incorporation authorized the Company to issue 10,000,000 shares of undesignated preferred stock.  There were no shares of preferred stock outstanding as of June 30, 2022 or December 31, 2021.

Common Stock

As of June 30, 2022 and December 31, 2021, the Company’s amended and restated certificate of incorporation authorized the Company to issue 100,000,000 shares of $0.00001 par value common stock. There were 66,667,580 and 61,228,446 shares of common stock issued and outstanding as of June 30, 2022 and December 31, 2021, respectively.

Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any, subject to any preferential dividend rights of any series of preferred stock that may be outstanding.  No dividends have been declared through June 30, 2022.  

Warrants

The Warrant issued to SVB in March 2020 had an initial exercise price of $0.956 per share, subject to adjustment as provided in the Warrant.  The Warrant became immediately exercisable in full upon the funding of the term loan facility.  The Company assigned a fair value of $0.4 million to the Warrant using a Black-Scholes valuation methodology, and also concluded that the Warrant was indexed to its own stock and therefore classified the Warrant as an equity instrument.  In January 2021, SVB net exercised the Warrant in full, and the Company issued 388,119 shares of common stock to SVB.  

11

January 2021 Public Offering

In January 2021, the Company closed a public offering in which it sold 6,306,271 shares of common stock at a price to the public of $17.50 per share, for aggregate gross proceeds of $110.4 million. The Company paid underwriting discounts and commissions of $6.6 million, and also incurred expenses of $0.4 million in connection with the offering.  As a result, the net offering proceeds received by the Company, after deducting underwriting discounts, commissions and offering expenses, were $103.3 million.

June 2021 Public Offering

In June 2021, the Company closed a public offering in which it sold 8,098,592 shares of common stock at a price to the public of $17.75 per share, for aggregate gross proceeds of $143.8 million. The Company paid underwriting discounts and commissions of $8.6 million, and also incurred expenses of $0.3 million in connection with the offering.  As a result, the net offering proceeds received by the Company, after deducting underwriting discounts, commissions and offering expenses, were $134.9 million.

Sales of Common Stock Pursuant to At-The-Market Facility

In April 2022, the Company sold 4,838,709 shares of its common stock at a weighted average price per share of $15.50, for aggregate gross proceeds of $75.0 million, pursuant to a sales agreement with SVB Securities LLC and Cantor Fitzgerald & Co., as sales agents, dated May 20, 2021.  The Company paid selling commissions and other fees of $2.2 million in connection with the sale.

9. Stock-Based Awards

2015 Equity Incentive Plan

In September 2015, the Company’s board of directors adopted the 2015 Equity Incentive Plan (the “2015 Plan”), and the Company’s stockholders approved the 2015 Plan. The 2015 Plan became effective in connection with the Company’s initial public offering in October 2015.  Beginning at the time the 2015 Plan became effective, no further grants may be made under the Company’s 2012 Equity Compensation Plan, as amended and restated (the “2012 Plan”).  The 2015 Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock unit (“RSU”) awards, performance stock awards, cash-based awards and other stock-based awards. The number of shares initially reserved for issuance under the 2015 Plan was 1,643,872 shares of common stock. The number of shares of common stock that may be issued under the 2015 Plan will automatically increase on January 1 of each year ending on January 1, 2025, in an amount equal to the lesser of (i) 4.0% of the shares of the Company’s common stock outstanding on December 31st of the preceding calendar year or (ii) an amount determined by the Company’s board of directors. The shares of common stock underlying any awards that expire, are otherwise terminated, settled in cash or repurchased by the Company under the 2015 Plan and the 2012 Plan will be added back to the shares of common stock available for issuance under the 2015 Plan.  As of January 1, 2022, the number of shares of common stock that may be issued under the 2015 Plan was automatically increased by 2,449,137 shares.  As of June 30, 2022, 3,372,766 shares remained available for grant under the 2015 Plan.  The Company had 4,130,376 stock options and 1,454,934 RSUs outstanding as of June 30, 2022 under the 2015 Plan.

2017 Inducement Plan

In July 2017, the Company’s board of directors adopted the 2017 Inducement Plan (the “2017 Inducement Plan”).  The 2017 Inducement Plan is a non-stockholder approved stock plan adopted pursuant to the “inducement exception” provided under Nasdaq listing rules.  The Company had 410,600 stock options and 2,375 RSUs outstanding as of June 30, 2022 under the 2017 Inducement Plan.  All shares of common stock that were eligible for issuance under the 2017 Inducement Plan after October 1, 2018, including any shares underlying any awards that expire or are otherwise terminated, reacquired to satisfy tax withholding obligations, settled in cash or repurchased by the Company in the future that would have been eligible for re-issuance under the 2017 Inducement Plan, were retired.  

12

2012 Equity Compensation Plan

Upon the 2015 Plan becoming effective, no further grants can be made under the 2012 Plan.  The Company granted stock options to purchase a total of 1,140,524 shares under the 2012 Plan, of which 473,977 were outstanding as of June 30, 2022.  Stock options granted under the 2012 Plan expire after ten years.  

Stock Option Valuation

The weighted average assumptions the Company used to estimate the fair value of stock options granted during the six months ended June 30, 2022 and 2021 were as follows:

    

Six Months Ended

June 30, 

2022

2021

Risk-free interest rate

 

1.90

%

0.91

%

Expected term (in years)

 

6.2

6.2

Expected volatility

 

77.95

%

76.60

%

Expected dividend yield

 

0

%

0

%

The Company recognizes compensation expense for awards over their vesting period.  Compensation expense for awards includes the impact of forfeitures in the period when they occur.  

Stock Options

The following table summarizes stock option activity for the six months ended June 30, 2022:

    

    

    

Weighted

    

Weighted

Average

Average

Remaining

Aggregate

Number

Exercise

Contractual

Intrinsic

(In thousands, except share and per share data and years)

of Shares

Price

Term

Value

(in years)

Outstanding as of December 31, 2021

 

3,792,450

$

17.50

 

6.8

$

13,710

Granted

 

1,891,950

14.40

Exercised

 

(85,672)

1.40

1,115

Forfeited and cancelled

 

(583,775)

15.70

Outstanding as of June 30, 2022

 

5,014,953

$

16.81

 

7.1

$

10,817

Options vested and expected to vest as of June 30, 2022

 

5,014,953

$

16.81

 

7.1

$

10,817

Options exercisable as of June 30, 2022

 

2,519,499

$

18.26

 

4.8

$

7,784

The weighted average grant date fair value of stock options granted during the six months ended June 30, 2022 was $9.89 per share.

13

Restricted Stock Units

The following table summarizes RSU activity for the six months ended June 30, 2022:

Weighted

Average

Grant Date

Aggregate

Number

Fair Value

Intrinsic

(In thousands, except share and per share data)

of Shares

Per Share

Value

Outstanding as of December 31, 2021

1,496,946

$

12.75

Granted

720,134

14.44

Vested

(513,958)

11.55

$

7,645

Forfeited and cancelled

(245,813)

12.17

Outstanding as of June 30, 2022

1,457,309

$

14.11

Stock-Based Compensation

Stock-based compensation expense included in total costs and expenses on the condensed consolidated statement of operations included the following:

Three Months Ended

Six Months Ended

June 30, 

June 30, 

(In thousands)

    

2022

    

2021

    

2022

    

2021

Cost of revenue

    

$

302

    

$

335

  

$

530

    

$

582

Research and development

941

1,154

828

2,030

General and administrative

 

2,449

 

2,343

 

4,680

 

3,895

Total stock-based compensation expense

$

3,692

$

3,832

$

6,038

$

6,507

As of June 30, 2022, the Company had unrecognized stock-based compensation expense for stock options and RSUs of $23.7 million and $18.3 million, respectively, which is expected to be recognized over weighted average periods of 3.2 years and 3.0 years, respectively.  

10. Net Loss per Share

Basic and diluted net loss per share is summarized in the following table:

Three Months Ended

Six Months Ended

June 30, 

June 30, 

(In thousands, except for share and per share data)

2022

2021

    

2022

    

2021

Numerator:

    

    

    

    

    

    

    

Net loss

$

(20,532)

$

(18,161)

$

(39,321)

$

(46,915)

Denominator:

Weighted average shares of common stock outstanding, basic and diluted

 

65,990,031

 

53,968,405

 

63,723,123

 

52,163,136

Net loss per share, basic and diluted

$

(0.31)

$

(0.34)

$

(0.62)

$

(0.90)

The Company’s potentially dilutive securities, which included stock options and RSUs, have been excluded from the computation of diluted net loss per share since the effect would be to reduce the net loss per share. Therefore, the weighted average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share is the same.  The following table presents potential shares of common stock excluded from the calculation of diluted

14

net loss per share for the three and six months ended June 30, 2022 and 2021.  All share amounts presented in the table below represent the total number outstanding as of June 30, 2022 and 2021.

June 30, 

2022

2021

Options to purchase common stock

5,014,953

3,738,625

Restricted stock unit awards

1,457,309

1,498,716

Total potential shares of common stock

6,472,262

5,237,341

11. Leases

Operating Leases

Agreements for Office and Laboratory Space

The Company has a sublease agreement pursuant to which it subleases 33,019 square feet of office space for its headquarters in Wayne, Pennsylvania.  The sublease has a term that runs through October 2023.  If for any reason the lease between the landlord and sublandlord is terminated or expires prior to October 2023, the Company’s sublease will automatically terminate.  In December 2020, the Company entered into a sub-sublease agreement under which it sub-subleased 8,115 square feet to a third party.  The sub-sublease term runs concurrently with the original sublease agreement.

In February 2019, the Company entered into a sublease agreement with a third party for 20,433 square feet of office and laboratory space in St. Louis, Missouri.  The lease commenced in June 2019 and has a term that runs through June 2029.

Supplemental balance sheet information related to operating leases is as follows:  

June 30, 

December 31,

(In thousands)

2022

2021

Operating Leases:

Gross cost

$

5,240

$

5,240

Accumulated amortization

(2,173)

(1,803)

Other assets

$

3,067

$

3,437

Current portion of lease liabilities

$

741

$

693

Other liabilities

1,820

2,151

Total operating lease liabilities

$

2,561

$

2,844

Amortization expense related to operating lease right-of-use assets and accretion of operating lease liabilities totaled $0.3 million for each of the three months ended June 30, 2022 and 2021 and $0.5 million for each of the six months ended June 30, 2022 and 2021.

12. Agreements Related to Intellectual Property

Asset Purchase Agreement – EPI Health, LLC

In October 2019, the Company sold RHOFADE (oxymetazoline hydrochloride) cream, 1% (“RHOFADE”) to EPI Health, LLC (“EPI Health”) pursuant to an asset purchase agreement.  EPI Health agreed to pay the Company a high single-digit royalty calculated as a percentage of net sales on a country-by-country basis until the date that the patent rights related to RHOFADE have expired or, if later, ten years from the date of the first commercial sale of RHOFADE in such country.  The Company recorded royalty income under the asset purchase agreement of $0.3 million and $0.2 million

15

during the three months ended June 30, 2022 and 2021, respectively, and $0.5 million and $0.4 million during the six months ended June 30, 2022 and 2021, respectively.  Royalty income is included in other revenue on the condensed consolidated statements of operations and comprehensive loss.  EPI Health has also agreed to pay the Company potential sales milestone payments of up to $20.0 million in the aggregate upon the achievement of specified levels of net sales of products covered by the asset purchase agreement, and 25% of any upfront, license, milestone, maintenance or fixed payment received by EPI Health in connection with any license or sublicense of the assets transferred in the disposition in any territory outside of the United States, subject to specified exceptions.  

Agreement and Plan of Merger – Confluence

The Company entered into an Agreement and Plan of Merger, pursuant to which it acquired Confluence (the “Confluence Agreement”).  Under the Confluence Agreement, the Company has agreed to pay the former Confluence equity holders aggregate remaining contingent consideration of up to $75.0 million based upon the achievement of specified future regulatory and commercial milestones set forth in the Confluence Agreement.  In addition, the Company has agreed to pay the former Confluence equity holders future royalty payments calculated as a low single-digit percentage of annual net sales, subject to specified reductions, limitations and other adjustments, until the date that all of the patent rights for that product have expired, as determined on a country-by-country and product-by-product basis or, in specified circumstances, ten years from the first commercial sale of such product.  In addition to the payments described above, if the Company sells, licenses or transfers any of the intellectual property acquired from Confluence pursuant to the Confluence Agreement to a third party, the Company will be obligated to pay the former Confluence equity holders a portion of any consideration received from such sale, license or transfer in specified circumstances.

As of June 30, 2022 and December 31, 2021, the balance of the Company’s contingent consideration liability was $23.8 million and $28.4 million, respectively (see Note 3).

13. Income Taxes

The Company did not record a federal or state income tax benefit for losses incurred during the three and six months ended June 30, 2022 and 2021.  The Company concluded that it is more likely than not that its deferred tax assets will not be realized which resulted in recording a full valuation allowance during those periods.

14. Discontinued Operations

The following table presents information related to liabilities reported as discontinued operations in the Company’s condensed consolidated balance sheet:  

June 30, 

December 31,

(In thousands)

    

2022

    

2021

Accrued expenses

  

$

2,202

$

2,202

Discontinued operations - current liabilities

$

2,202

$

2,202

 

15. Segment Information

The Company has two reportable segments, therapeutics and contract research.  The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.  The contract research segment earns revenue from the provision of laboratory services.  Contract research revenue is generally evidenced by contracts with clients which are on an agreed upon fixed-price, fee-for-service basis.  Corporate and other includes general and administrative expenses as well as eliminations of intercompany transactions.  The Company does not report balance sheet information by segment since it is not reviewed by the chief operating decision maker, and all of the Company’s tangible assets are held in the United States.  

16

The Company’s results of operations by segment for the three and six months ended June 30, 2022 and 2021 are summarized in the tables below:

(In thousands)

Contract

Corporate

Total

Three Months Ended June 30, 2022

Therapeutics

Research

and Other

Company

Total revenue

$

309

$

4,399

$

(3,180)

$

1,528

Cost of revenue

4,041

(2,973)

1,068

Research and development

18,986

(207)

18,779

General and administrative

854

5,221

6,075

Revaluation of contingent consideration

(3,400)

(3,400)

Loss from operations

$

(15,277)

$

(496)

$

(5,221)

$

(20,994)

(In thousands)

Contract

Corporate

Total

Three Months Ended June 30, 2021

Therapeutics

Research

and Other

Company

Total revenue

$

218

$

3,481

$

(1,875)

$

1,824

Cost of revenue

3,024

(1,761)

1,263

Research and development

8,011

(114)

7,897

Sales and marketing

General and administrative

879

4,991

5,870

Revaluation of contingent consideration

4,800

4,800

Loss from operations

$

(12,593)

$

(422)

$

(4,991)

$

(18,006)

(In thousands)

Contract

Corporate

Total

Six Months Ended June 30, 2022

Therapeutics

Research

and Other

Company

Total revenue

$

541

$

8,495

$

(6,055)

$

2,981

Cost of revenue

7,897

(5,674)

2,223

Research and development

33,466

(381)

33,085

General and administrative

1,695

10,479

12,174

Revaluation of contingent consideration

(4,600)

(4,600)

Loss from operations

$

(28,325)

$

(1,097)

$

(10,479)

$

(39,901)

(In thousands)

Contract

Corporate

Total

Six Months Ended June 30, 2021

Therapeutics

Research

and Other

Company

Total revenue

$

460

$

6,681

$

(3,540)

$

3,601

Cost of revenue

5,793

(3,328)

2,465

Research and development

15,946

(211)

15,735

General and administrative

1,507

9,190

10,697

Revaluation of contingent consideration

21,239

21,239

Loss from operations

$

(36,725)

$

(619)

$

(9,191)

$

(46,535)

Intersegment Revenue

Revenue for the contract research segment included $3.2 million and $1.9 million for services performed on behalf of the therapeutics segment for the three months ended June 30, 2022 and 2021, respectively, and $6.1 million and $3.5 million for the six months ended June 30, 2022 and 2021, respectively.  All intersegment revenue has been eliminated in the Company’s condensed consolidated statement of operations.  

16. Legal Proceedings

Securities Class Action

On July 30, 2019, plaintiff Linda Rosi (“Rosi”) filed a putative class action complaint captioned Rosi v. Aclaris Therapeutics, Inc., et al. in the U.S. District Court for the Southern District of New York against the Company and certain of its executive officers.  The complaint alleged that the defendants violated federal securities laws by, among other things, failing to disclose an alleged likelihood that regulators would scrutinize advertising materials related to ESKATA (hydrogen peroxide) topical solution, 40% (w/w) (“ESKATA”) and find that the materials minimized the risks or overstated the efficacy of the product.  The complaint sought unspecified compensatory damages on behalf of Rosi and all

17

other persons and entities that purchased or otherwise acquired the Company’s securities between May 8, 2018 and June 20, 2019. 

On September 5, 2019, an additional plaintiff, Robert Fulcher (“Fulcher”), filed a substantially identical putative class action complaint captioned Fulcher v. Aclaris Therapeutics, Inc., et al. in the same court against the same defendants.

On November 6, 2019, the court consolidated the Rosi and Fulcher actions (together, the “Consolidated Securities Action”) and appointed Fulcher “lead plaintiff” for the putative class. 

On January 24, 2020, Fulcher filed a consolidated amended complaint in the Consolidated Securities Action, naming two additional executive officers as defendants, extending the putative class period to August 12, 2019, and adding allegations concerning, among other things, alleged statements and omissions throughout the putative class period concerning ESKATA’s risks, tolerability and effectiveness. The defendants filed a motion to dismiss the consolidated amended complaint on April 17, 2020. Following briefing and oral argument on February 25, 2021, the motion was granted in part and denied in part on March 29, 2021, and the issues in dispute significantly narrowed. The defendants filed an answer to the remaining aspects of the consolidated amended complaint on April 19, 2021.

In June 2021, the defendants and the plaintiffs agreed to settle the Consolidated Securities Action. The parties signed and filed a settlement agreement in July 2021. On August 18, 2021, the court preliminarily approved the proposed settlement, directed that notice be given to the putative class and scheduled the final approval settlement hearing for November 30, 2021. Notice was subsequently given to the putative class. The court granted final approval of the settlement on December 9, 2021.

The Company’s financial obligation under the settlement was $2.7 million, which was within the limits of its insurance coverage.

18

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Certain statements contained in this Quarterly Report on Form 10-Q may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “may,” “might,” “can,” “will,” “to be,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “likely,” “continue,” “ongoing” or similar expressions, or the negative of such words, are intended to identify “forward-looking statements.” We have based these forward-looking statements on our current expectations and projections about future events. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to these differences include those below in this Quarterly Report on Form 10-Q and those in our Annual Report on Form 10-K, in each case under the caption “Risk Factors,” and in our other filings with the Securities and Exchange Commission, or SEC. Statements made herein are as of the date of the filing of this Form 10-Q with the SEC and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim, any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes that appear in Item 1 of this Quarterly Report on Form 10-Q and with our audited consolidated financial statements and related notes for the year ended December 31, 2021, which are included in our Annual Report on Form 10-K filed with the SEC on February 24, 2022.

Overview

We are a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases.  In addition to developing our novel drug candidates, we are pursuing strategic alternatives, including identifying and consummating transactions with third-party partners, to further develop, obtain marketing approval for and/or commercialize our novel drug candidates.

Clinical Programs

Zunsemetinib, an Investigational Oral MK2 Inhibitor

We are developing zunsemetinib, an investigational oral, novel, small molecule selective MK2 inhibitor compound, as a potential treatment for rheumatoid arthritis and other immuno-inflammatory diseases.  MK2 is a key regulator of pro-inflammatory mediators including TNFα, IL1β, IL6, IL8, IL17 and other essential pathogenic signals in chronic immuno-inflammatory diseases, as well as in oncology.  As an oral drug candidate, we are developing zunsemetinib as a potential alternative to injectable anti-TNF/IL1/IL6 biologics and JAK inhibitors for treating certain immuno-inflammatory diseases. Zunsemetinib has been adopted as the nonproprietary name for ATI-450.

We initiated a Phase 1 single (at 10 mg, 30 mg, 50 mg and 100 mg doses) and multiple ascending (at 10 mg, 30 mg and 50 mg doses) dose clinical trial evaluating zunsemetinib in 77 healthy subjects in August 2019 (ATI-450-PKPD-101). Final data from this trial demonstrated that zunsemetinib resulted in marked inhibition of TNFα, IL1β, IL8 and IL6. We also observed that zunsemetinib had dose-proportional pharmacokinetics with a terminal half-life of 9-12 hours in the multiple ascending dose cohort, and had no meaningful food effect or drug-drug interaction with methotrexate.  Zunsemetinib was generally well-tolerated at all doses tested in the trial.  The most common adverse events (reported by 2 or more subjects who received zunsemetinib) were dizziness, headache, upper respiratory tract infection, constipation, abdominal pain and nausea. 

Zunsemetinib was also evaluated at 80 mg and 120 mg doses twice daily in a second Phase 1 clinical trial in healthy subjects (ATI-450-PKPD-102). Final data from this trial showed that no dose-limiting toxicity was observed. Ex vivo analysis of blood samples from this Phase 1 trial showed that increased cytokine inhibition was achieved with these higher doses of zunsemetinib relative to doses tested in the first Phase 1 trial. No serious adverse events were reported and

19

all adverse events were mild. The most common adverse events (reported by 2 or more subjects who received zunsemetinib) were headache, dizziness, nausea, parasthesia and, in the post-dosing follow-up period of the trial, dry skin.

Moderate to Severe Rheumatoid Arthritis

Following the completion of the first Phase 1 clinical trial, in March 2020 we initiated a 12-week, Phase 2a, multicenter, randomized, investigator and patient-blind, sponsor-unblinded, parallel group, placebo-controlled clinical trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of zunsemetinib in subjects with moderate to severe rheumatoid arthritis (ATI-450-RA-201). In the trial, which consisted of a 12-week treatment period and a 4-week follow-up period, 19 subjects were randomized in a 3:1 ratio and received either zunsemetinib at 50 mg twice daily or placebo, in combination with methotrexate, for 12 weeks.

The final per-protocol analysis, which consisted of the 17 subjects who completed the treatment period (15 in the treatment arm and two in the placebo arm), showed that zunsemetinib demonstrated durable clinical activity, as defined by a marked and sustained reduction in DAS28-CRP and improvement of American College of Rheumatology 20%/50%/70% (ACR20/50/70) responses over 12 weeks. Zunsemetinib was generally well tolerated. All adverse events were mild to moderate. The most common adverse events (each reported in 2 subjects) were urinary tract infection, or UTI, and ventricular extrasystoles, all of which were determined to be unrelated to treatment except for one UTI. Two subjects withdrew from the trial during the treatment period, one in the treatment arm and one in the placebo arm. The subject in the treatment arm withdrew due to an elevated creatine phosphokinase, or CPK, level, which was determined by the site investigator to be treatment-related; this subject also had palpitations and ventricular extrasystoles, which were unrelated to the trial medication. The subject in the placebo arm withdrew as a result of prohibited medication needed to treat muscle strain. There was also one non-treatment-related serious adverse event (COVID-19) reported in the 4-week follow-up period of the trial in a subject who was no longer receiving treatment; the subject withdrew during the 4-week follow-up period of the trial.

A final analysis, which consisted of the 17 subjects, of ex vivo stimulated cytokines from blood samples taken from the treatment arm showed a marked and durable inhibition of TNFα, IL1β, IL6, and IL8 over the 12-week treatment period. Similarly, analysis of endogenous inflammation biomarkers also demonstrated a marked and sustained inhibition of median concentrations of hsCRP, TNFα, IL6, IL8 and MIP1β in the treatment arm over the 12-week period.

In December 2021, we initiated study activities in a Phase 2b randomized, multicenter, double-blind, parallel group, placebo-controlled, dose-ranging trial to investigate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses (20 mg and 50 mg twice daily) of zunsemetinib in combination with methotrexate in subjects with moderate to severe rheumatoid arthritis (ATI-450-RA-202). This trial consists of a 12-week treatment period and a 30-day follow-up period, and seeks to enroll approximately 240 subjects in the United States and in multiple countries in Europe. The primary endpoint is the proportion of subjects achieving ACR20 at week 12. We expect topline data in 2023.

Moderate to Severe Hidradenitis Suppurativa

In December 2021, we initiated study activities in a Phase 2a, randomized, multicenter, double-blind, placebo-controlled trial to investigate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of zunsemetinib (50 mg twice daily) in subjects with moderate to severe hidradenitis suppurativa (ATI-450-HS-201). This trial consists of a 12-week treatment period and a 30-day follow-up period, and seeks to enroll approximately 70 subjects in the United States. The primary endpoint is the change in inflammatory nodule and abscess count at week 12. We expect topline data in the first half of 2023.

Moderate to Severe Psoriatic Arthritis

In June 2022, we initiated study activities in a Phase 2a, randomized, multicenter, double-blind, placebo-controlled trial to investigate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of zunsemetinib (50 mg twice daily) in subjects with moderate to severe psoriatic arthritis (ATI-450-PsA-201). This trial consists of a 12-week treatment period and a 30-day follow-up period, and seeks to enroll approximately 70 subjects in the United States

20

and in Poland. The primary endpoint is the proportion of subjects achieving ACR20 at week 12.  We expect topline data in the first half of 2023.

ATI-1777, an Investigational Topical “Soft” JAK 1/3 Inhibitor

We are developing ATI-1777, an investigational topical “soft” JAK 1/3 inhibitor compound, as a potential treatment for moderate to severe atopic dermatitis. “Soft” JAK inhibitors are designed to be topically applied and active in the skin, but rapidly metabolized and inactivated when they enter the bloodstream, which may result in low systemic exposure.

In October 2020, we initiated a Phase 2a, multicenter, randomized, double-blind, vehicle-controlled, parallel-group clinical trial to determine the efficacy, safety, tolerability and pharmacokinetics of ATI-1777 in subjects with moderate to severe atopic dermatitis (ATI-1777-AD-201). In the trial, which consisted of a 4-week treatment period and a 2-week follow-up period during which no treatment was given, 50 subjects with moderate to severe atopic dermatitis were randomized in a 1:1 ratio into one of two arms: ATI-1777 topical solution 2.0% w/w or vehicle applied twice daily. In June 2021, we announced that the trial achieved its primary endpoint, which was the percent change from baseline in the modified Eczema Area and Severity Index, or mEASI, score at week 4, with a high degree of statistical significance (p<0.001) (one-sided p-value), which corresponded to a 74.4% reduction in mEASI score from baseline at week 4 in subjects applying ATI-1777 compared to a 41.4% reduction in subjects applying vehicle. The final data was based on the full analysis set, or FAS, which was comprised of 48 subjects randomized and documented to have received at least one dose of trial medication. Positive trends in favor of ATI-1777 were observed in key secondary efficacy endpoints, such as improvement in itch, percent of mEASI-50 responders, investigator’s global assessment responder analysis, and reduction in body surface area impacted by disease. In addition, the FAS analysis also showed positive trends in favor of ATI-1777 in percent of mEASI-75 responders (65.2% for ATI-1777 compared to 24.0% for vehicle) and mEASI-90 responders (30.4% for ATI-1777 compared to 20.0% for vehicle). These secondary efficacy endpoints were not powered for statistical significance. Based on an analysis of pharmacokinetic plasma samples in the ATI-1777 arm at multiple timepoints, minimal systemic exposure was observed, which supports a “soft” topical JAK inhibitor approach.

ATI-1777 was generally well tolerated. No serious adverse events were reported. The most common adverse events (reported in at least 2 subjects in the trial) were increased blood CPK levels and headache in subjects in the ATI-1777 arm and urinary tract infection (one in each of the ATI-1777 and the vehicle arm); none of these adverse events in the ATI-1777 arm were determined by the clinical trial investigators to be related to ATI-1777. One treatment-related adverse event, application site pruritus, was reported in one subject in the ATI-1777 arm.

In May 2022, we activated multiple clinical sites in a Phase 2b, multicenter, randomized, double-blind, vehicle-controlled, parallel-group trial to determine the efficacy, safety, tolerability and pharmacokinetics of ATI-1777 in subjects with moderate to severe atopic dermatitis (ATI-1777-AD-202). In this trial, we will explore multiple concentrations of twice daily treatment with ATI-1777 and a single concentration of once daily treatment with ATI-1777, in patients 12 years and older. This trial will consist of a 4-week treatment period and a 2-week follow-up period, and seeks to enroll approximately 240 subjects in the United States. The primary endpoint is the percentage change from baseline in EASI score at week 4. We expect topline data in the first half of 2023.

ATI-2138, an Investigational Oral ITJ Inhibitor

We are developing ATI-2138, an investigational oral ITK/TXK/JAK3, or ITJ, inhibitor compound, as a potential treatment for T cell-mediated autoimmune diseases.  The ITJ compound interrupts T cell signaling through the combined inhibition of ITK/TXK/JAK3 pathways in lymphocytes. We submitted an Investigational New Drug application, or IND, for ATI-2138 for the treatment of psoriasis in October 2021, which was allowed by the U.S. Food and Drug Administration, or FDA, in November 2021.

In December 2021, we initiated a Phase 1 randomized, observer-blind, placebo-controlled, single ascending dose (SAD) trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-2138 in healthy subjects (ATI-2138-PKPD-101). We expect topline data in 2022.

21

If the Phase 1 SAD trial is successful, we currently plan to initiate a Phase 1 multiple ascending dose (MAD) trial of ATI-2138 in subjects with psoriasis in 2022, with topline data expected in the first half of 2023. We are also currently exploring alternative indications that are relevant to the mechanism of action, which may impact the trial design and require the submission of additional INDs to different reviewing divisions of the FDA before we can conduct further clinical trials.

Preclinical Programs

ATI-2231, an Investigational Oral MK2 Inhibitor

We are exploring the use of ATI-2231, an investigational oral MK2 inhibitor compound designed to have a long half-life, as a potential treatment for pancreatic cancer and metastatic breast cancer as well as in preventing bone loss in patients with metastatic breast cancer. IND-enabling studies are currently underway. We expect to submit an IND for ATI-2231 by the end of 2022. If allowed, we expect to progress ATI-2231 into the clinic in 2023. We are currently evaluating the clinical development program for this asset, which may include a collaboration with a third party.

Discovery Programs

We are developing oral gut-biased JAK inhibitors with limited systemic exposure as potential treatments for inflammatory bowel disease. In addition, we are engaged in research to identify brain penetrant kinase inhibitor candidates as potential treatments for neurodegenerative diseases.

Financial Overview

Since our inception, we have incurred significant net losses.  Our net loss was $39.3 million for the six months ended June 30, 2022 and $90.9 million for the year ended December 31, 2021.  As of June 30, 2022, we had an accumulated deficit of $634.7 million.  We expect to incur significant expenses and operating losses for the foreseeable future as we advance our drug candidates from discovery through preclinical and clinical development.  In addition, our drug candidates, even if they are approved by regulatory agencies for marketing, may not achieve commercial success.  We may also not be successful in pursuing strategic alternatives, including identifying and consummating transactions with third-party partners, to further develop, obtain marketing approval for and/or commercialize our drug candidates.  Furthermore, we have incurred and expect to continue to incur significant costs associated with operating as a public company, including legal, accounting, investor relations and other expenses.  We also expect to add additional personnel to support our operational plans and strategic direction. As a result, we will need substantial additional funding to support our continuing operations.

We have historically financed our operations primarily with sales of equity securities and incurring indebtedness in the form of loans from commercial lenders.  In the near term, we expect to finance our operations through these and other capital sources, including potential partnerships with other companies or other strategic transactions.  We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on commercially acceptable terms, or at all.  If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back or discontinue the development of one or more of our drug candidates.  

Impacts of COVID-19 on Our Business

The impacts of the global COVID-19 pandemic continue to evolve. We have implemented a virtual operations strategy, including teleworking, staggered work schedules for lab personnel and other alternative work arrangements for our employees, intended to protect the health and safety of our employees while enabling us to continue to develop our drug candidates and provide contract research services to our clients. We are focused on ensuring the continuity of our operations. However, COVID-19 has caused disruptions to our business.

If COVID-19 continues to spread, we may experience additional disruptions that could severely impact our business, results of operations and prospects, including the timing of our development programs and our clinical trials, including our trials of zunsemetinib as a potential treatment for moderate to severe rheumatoid arthritis and other immuno-inflammatory diseases and ATI-1777 as a potential treatment for moderate to severe atopic dermatitis, and the supply of

22

active pharmaceutical ingredients and drug product for our clinical trials. The extent to which the COVID-19 pandemic impacts our business, our preclinical and clinical development and our regulatory efforts will depend on future developments that are highly uncertain and cannot be predicted, such as the spread of the disease, the introduction and spread of new variants, travel restrictions, quarantines, stay-at-home orders, social distancing requirements, business closures, staffing shortages, and supply chain and other disruptions in the United States and other countries, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease, including the administration of vaccines.  Accordingly, we do not know the full extent of the potential impacts on our business, our preclinical and clinical development and regulatory activities.

Acquisition and License Agreements

Agreement and Plan of Merger with Confluence

In 2017, we entered into an Agreement and Plan of Merger, or the Confluence Agreement, with Confluence Life Sciences, Inc. (now known as Aclaris Life Sciences, Inc.), or Confluence, Aclaris Life Sciences, Inc., our wholly-owned subsidiary, or Merger Sub, and Fortis Advisors LLC, as representative of the equity holders of Confluence.  Pursuant to the terms of the Confluence Agreement, Merger Sub merged with and into Confluence, with Confluence surviving as our wholly-owned subsidiary.

Under the Confluence Agreement, we have agreed to pay the former Confluence equity holders aggregate remaining contingent consideration of up to $75.0 million based upon the achievement of specified future regulatory and commercial milestones set forth in the Confluence Agreement.  In addition, we have agreed to pay the former Confluence equity holders future royalty payments calculated as a low single-digit percentage of annual net sales, subject to specified reductions, limitations and other adjustments, until the date that all of the patent rights for that product have expired, as determined on a country-by-country and product-by-product basis or, in specified circumstances, ten years from the first commercial sale of such product.  In addition to the payments described above, if we sell, license or transfer any of the intellectual property acquired from Confluence pursuant to the Confluence Agreement to a third party, we will be obligated to pay the former Confluence equity holders a portion of any consideration received from such sale, license or transfer in specified circumstances.  

Asset Purchase Agreement with EPI Health

In 2019, we entered into an asset purchase agreement with EPI Health, LLC, or EPI Health, pursuant to which we sold the worldwide rights to RHOFADE (oxymetazoline hydrochloride) cream, 1%, or RHOFADE, which included the assignment of certain licenses for related intellectual property assets, or the Disposition.  

 

Pursuant to the asset purchase agreement, EPI Health paid us closing consideration of $35.2 million.  In addition, EPI Health has agreed to pay us (i) potential sales milestone payments of up to $20.0 million in the aggregate upon the achievement of specified levels of net sales of products covered by the agreement, (ii) a specified high single-digit royalty calculated as a percentage of net sales, on a product-by-product and country-by-country basis, until the date that the patent rights related to a particular product, such as RHOFADE, have expired, provided, that with respect to sales of RHOFADE in any territory outside of the United States, such royalty shall be paid on a country-by-country basis until the date that the RHOFADE patent rights in the particular country have expired or, if later, 10 years from the date of the first commercial sale of RHOFADE in such country and (iii) 25% of any upfront, license, milestone, maintenance or fixed payment received by EPI Health in connection with any license or sublicense of the assets transferred in the Disposition in any territory outside of the United States, subject to specified exceptions.  In addition, EPI Health has agreed to assume our obligation to pay specified royalties and milestone payments under certain agreements with third parties.

23

Components of Our Results of Operations

Revenue

Contract Research

We earn revenue from the provision of laboratory services.  Contract research revenue is generally evidenced by contracts with clients which are on an agreed upon fixed-price, fee-for-service basis and are generally billed on a monthly basis in arrears for services rendered.  

Other Revenue

Other revenue primarily consists of royalties earned on net sales of RHOFADE pursuant to the asset purchase agreement with EPI Health described above.

Cost of Revenue

Cost of revenue consists of the costs incurred in connection with the provision of contract research services.  Cost of revenue primarily includes:

employee-related expenses, which include salaries, benefits and stock-based compensation;
outsourced professional scientific services;
depreciation of laboratory equipment;
facility-related costs; and
laboratory materials and supplies used to support the services provided.

Research and Development Expenses

Research and development expenses consist of expenses incurred in connection with the discovery and development of our drug candidates.  These expenses primarily include:

expenses incurred under agreements with contract research organizations, or CROs, as well as clinical trial sites and consultants that conduct our clinical trials and preclinical studies, and investigator-initiated trials;
manufacturing scale-up expenses and the cost of acquiring and manufacturing active pharmaceutical ingredients and preclinical and clinical trial materials, including domestic technology transfer expenses;
outsourced professional scientific development services;
medical affairs expenses related to our drug candidates;
employee-related expenses, which include salaries, benefits and stock-based compensation;
payments made under agreements with third parties under which we have acquired or licensed intellectual property;
expenses relating to regulatory activities, including filing fees paid to regulatory agencies; and
laboratory materials and supplies used to support our research activities.

Research and development activities are central to our business model.  Drug candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect to continue to incur research and development expenses in the near term as we continue the clinical development of zunsemetinib as a potential treatment for moderate to severe rheumatoid arthritis and other immuno-inflammatory diseases, ATI-1777 as a potential treatment for moderate to severe atopic dermatitis and ATI-2138 as a potential treatment for T cell-mediated autoimmune diseases, and as we continue the development of our preclinical compounds and discover and develop additional drug candidates.  We expense research and development costs as incurred.  Our direct research and development expenses primarily consist of external costs including fees paid to CROs, consultants, clinical trial sites, regulatory agencies and third parties that manufacture

24

our preclinical and clinical trial materials, and are tracked on a program-by-program basis.  We do not allocate personnel costs or other indirect expenses to specific research and development programs.  

The successful development of our drug candidates is highly uncertain. We cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the remainder of the development of, or when, if ever, material net cash inflows may commence from any of our drug candidates. This uncertainty is due to the numerous risks and uncertainties associated with the duration and cost of clinical trials, which vary significantly over the life of a project as a result of many factors, including:

the number of clinical sites included in the trials;
the length of time required to enroll suitable subjects;
the number of subjects that ultimately participate in the trials;
the number of doses subjects receive;
the impact on the recruitment, enrollment, conduct and timing of our clinical trials due to the COVID-19 pandemic;
the duration of subject follow-up; and
the results of our clinical trials.

Our expenditures are subject to additional uncertainties, including the preparation of regulatory filings for our drug candidates.  We may obtain unexpected results from our clinical trials or other development activities.  We may elect to discontinue, delay or modify the development, including clinical trials, of some drug candidates or focus on others.  A change in the outcome of any of these variables with respect to the development of a drug candidate could mean a significant change in the costs and timing associated with the development of that drug candidate.  For example, if the FDA or other regulatory authorities were to require us to conduct clinical trials beyond those that we currently anticipate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development.

General and Administrative Expenses

General and administrative expenses consist principally of salaries and related costs, including stock-based compensation, for personnel in executive, administrative, finance and legal functions.  General and administrative expenses also include facility-related costs, patent filing and prosecution costs, professional fees for legal, auditing and tax services, investor relations costs, insurance costs and travel expenses.

Revaluation of Contingent Consideration

Revaluation of contingent consideration consists of changes in the fair value of our contingent consideration liability between reporting dates.

Other Income (Expense), Net

Other income (expense), net primarily consists of interest earned on our cash, cash equivalents and marketable securities and in prior periods included interest expense related to our debt obligations.

Critical Accounting Estimates

This discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of our condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our condensed consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.  We evaluate our estimates and judgments on an ongoing basis.  Our actual results may differ from

25

these estimates under different assumptions or conditions.  Except as described below, there have been no material changes to our significant accounting policies and use of estimates as disclosed in the footnotes to our audited consolidated financial statements for the year ended December 31, 2021 included in our Annual Report on Form 10-K filed with the SEC on February 24, 2022.  

Contingent Consideration

We initially recorded a contingent consideration liability at fair value on the date of acquisition related to future potential payments resulting from the acquisition of Confluence based upon significant unobservable inputs including the achievement of development, regulatory and commercial milestones, as well as estimated future sales levels and the discount rates applied to calculate the present value of the potential payments. Significant judgement was involved in determining the appropriateness of these assumptions.  These assumptions are considered Level 3 inputs.  Revaluation of our contingent consideration liability can result from changes to one or more of these assumptions.  We evaluate the fair value estimate of our contingent consideration liability on a quarterly basis with changes, if any, recorded as income or expense in our consolidated statement of operations.  Any such changes could have a material impact on our financial results.

The fair value of contingent consideration is estimated using a probability-weighted expected payment model for regulatory milestone payments and a Monte Carlo simulation model for commercial milestone and royalty payments and then applying a risk-adjusted discount rate to calculate the present value of the potential payments.  Significant assumptions used in our estimates include the probability of achieving regulatory milestones and commencing commercialization, which are based on an asset’s current stage of development and a review of existing clinical data. Probability of success assumptions ranged between 10% and 40% at June 30, 2022 compared to between 4% and 40% at June 30, 2021. Additionally, estimated future sales levels and the risk-adjusted discount rate applied to the potential payments are also significant assumptions used in calculating the fair value. The discount rate ranged between 10.2% and 10.9% depending on the year of each potential payment.

During the six months ended June 30, 2022, we did not modify any significant assumptions; however, due to higher discount rates resulting from higher risk-free rates and wider credit spreads being applied to potential payments relative to prior periods, we recorded a decrease in contingent consideration of $4.6 million.  The overall decrease was partially offset by the increase in contingent consideration as a result of the impact of the passage of time.

During the six months ended June 30, 2021, we updated assumptions for probability of success and estimated future sales levels as a result of the completion of a Phase 2a clinical trial of zunsemetinib in subjects with moderate to severe rheumatoid arthritis and as a result of the completion of a Phase 2a clinical trial of ATI-1777 in subjects with moderate to severe atopic dermatitis.  We also included estimated future sales of zunsemetinib as a potential treatment for hidradenitis suppurativa and psoriatic arthritis, which are additional planned indications for zunsemetinib.  These updates resulted in an increase in the fair value of the contingent consideration liability of $21.2 million.

26

Results of Operations

Comparison of Three and Six Months Ended June 30, 2022 and 2021

Three Months Ended June 30, 

Six Months Ended June 30, 

(In thousands)

    

2022

    

2021

    

Change

    

2022

    

2021

    

Change

Revenues:

Contract research

$

1,218

$

1,606

$

(388)

$

2,439

$

3,141

$

(702)

Other revenue

310

218

92

542

460

82

Total revenue

1,528

1,824

(296)

2,981

3,601

(620)

Costs and expenses:

Cost of revenue

1,068

1,263

(195)

2,223

2,465

(242)

Research and development

 

18,779

 

7,897

 

10,882

 

33,085

 

15,735

 

17,350

General and administrative

 

6,075

 

5,870

 

205

 

12,174

 

10,697

 

1,477

Revaluation of contingent consideration

(3,400)

4,800

(8,200)

(4,600)

21,239

(25,839)

Total costs and expenses

 

22,522

 

19,830

 

2,692

 

42,882

 

50,136

 

(7,254)

Loss from operations

 

(20,994)

 

(18,006)

 

(2,988)

 

(39,901)

 

(46,535)

 

6,634

Other income (expense), net

 

462

 

(155)

 

617

 

580

 

(380)

 

960

Net loss

$

(20,532)

$

(18,161)

$

(2,371)

$

(39,321)

$

(46,915)

$

7,594

Revenue

Contract research revenue was $1.2 million and $1.6 million for the three months ended June 30, 2022 and 2021, respectively, and was comprised of fees earned from the provision of laboratory services.  The $0.4 million decrease was driven by lower overall hours billed, partially offset by a higher average billing rate.  Other revenue for the three months ended June 30, 2022 and 2021 primarily consisted of $0.3 million and $0.2 million of royalties earned on net sales of RHOFADE, respectively.

Contract research revenue was $2.4 million and $3.1 million for the six months ended June 30, 2022 and 2021, respectively, and was comprised of fees earned from the provision of laboratory services. The $0.7 million decrease was driven by lower overall hours billed, partially offset by a higher average billing rate. Other revenue for the six months ended June 30, 2022 and 2021 primarily consisted of $0.5 million and $0.4 million of royalties earned on net sales of RHOFADE, respectively.

Cost of Revenue

Cost of revenue was $1.1 million and $2.2 million for the three and six months ended June 30, 2022, respectively, and $1.3 million and $2.5 million for the three and six months ended June 30, 2021, respectively.  In each case cost of revenue related to providing laboratory services.  Changes in cost of revenue generally correlate to changes in contract research revenue.  Cost of revenue decreased in the three and six months ended June 30, 2022 due to lower variable costs resulting from the decrease in hours billed, partially offset by an increase in fixed overhead costs, including personnel-related costs.

27

Research and Development Expenses

The following table summarizes our research and development expenses by drug candidate or, for unallocated expenses, by type:

Three Months Ended

Six Months Ended

June 30, 

June 30, 

(In thousands)

2022

    

2021

Change

2022

    

2021

Change

Zunsemetinib

    

$

6,606

$

2,252

  

$

4,354

    

$

11,318

$

4,325

  

$

6,993

ATI-1777

3,510

497

3,013

5,866

1,444

4,422

ATI-2138

1,141

967

174

2,267

2,350

(83)

ATI-2231

1,503

70

1,433

3,089

70

3,019

Discovery

1,183

774

409

2,272

1,466

806

Other research and development

343

385

(42)

665

800

(135)

Personnel

3,552

1,798

1,754

6,780

3,250

3,530

Stock-based compensation

941

1,154

(213)

828

2,030

(1,202)

Total research and development expenses

$

18,779

$

7,897

$

10,882

$

33,085

$

15,735

$

17,350

Zunsemetinib

The increase in expenses for zunsemetinib during the three and six months ended June 30, 2022 compared to the three and six months ended June 30, 2021 was primarily due to costs associated with clinical development activities for a Phase 2b trial in subjects with rheumatoid arthritis, which initiated in December 2021, a Phase 2a trial in subjects with hidradenitis suppurativa, which initiated in December 2021 and start-up activities for a Phase 2a trial in subjects with psoriatic arthritis, which initiated in June 2022.

ATI-1777

The increase in expenses for ATI-1777 during the three and six months ended June 30, 2022 compared to the three and six months ended June 30, 2021 was primarily due to higher costs associated with drug candidate manufacturing and other preclinical development activities as well start-up costs associated with a Phase 2b clinical trial in subjects with atopic dermatitis.  Lower costs associated with a Phase 2a clinical trial in subjects with atopic dermatitis, which commenced in 2020 and concluded in 2021, partially offset the overall increase in expenses.

ATI-2138

Expenses for ATI-2138 were relatively flat during the three and six months ended June 30, 2022 compared to the three and six months ended June 30, 2021 due to a decrease in preclinical development activities and IND-enabling study expenses following our IND submission in October 2021, offset by clinical development expenses associated with a Phase 1 SAD trial, which initiated in December 2021.

ATI-2231

Expenses for ATI-2231 were higher during the three and six months ended June 30, 2022 compared to the three and six months ended June 30, 2021 primarily due to preclinical development activities and IND-enabling studies.

Discovery

Expenses related to discovery increased during the three and six months ended June 30, 2022 compared to the three and six months ended June 30, 2021 due to continued investment in our discovery-stage programs as we progressed programs toward candidate selection.

28

Personnel and stock-based compensation

Personnel and stock-based compensation expenses increased in the aggregate during the three and six months ended June 30, 2022 compared to the three and six months ended June 30, 2021 primarily due to an increase in costs associated with higher average headcount.  For the six months ended June 30, 2022 the increase in costs associated with higher average headcount was partially offset by a decrease in stock-based compensation expense mainly attributable to forfeiture credits recorded between the period.

General and Administrative Expenses

The following table summarizes our general and administrative expenses:

Three Months Ended

Six Months Ended

June 30, 

June 30, 

(In thousands)

2022

    

2021

Change

2022

    

2021

Change

Personnel

    

$

1,365

    

$

1,147

  

$

218

    

$

2,938

    

$

2,106

  

$

832

Professional and legal fees

1,160

1,336

(176)

2,289

2,691

(402)

Facility and support services

 

482

 

414

 

68

 

1,091

 

812

 

279

Other general and administrative

619

630

(11)

1,176

1,193

(17)

Stock-based compensation

2,449

2,343

106

4,680

3,895

785

Total general and administrative expenses

$

6,075

$

5,870

$

205

$

12,174

$

10,697

$

1,477

Personnel and stock-based compensation

Personnel and stock-based compensation expenses in the aggregate increased during the three and six months ended June 30, 2022 compared to the three and six months ended June 30, 2021 primarily due to an increase in costs associated with higher average headcount and an increase in stock-based compensation expense associated with new equity awards granted in 2022.

Professional and legal fees

Professional and legal fees, including accounting, investor relations and corporate communication costs, decreased during the three and six months ended June 30, 2022 compared to the three and six months ended June 30, 2021 primarily as a result of lower legal fees, partially offset by higher Sarbanes-Oxley and other accounting compliance expenses.

Facility and support services

Facility and support services, including general office expenses, information technology costs and other expenses, was relatively flat during the three months ended June 30, 2022 compared to the three months ended June 30, 2021.

Facility and support services, including general office expenses, information technology costs and other expenses, increased during the six months ended June 30, 2022 compared to the six months ended June 30, 2021 primarily due to an increase in overhead expenses including increases in tax and license fees and information technology support costs.

Revaluation of Contingent Consideration

The decrease in the fair value of our contingent consideration liability during the three months ended June 30, 2022 was mainly due to higher discount rates, resulting from higher risk-free rates and wider credit spreads, being applied to potential payments relative to prior periods in 2022.  Additionally, increases recorded during the three months ended June 30, 2021 from updates to the probability of success and estimated future sales level assumptions as a result of the completion of a Phase 2a clinical trial of ATI-1777 in subjects with atopic dermatitis contributed to the decrease.

The decrease in the fair value of our contingent consideration liability during the six months ended June 30, 2022 compared to the six months ended June 30, 2021 was mainly due to higher discount rates, resulting from higher risk-free

29

rates and wider credit spreads, being applied to potential payments relative to prior periods in 2022.  Additionally, increases recorded during the six months ended June 30, 2021 from updates to the probability of success and estimated future sales level assumptions as a result of the completion of a Phase 2a clinical trial of zunsemetinib in subjects with rheumatoid arthritis, as well as the completion of a Phase 2a clinical trial of ATI-1777 in subjects with atopic dermatitis.  Additionally, the inclusion of estimated future sales of zunsemetinib as a potential treatment for hidradenitis suppurativa and psoriatic arthritis, which are additional planned indications for zunsemetinib, also contributed to the increase during the six months ended June 30, 2021.

Other Income (Expense), net

Other income (expense), net increased during the three and six months ended June 30, 2022 compared to the three and six months ended June 30, 2021 due to lower interest expense associated with the Loan and Security Agreement with Silicon Valley Bank, or SVB, which was repaid in July 2021, and higher interest income on investment portfolio balances.

Liquidity and Capital Resources

Overview

Since our inception, we have incurred net losses and negative cash flows from our operations.  Prior to our acquisition of Confluence, we did not generate any revenue.  We have financed our operations over the last several years primarily through sales of our equity securities and incurring indebtedness in the form of loans from commercial lenders.  We may engage in additional debt and equity financing transactions in order to raise funds.  We may also receive royalties and milestone payments from EPI Health in connection with the sale of RHOFADE. In addition, to the extent we are able to consummate transactions with potential third-party partners to further develop, obtain marketing approval for and/or commercialize our drug candidates, we may receive upfront payments, milestone payments or royalties from such arrangements that would increase our liquidity.

As of June 30, 2022, we had cash, cash equivalents and marketable securities of $255.8 million.  Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view towards liquidity and capital preservation.

We currently have no ongoing material financing commitments, such as lines of credit or guarantees, that are expected to affect our liquidity, other than our contingent obligations under the Confluence Agreement, which is summarized above under “Overview—Acquisition and License Agreements,” and our lease obligations.  

Equity Financing

Sale of Common Stock Pursuant to At-the-Market Offering

In April 2022, we sold 4,838,709 shares of our common stock at a weighted average price per share of $15.50, for aggregate gross proceeds of $75.0 million, pursuant to a sales agreement with SVB Securities LLC and Cantor Fitzgerald & Co., as sales agents, dated May 20, 2021.  We paid selling commissions and other fees of $2.2 million in connection with the sale.

June 2021 Public Offering

In June 2021, we closed a public offering in which we sold 8,098,592 shares of common stock at a price to the public of $17.75 per share, for aggregate gross proceeds of $143.8 million. We paid underwriting discounts and commissions of $8.6 million, and also incurred expenses of $0.3 million in connection with the offering.  As a result, the net offering proceeds received by us, after deducting underwriting discounts, commissions and offering expenses, were $134.9 million.

30

January 2021 Public Offering

In January 2021, we closed a public offering in which we sold 6,306,271 shares of common stock at a price to the public of $17.50 per share, for aggregate gross proceeds of $110.4 million. We paid underwriting discounts and commissions of $6.6 million, and also incurred expenses of $0.4 million in connection with the offering.  As a result, the net offering proceeds received by us, after deducting underwriting discounts, commissions and offering expenses, were $103.3 million.

Debt Financing

Loan and Security Agreement with Silicon Valley Bank  

In March 2020, we entered into a Loan and Security Agreement with SVB.  The Loan and Security Agreement provided for $11.0 million in term loans, of which we borrowed the entire amount on March 30, 2020.  In July 2021, we repaid in full the $11.0 million that was outstanding under the Loan and Security Agreement, together with all accrued and unpaid interest and fees as of the payoff date, for a total payment of $11.7 million.

Cash Flows

Cash and cash equivalents were $68.3 million as of June 30, 2022 compared to $27.3 million as of December 31, 2021.  We also had $187.6 million in short- and long-term marketable securities as of June 30, 2022 compared to $198.3 million as of December 31, 2021.

The sources and uses of cash that contributed to the change in cash and cash equivalents were:

Six Months Ended

June 30, 

(In thousands)

    

2022

    

2021

Cash and cash equivalents beginning balance

$

27,349

$

22,063

Net cash used in operating activities

 

(40,635)

 

(24,453)

Net cash provided by (used in) investing activities

 

8,709

 

(120,784)

Net cash provided by financing activities

72,841

236,621

Cash and cash equivalents ending balance

$

68,264

$

113,447

Operating Activities

Cash flow related to operating activities was the result of:

Six Months Ended

June 30, 

(In thousands)

    

2022

    

2021

Net loss

$

(39,321)

$

(46,915)

Non-cash adjustments to reconcile net loss to net cash used in operating activities

 

1,852

 

28,281

Change in accounts payable and accrued expenses

(4,461)

(429)

Change in accounts receivable

(14)

(167)

Change in prepaid expenses and other assets

 

1,309

 

(5,223)

Net cash used in operating activities

$

(40,635)

$

(24,453)

Net cash used in operating activities increased for the six months ended June 30, 2022 compared to the six months ended June 30, 2021 primarily as a result of higher net losses after adjusting for non-cash items and an increase in cash paid for accounts payable and accrued expenses.  The increase was partially offset by a decrease in cash paid for prepaid expenses and other assets.

31

The decrease in non-cash adjustments to reconcile net loss to net cash used in operating activities was mainly the result of a decrease in revaluation of contingent consideration during the six months ended June 30, 2022 compared to the six months ended June 30, 2021 due to higher discount rates, resulting from higher risk-free rates and wider credit spreads, being applied to potential payments relative to prior periods in 2022.  Additionally, increases recorded during the six months ended June 30, 2021 from updates to the probability of success and estimated future sales level assumptions as a result of the completion of a Phase 2a clinical trial of zunsemetinib in subjects with rheumatoid arthritis, as well as the completion of a Phase 2a clinical trial of ATI-1777 in subjects with atopic dermatitis.  Additionally, the inclusion of estimated future sales of zunsemetinib as a potential treatment for hidradenitis suppurativa and psoriatic arthritis, which are additional planned indications for zunsemetinib, also contributed to the increase during the six months ended June 30, 2021.

The increase in cash paid for accounts payable and accrued expenses was primarily driven by the timing of receipt and payment of invoices around quarter-end relative to the prior year period.  The decrease in cash paid for prepaid expenses and other assets resulted from an increase in the prepaid research and development balance at June 30, 2021 relative to the balance at December 31, 2020, as compared to the prepaid research and development balance at June 30, 2022 which was flat relative to the balance at December 31, 2021.

Investing Activities

Cash flow related to investing activities was the result of:

Six Months Ended

June 30, 

(In thousands)

    

2022

    

2021

Purchases of property and equipment

$

(350)

$

(52)

Purchases of marketable securities

 

(85,096)

 

(147,289)

Proceeds from sales and maturities of marketable securities

94,155

26,557

Net cash provided by (used in) investing activities

$

8,709

$

(120,784)

Net cash provided by investing activities for the six months ended June 30, 2022 compared to net cash used in investing activities for the six months ended June 30, 2021 primarily resulted from sales and maturities of marketable securities during the six months ended June 30, 2022, which were used to fund our operations, and a reduction of purchases of marketable securities, which were higher during the six months ended June 30, 2021 following our January 2021 and June 2021 public offerings.

Financing Activities

Cash flow related to financing activities was the result of:

Six Months Ended

June 30, 

(In thousands)

    

2022

    

2021

Proceeds from issuance of common stock in connection with public offerings, net of issuance costs

$

$

238,200

Proceeds from issuance of common stock under the at-the-market sales agreement, net of issuance costs

72,744

Payments of employee withholding taxes related to restricted stock unit award vesting

(23)

(3,038)

Proceeds from exercise of employee stock options and the issuance of stock

 

120

 

1,459

Net cash provided by financing activities

$

72,841

$

236,621

Net cash provided by financing activities decreased for the six months ended June 30, 2022 compared to the six months ended June 30, 2021 primarily due to our January 2021 and June 2021 public offerings, partially offset by our April 2022 sales under the at-the-market sales agreement.

32

Funding Requirements

We anticipate we will incur net losses in the near term as we continue the clinical development of zunsemetinib as a potential treatment for moderate to severe rheumatoid arthritis and other immuno-inflammatory diseases, ATI-1777 as a potential treatment for moderate to severe atopic dermatitis and ATI-2138 as a potential treatment for T cell-mediated autoimmune diseases, as well as continue the development of our preclinical compounds and discover and develop additional drug candidates.  We may not be able to generate revenue from these programs if, among other things, our clinical trials are not successful, the FDA does not approve our drug candidates currently in clinical trials when we expect, or at all, or we are not able to identify and consummate transactions with third-party partners to further develop, obtain marketing approval for and/or commercialize our drug candidates.  

Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, clinical costs, external research and development services, laboratory and related supplies, legal and other regulatory expenses, and administrative and overhead costs.  We expect to add additional personnel to support our operational plans and strategic direction. Our future funding requirements will be heavily determined by the resources needed to support the development of our drug candidates.

As a publicly traded company, we incur and will continue to incur significant legal, accounting and other similar expenses.  In addition, the Sarbanes-Oxley Act of 2002, as well as rules adopted by the SEC and the Nasdaq Stock Market LLC, requires public companies to implement specified corporate governance practices that could increase our compliance costs.  

We believe our existing cash, cash equivalents and marketable securities are sufficient to fund our operating and capital expenditure requirements for a period greater than 12 months from the date of issuance of our condensed consolidated financial statements that appear in Item 1 of this Quarterly Report on Form 10-Q based on our current operating assumptions.  We will require additional capital to complete the clinical development of zunsemetinib, ATI-1777 and ATI-2138, to develop our preclinical compounds, and to support our discovery efforts.  Additional funds may not be available on a timely basis, on commercially acceptable terms, or at all, and such funds, if raised, may not be sufficient to enable us to continue to implement our long-term business strategy. Our ability to raise additional capital may be adversely impacted by the potential worsening of global economic conditions, including inflationary pressures, and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the COVID-19 pandemic and geopolitical tensions. If we are unable to raise sufficient additional capital or generate revenue from transactions with potential third-party partners for the development and/or commercialization of our drug candidates, we may need to substantially curtail our planned operations.  

We may raise additional capital through the sale of equity or debt securities. In such an event, our stockholders’ ownership will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of a holder of our common stock.

Because of the numerous risks and uncertainties associated with research and development of pharmaceutical drugs, we are unable to estimate the exact amount of our working capital requirements. Our funding requirements in the near term will depend on many factors, including:

the number and development requirements of the drug candidates that we may pursue;
the scope, progress, results and costs of preclinical development, laboratory testing and conducting preclinical and clinical trials for our drug candidates;
the costs, timing and outcome of regulatory review of our drug candidates;
the extent to which we in-license or acquire additional drug candidates and technologies;
the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;
the impact on the timing of our preclinical studies, the recruitment, enrollment, conduct and timing of our clinical trials and our business due to the COVID-19 pandemic;
our ability to identify and consummate transactions with third-party partners to further develop, obtain marketing approval for and/or commercialize our drug candidates; and

33

our ability to earn revenue as a result of licenses to, or partnerships or other arrangements with, third parties.

Leases

We occupy space for our headquarters in Wayne, Pennsylvania under a sublease agreement which has a term through October 2023.  In December 2020, we entered into a sub-sublease agreement under which we sub-subleased 8,115 square feet to a third party.  The sub-sublease term runs concurrently with the original sublease agreement. We occupy office and laboratory space in St. Louis, Missouri under a sublease agreement which has a term through June 2029. Our aggregate remaining lease payment obligations for these two spaces was $3.3 million as of June 30, 2022.

Agreement and Plan of Merger – Confluence

Under the Confluence Agreement, we have agreed to pay the former Confluence equity holders aggregate remaining contingent consideration of up to $75.0 million based upon the achievement of specified future regulatory and commercial milestones set forth in the Confluence Agreement.  In addition, we have agreed to pay the former Confluence equity holders future royalty payments calculated as a low single-digit percentage of annual net sales, subject to specified reductions, limitations and other adjustments, until the date that all of the patent rights for that product have expired, as determined on a country-by-country and product-by-product basis or, in specified circumstances, ten years from the first commercial sale of such product.  In addition to the payments described above, if we sell, license or transfer any of the intellectual property acquired from Confluence pursuant to the Confluence Agreement to a third party, we will be obligated to pay the former Confluence equity holders a portion of any consideration received from such sale, license or transfer in specified circumstances.  

R&D Obligations

We enter into contracts in the normal course of business with CROs, contract manufacturing organizations and other service providers for clinical trials, preclinical studies and testing, manufacturing and other services and products for operating purposes. These contracts generally provide for termination upon notice, and therefore we believe that our non-cancelable obligations under these agreements are not material.

Segment Information

We have two reportable segments, therapeutics and contract research.  The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.  The contract research segment earns revenue from the provision of laboratory services.  

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Our cash equivalents and marketable securities consist of money market funds, asset-backed debt securities, commercial paper, corporate debt securities and U.S. government agency debt securities. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates.  Our marketable securities are subject to interest rate risk and will fall in value if market interest rates increase.  However, due to the short-term nature and low-risk profile of our investment portfolio, we do not expect that an immediate 10% change in market interest rates would have a material effect on the fair market value of our investment portfolio.  We have the ability to hold our marketable securities until maturity, and therefore we would not expect our operating results or cash flows to be affected to any significant degree by the effect of a change in market interest rates on our investments.

The uncertainty that exists with respect to the economic impact of the global COVID-19 pandemic and ongoing geopolitical tensions has introduced significant volatility in the financial markets during and subsequent to the quarter ended June 30, 2022.

34

Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

Under the supervision of and with the participation of our management, including our chief executive officer, who is our principal executive officer, and our chief financial officer, who is our principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of June 30, 2022, the end of the period covered by this Quarterly Report on Form 10-Q. The term “disclosure controls and procedures,” as set forth in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms promulgated by the SEC. Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of June 30, 2022, our chief executive officer and chief financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

(b) Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended June 30, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

35

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

From time to time we are subject to litigation and claims arising in the ordinary course of business including intellectual property and product liability litigation. We are not currently a party to any material legal proceedings and we are not aware of any other pending or threatened legal proceeding against us that we believe could have a material adverse effect on our business, operating results, cash flows or financial condition.

Item 1A. Risk Factors

Our business is subject to risks and events that, if they occur, could adversely affect our financial condition and results of operations and the trading price of our securities.  Our risk factors have not changed materially from those described in “Part I, Item 1A. Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on February 24, 2022.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 6. Exhibits

Exhibit
No.

    

Document

3.1

Amended and Restated Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37581), filed with the SEC on October 13, 2015).

3.2

Amended and Restated Bylaws of the Registrant (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37581), filed with the SEC on June 24, 2020).

10.1*+

Employment Agreement, dated as of June 27, 2022, by and between the Registrant and Gail Cawkwell.

10.2+

Employment Agreement, dated as of August 1, 2022, by and between the Registrant and Douglas Manion (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37581), filed with the SEC on August 1, 2022).

31.1*

Certification of Principal Executive Officer under Section 302 of the Sarbanes-Oxley Act.

31.2*

Certification of Principal Financial Officer under Section 302 of the Sarbanes-Oxley Act.

32.1**

Certifications of Principal Executive Officer and Principal Financial Officer under Section 906 of the Sarbanes-Oxley Act.

101.INS

XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)

101.SCH

Inline XBRL Taxonomy Extension Schema Document

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

36

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

*

Filed herewith.

**

These certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Exchange Act and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

+

Indicates management contract or compensatory plan.

37

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.  

ACLARIS THERAPEUTICS, INC.

Date: August 3, 2022

By:

/s/ Neal Walker

Neal Walker

Chief Executive Officer

(On behalf of the Registrant)

Date: August 3, 2022

By:

/s/ Frank Ruffo

Frank Ruffo

Chief Financial Officer

(Principal Financial Officer)

38

EX-10.1 2 acrs-20220630xex10d1.htm EX-10.1

Exhibit 10.1

EMPLOYMENT AGREEMENT

This EMPLOYMENT AGREEMENT (the “Employment Agreement”), effective as of June 27, 2022 (“Agreement Effective Date”), is made by and between Aclaris Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (“Employer”) and Gail Cawkwell (“Executive”).

WHEREAS, Executive desires to provide services to Employer and Employer desires to retain the services of Executive;

WHEREAS, Employer and Executive desire to formalize the terms and conditions of Executive’s employment with Employer; and

WHEREAS, this Employment Agreement has been duly approved and its execution has been duly authorized by the Employer’s Board of Directors (the “Board”).

NOW, THEREFORE, Employer and Executive hereby agree as follows:

SECTION 1. EMPLOYMENT

1.1General. Employer hereby agrees to employ Executive in the capacity of Chief Medical Officer (“CMO”). Executive hereby accepts such employment upon the terms and subject to the conditions herein contained.

1.2Authority and Duties. Executive shall have full responsibility as the CMO of Employer and all authority normally accorded to such position. Executive agrees to perform such duties and responsibilities commensurate with the position of CMO as may reasonably be determined by the Board.

1.2.1 Reporting. During Executive’s employment with Employer, Executive will report directly to, and take direction from, the Chief Executive Officer (the “CEO”).  

1.2.2 Time to Be Devoted to Employment. During Executive’s Employment with Employer, Executive shall diligently devote her efforts, business time, attention and energies to the business of Employer and will not, while employed by Employer, undertake or engage in any other employment, occupation or business enterprise that would interfere with Executive’s responsibilities and the performance of Executive’s duties hereunder except for (i) reasonable time devoted to volunteer services for or on behalf of such religious, educational, non-profit and/or other charitable organization as Executive may wish to serve, (ii) reasonable time devoted to activities in the non-profit and business communities consistent with Executive’s duties; and (iii) reasonable time devoted to service as a member of the board of directors of the entities listed on Exhibit A or as otherwise permitted pursuant to Section 1.3. This restriction shall not, however, preclude Executive (x) from owning less than one percent (1%) of the total outstanding shares of a publicly traded company, or (y) from employment or service in any capacity with Affiliates of Employer.  As used in this Employment Agreement, “Affiliates” means an entity under common management or control with Employer.

1


1.3Other Responsibilities. Notwithstanding Section 1.2.2 above, Executive will not engage in any other for-profit business, profession or occupation, including as a member of a board of directors of any third party, for compensation which would materially conflict or materially interfere with the rendition of services hereunder, without the prior written consent of the Board, which shall not be unreasonably withheld.  Any uncertainty as to whether such a conflict exists will be raised by Executive for determination by the Board, acting reasonably. The Board acknowledges that Executive has ongoing participation in other private and public businesses that have been disclosed by Executive and are listed on Exhibit A and that such participation does not, in any way, conflict with her role at Employer.  Except for the businesses listed on Exhibit A, which have already been approved, Executive agrees to disclose to the Board and receive prior written consent from the Board to participate as a director, with any competing company whether it is a private or public company. Executive further agrees to disclose any other director positions with any other company that may materially affect her ability to perform her duties and responsibilities under this Employment Agreement.  Notwithstanding the above, nothing herein shall limit or preclude Executive from managing any passive investments made by Executive.

1.4Location of Employment. Executive’s principal place of employment during her employment with Employer shall be Executive’s primary residence (or other remote work location) or such other location as Employer and Executive shall agree; provided however, that from time to time Executive may be required to travel to Employer’s principal executive office currently located in Wayne, Pennsylvania.

SECTION 2. COMPENSATION AND BENEFITS

2.1Salary. Employer will pay to Executive an annual base salary of $480,000 payable subject to standard federal and state payroll withholding requirements in accordance with the regular payroll practices of Employer (“Base Salary”). The annual Base Salary may be increased (but not decreased) during the term of this Employment Agreement by the Board in its sole discretion.

2.2Additional Compensation. In addition to the salary set forth in Section 2.1, Executive shall be entitled to receive a cash bonus in accordance with the terms of this Section 2.2. For each fiscal year of Employer, beginning January 1, during the Employment Term (as defined in Section 2.5 hereof), Executive shall be eligible to receive a cash bonus based on (i) the “Annual Bonus Expectancy Amount,” which shall be an amount equal to 40% of Executive’s Base Salary for the applicable fiscal year, and (ii) Executive’s attainment of performance targets and other reasonable criteria established by the Board, to the extent possible, by the end of the first month of such fiscal year. Depending on the targets and criteria which are achieved or met, the amount of the cash bonus actually payable to Executive for each fiscal year will be an amount from zero to and including the Annual Bonus Expectancy Amount. Any cash bonus amount payable pursuant to this Section 2.2 shall be paid to Executive as soon as practicable, but in no event later than two and one-half (2 1/2) months, following the end of the fiscal year to which it relates. For the avoidance of doubt, Executive does not have to be employed by Employer on the date such bonus is approved or paid by Employer to receive such bonus.

2


2.3Signing Bonus.  Within thirty (30) days of the Agreement Effective Date, Employer will pay Employee a one-time signing bonus in the amount of $25,000 (the “Signing Bonus”), subject to standard federal and state payroll withholding requirements in accordance with the regular payroll practices of Employer. If, within twelve (12) months from the Agreement Effective Date, Executive terminates her employment with the Company without Good Reason or the Company terminates Executive’s employment for Cause, then Executive will promptly repay a percentage of the Signing Bonus equal to the following: 1 – (x / 365), where “x” equals Executive’s total number of days of service as an employee of the Company.

2.4Executive Benefits. In addition to the salary and additional compensation set forth in Sections 2.1 through 2.3, Executive shall also be entitled to the following benefits during Executive’s employment hereunder:

2.4.1 Expenses. Employer will promptly reimburse Executive for expenses she reasonably incurs in connection with the performance of her duties (including business travel and entertainment expenses), in accordance with Employer’s standard expense reimbursement policy, as the same may be modified by Employer from time to time; provided, however, that Executive has provided Employer with documentation of such expenses in accordance with the Employer’s expense reimbursement policies and applicable tax requirements. For the avoidance of doubt, to the extent that any reimbursements payable to Executive are subject to the provisions of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”): (a) any such reimbursements will be paid no later than December 31 of the year following the year in which the expense was incurred, (b) the amount of expenses reimbursed in one year will not affect the amount eligible for reimbursement in any subsequent year, and (c) the right to reimbursement under this Employment Agreement will not be subject to liquidation or exchange for another benefit.

2.4.2 Employer Plans.  Executive will be eligible to participate on the same basis as similarly situated employees in Employer’s employee benefit plans and programs, as they may be interpreted, adopted, revised or deleted from time to time in Employer’s sole discretion, subject to and on a basis consistent with the terms, conditions and overall administration of such plans and programs. All matters of eligibility for coverage or benefits under any benefit plan shall be determined in accordance with the provisions of such plan. Employer retains the unilateral right to amend, modify or terminate any of its employee benefit plans and programs at any time.

2.4.3 Vacation. Executive shall be eligible for paid vacation leave (not including regular holidays) consistent with the needs of the business. Vacation must be scheduled at those times convenient to Employer’s business as reasonably determined by the CEO.

2.4.4 Coverage. Nothing in this Employment Agreement shall prevent Executive from participating in any other compensation plan or benefit plan made available to her by Employer.

2.4.5 Withholding. All compensation shall be subject to withholding of taxes and deductions of other amounts as may be required by law.

3


2.5       Employment Term. Unless earlier terminated pursuant to Section 3.1, Executive’s employment by Employer pursuant to this Employment Agreement shall continue until the second anniversary of the Agreement Effective Date (the “Initial Term”). Thereafter, this Employment Agreement shall be automatically renewed for successive one (1) year periods (any subsequent employment period being referred to herein as the “Renewal Term”, and together with the Initial Term, the “Employment Term”); provided, however, that either party may elect to not renew this Employment Agreement by written notice to such effect delivered to the other party at least ninety (90) days prior to expiration of the Initial Term or the Renewal Term.

SECTION 3. TERMINATION OF EMPLOYMENT

3.1Events of Termination. Executive’s employment with Employer will terminate upon the occurrence of any one or more of the following events:

3.1.1 Death. In the event of Executive’s death, Executive’s employment will terminate on the date of death.

3.1.2 Disability. In the event of Executive’s Disability (as hereinafter defined), Employer will have the option to terminate Executive’s employment by giving a notice of termination to Executive. The notice of termination shall specify the date of termination, which date shall not be earlier than thirty (30) calendar days after the notice of termination is given. For purposes of this Employment Agreement, “Disability” has the meaning set forth in Employer’s long term disability plan.  

3.1.3 Termination by Employer for Cause. Employer may, at its option, terminate Executive’s employment for Cause (as hereinafter defined) by unilateral action of the Board of Directors upon giving a notice of termination to Executive. “Cause” shall mean (i) Executive’s conviction of, or guilty plea to, a felony (other than traffic violations); (ii) any act(s) or omission(s) by Executive which constitutes gross negligence or a material breach of Executive’s duty of loyalty; (iii) any material breach by Executive of Employer’s personnel policies; (iv) refusal to follow or implement a clear and reasonable directive of Employer; (v) breach of fiduciary duty; or (vi) a material violation or breach by Executive of this Employment Agreement (other than an event described in the foregoing clauses) or any other agreement between the parties.

3.1.4 Without Cause By Employer. Employer may, at its option, terminate Executive’s employment for any reason whatsoever (other than for the other reasons set forth above in this Section 3.1 that would constitute “Cause” to terminate) by giving a notice of termination to Executive, and Executive’s employment shall terminate on the later of the date the notice of termination is given or the date set forth in such notice of termination.

3.1.5 By Executive. Executive may, at any time, terminate Executive’s employment for any reason whatsoever by giving a notice of termination to Employer. Executive’s employment shall terminate on the earlier of (i) thirty (30) calendar days after the date of receipt by Employer of the notice of termination or (ii) such earlier date as the Employer and Executive shall agree.

4


3.1.6 Termination Upon Non-Renewal. Either party may terminate this Employment Agreement and Executive’s employment hereunder by providing the other party notice in accordance with Section 2.5 above, in which case this Employment Agreement and Executive’s employment hereunder shall terminate on the last date of the Initial Term or the Renewal Term, as the case may be. For the avoidance of doubt, Executive shall continue to be employed by Employer, on the same terms and conditions as set forth in this Employment Agreement during the ninety (90)-day notice period provided by either party to the other party in accordance with Section 2.5 above, unless, Employer, in its sole discretion determines that it does not want Executive to continue to work for Employer, in any capacity, during such notice period. In such event, Employer shall pay Executive all compensation in accordance with Section 3.2.3.

3.1.7 For Good Reason by Executive. Executive may, at her option, terminate Executive’s employment for “Good Reason” by giving a notice of termination to Employer in the event that, in the absence of events that would support a termination of Executive for Cause:

(i)there is a material failure of Employer (or successor employer) to pay Executive’s salary or additional compensation or benefits hereunder in accordance with this Employment Agreement;
(ii)Executive’s Base Salary is materially decreased without her prior written consent;
(iii)Executive is assigned duties materially inconsistent with her title and the responsibilities set forth in Executive’s job description, without Executive’s prior written consent;
(iv)Executive’s place of employment is changed to a location that is greater than fifty (50) miles from Executive’s current place of employment (disregarding for this purpose any remote work arrangements); or
(v)any other material violation or breach by Employer of this Employment Agreement. Notwithstanding the foregoing, none of the events described in clauses (i) through (iv) above shall constitute Good Reason unless Executive shall have notified Employer in writing describing the event which constitute Good Reason within thirty (30) days after Executive first becomes aware of such event and then only if Employer shall have failed to reasonably cure such events, if curable, within thirty (30) days after Employer’s receipt of such written notice and Executive elects to terminate her employment as a result within thirty (30) days following the end of such thirty (30) day period (assuming, for the avoidance of doubt, that Employer does not elect to cure).

3.2Certain Obligations of Employer Following Termination of Executive’s Employment. Following the termination of Executive’s employment under the circumstances described below, Employer will pay to Executive, subject to standard federal and state payroll withholding requirements and in accordance with its regular payroll practices, the following compensation and provide the following benefits (provided that the continuing payments of

5


Executive’s then-current Base Salary, as described below, shall occur no less frequently than monthly):

3.2.1 Death; Disability; Termination by Employer Without Cause or by Executive for Good Reason. In the event that Executive’s employment is terminated by Employer pursuant to Section 3.1.1 (“Death”), Section 3.1.2 (“Disability”), Section 3.1.4 (“Without Cause by Employer”) or by Executive pursuant to Section 3.1.7 (“Termination by Executive for Good Reason”) hereof, and Executive, or her estate, as the case may be, executes and does not revoke a separation agreement containing a release upon such termination, in a form provided by the Employer, of any and all claims against Employer and all related parties with respect to all matters arising out of Executive’s employment by Employer, or the termination thereof (the “Release”) in accordance with Section 3.7, Executive, or her estate, as the case may be, shall be entitled to the following payments and benefits, which payments and benefits shall be paid in accordance with this Section 3.2.1 and Section 3.7:

(i)Continuing payments of Executive’s then-current Base Salary for the Severance Period (as defined in Section 3.5 herein), payable subject to standard federal and state payroll withholding requirements in accordance with Employer’s regular payroll practices on Employer’s normal payroll schedule over the Severance Period, subject to Section 3.7;
(ii)Employer shall pay to Executive a lump sum payment equal to the gross sum of any bonuses or portion thereof for any preceding year or for the year of termination which have been or are approved by Employer, but has not been received by Executive prior to the effective date of termination, less applicable deductions and withholdings, paid in accordance with Section 2.2 but in no event later than two and one-half (2 1/2) months following the end of the fiscal year to which it relates. For the avoidance of doubt, Executive does not have to be employed by Employer on the date such bonuses are approved by Employer to receive such bonuses;
(iii)So long as Executive is eligible, and so long as Executive remains eligible, for and upon her timely election of coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, or, if applicable, state or local insurance laws (“COBRA”), Employer will continue to pay, directly to the healthcare provider when due, Employer’s portion of the medical, vision and dental coverage premiums (and Executive will be responsible for Executive’s portion) for a period of twelve (12) months after the effective date of Executive’s termination (the “COBRA Payment Period”); provided that, if at any time Employer determines, in its sole discretion, that the payment of the COBRA premiums would result in a violation of the nondiscrimination rules of Section 105(h)(2) of the Code or any statute or regulation of similar effect (including but not limited to the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), then in lieu of providing the COBRA premiums for the remainder of the COBRA Payment Period, Employer will instead pay Executive on the first day of each month of the remainder of the COBRA Payment Period, a fully taxable cash payment equal to the COBRA premiums for that month, subject to applicable tax withholdings, for the remainder of the COBRA Payment Period; and

6


(iv)In the event such termination of employment occurs on or within three (3) months prior to or within twelve (12) months following the effective date of a Change of Control (as defined herein), Executive shall be entitled to the additional following payments and benefits (for the avoidance of doubt, Executive shall also be entitled to the amounts set forth in Section 3.2.1(i)-(iii)):
(1)Employer shall pay to Executive a lump sum payment equal to the Annual Expectancy Bonus Amount (target bonus), less applicable deductions and withholdings, paid within thirty (30) days of the later of (a) the effective date of the Change of Control or (b) Executive’s termination, if such termination occurs on or after the effective date of a Change of Control; and
(2)In the event such termination of employment occurs (A) on or within three (3) months prior to the effective date of a Change of Control, all unvested stock options and other equity awards held by Executive and outstanding on the effective date of termination shall become fully vested on the effective date of the Change of Control, or (B) within twelve (12) months following the effective date of a Change of Control, provided that any surviving corporation or acquiring corporation assumes Executive’s stock options and/or other equity awards, as applicable, or substitutes similar stock options or equity awards for Executive’s stock options and/or equity awards, as applicable, in accordance with the terms of Employer’s applicable equity incentive plans, all such unvested stock options and other equity awards held by Executive and outstanding on the effective date of termination shall become fully vested on the date of such termination.

For purposes of this Employment Agreement, “Change of Control” means, in each case as approved by the Board and the requisite stockholders of Employer, (i) any consolidation or merger of Employer with or into any other corporation or other entity or person, or any other corporate reorganization, in which the stockholders of Employer immediately prior to such consolidation, merger or reorganization, own, in the aggregate, less than 50% of the surviving entity’s voting power and/or outstanding capital stock immediately after such consolidation, merger or reorganization, or any transaction or series of related transactions (including any transaction which results from an option agreement or binding letter of intent with a third party) to which Employer or any of its stockholders is a party in which in excess of 50% of Employer’s voting power and/or outstanding capital stock is transferred, or pursuant to which any person or group of affiliated persons obtains in excess of 50% of Employer’s voting power and/or outstanding capital stock, excluding any consolidation or merger effected exclusively to change the domicile of Employer; or (ii) any sale, license or other disposition (including through a Board and stockholder approved division or spin-off transaction) of all or substantially all of the assets of Employer and/or any of its subsidiaries or any sale, exclusive license or other disposition of all or substantially all of Employer’s intellectual property, as reasonably determined based upon the potential earning power of the assets or intellectual property; provided, however, that none of the following shall constitute a Change of Control: (A) transfers of capital stock by an existing stockholder as a result of death or otherwise for estate planning purposes or to such stockholder’s affiliates or to any of Employer’s other existing stockholders, and (B) issuances of equity securities of Employer in

7


connection with financings for working capital and other general corporate purposes; and, provided further, that such “Change of Control” qualifies as either a change in ownership of Employer as defined in Section 409A of the Code (“Section 409A”) or a change in the ownership of a substantial portion of Employer’s assets as defined in Section 409A, as the case may be.

3.2.2 Termination by Executive Other than For Good Reason; Termination Upon Non-Renewal by Executive; Termination by Employer for Cause. In the event Executive’s employment is terminated by Executive other than for Good Reason pursuant to Section 3.1.5 hereof (“By Executive”) or by Executive pursuant to Section 3.1.6 hereof (“Termination Upon Non-Renewal”) or by Employer pursuant to Section 3.1.3 hereof (“Termination by Employer for Cause”), Executive shall be entitled to no further compensation or other benefits under this Employment Agreement except as to that portion of any unpaid salary and other benefits accrued and earned by her hereunder up to and including the effective date of such termination and to offer COBRA coverage at Executive’s cost pursuant to applicable law.

3.2.3 Termination Upon Non-Renewal by Employer. In the event Executive’s employment is terminated by Employer pursuant to Section 3.1.6 hereof, then during the ninety (90)-day notice period of Section 2.5, Employer shall continue to pay to Executive her then-current Base Salary and benefits subject to standard federal and state payroll withholding requirements and in accordance with Employer’s regular payroll practices, and no later than the effective date of termination of employment, Employer shall pay to Executive any such unpaid salary accrued and earned by her up to and including the effective date of termination. In addition, in the event Executive’s employment is terminated by Employer pursuant to Section 3.1.6 hereof, then provided Executive executes and does not revoke a Release in accordance with Section 3.7, Executive shall be entitled to the following, which payments and benefits shall be paid in accordance with this Section 3.2.3 and Section 3.7:

(i)Continuing payments of Executive’s then-current Base Salary for the Severance Period payable subject to standard federal and state payroll withholding requirements in accordance with Employer’s regular payroll practices on Employer’s normal payroll schedule over the Severance Period, subject to Section 3.7;
(ii)Employer shall pay to Executive a lump sum payment equal to the gross sum of any bonuses or portion thereof for any preceding year or for the year of termination which have been or are approved by Employer, but has not been received by Executive prior to the effective date of termination, less applicable deductions and withholdings, paid in accordance with Section 2.2 but in no event later than two and one-half (2 1/2) months following the end of the fiscal year to which it relates. For the avoidance of doubt, Executive does not have to be employed by Employer on the date such bonuses are approved by Employer to receive such bonuses; and
(iii)So long as Executive is eligible, and so long as Executive remains eligible, for and upon her timely election of coverage under COBRA, Employer will continue to pay, directly to the healthcare provider when due, Employer’s portion of the medical, vision and dental coverage premiums (and Executive will be responsible for Executive’s

8


portion) for the COBRA Payment Period; provided that, if at any time Employer determines, in its sole discretion, that the payment of the COBRA premiums would result in a violation of the nondiscrimination rules of Section 105(h)(2) of the Code or any statute or regulation of similar effect (including but not limited to the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), then in lieu of providing the COBRA premiums for the remainder of the COBRA Payment Period, Employer will instead pay Executive on the first day of each month of the remainder of the COBRA Payment Period, a fully taxable cash payment equal to the COBRA premiums for that month, subject to applicable tax withholdings, for the remainder of the COBRA Payment Period.

3.3Nature of Payments. All amounts to be paid by Employer to Executive pursuant

to Sections 3.2.1(i) — (iv) and 3.2.3(i) — (iii) are considered by the parties to be severance payments and are in lieu of, and not in addition to, any benefits to which Executive may otherwise be entitled under any Employer severance plan, policy or program.

3.4Duties Upon Termination. During the Severance Period, if there is a Severance

Period applicable to Executive’s termination of employment from Employer, Executive shall fully cooperate with Employer in all matters relating to the winding up of Executive’s pending work including, but not limited to, any litigation in which Employer is involved, and the orderly transfer of any such pending work to such other employees as may be designated by Employer. Notwithstanding the foregoing, such cooperation requirement shall not unreasonably interfere with her then current employment or business activities. With Employer’s prior approval, Executive shall be reimbursed for all expenses reasonably incurred in connection with such cooperation. Following the end of the Severance Period, Executive will be released from any duties and obligations hereunder (except those duties and obligations set forth in Article 4 hereof). In the event of termination of Executive’s employment pursuant to Sections 3.1.1 through 3.1.7 hereof, the obligations of Employer to Executive will be as set forth in Section 3.2 hereof. Upon termination, Executive shall immediately resign from her position as CMO of Employer.

3.5Severance Period. “Severance Period” shall mean a period of twelve (12) months beginning on the effective date of Executive’s termination of employment with Employer.

3.6Release. Notwithstanding any provision of this Employment Agreement to the contrary, in no event shall the timing of Executive’s execution of the Release, directly or indirectly, result in Executive designating the calendar year of payment, and if a payment that is subject to the requirements of Section 409A of the Code and is subject to execution of the Release could be made in more than one taxable year based on when the Release is executed or becomes effective, payment shall be made in the later year.

3.7Commencement of Severance Payments. The severance payments and benefits set forth in Sections 3.2.1(i) — (iv) (Termination by Employer for Death, Disability, Without Cause, by Executive for Good Reason) and Sections 3.2.3(i) — (iii) (Termination Upon Non-Renewal by Employer) above will not be paid or provided unless Executive executes and does not revoke the Release and the Release is enforceable and effective as provided in the Release on or before the date that is the sixtieth (60th) day following the effective date of termination (such

9


60th day, the “Severance Pay Commencement Date”). No cash severance payments will be paid pursuant to Sections 3.2.1 or 3.2.3 prior to the Severance Pay Commencement Date. On the Severance Pay Commencement Date, Employer will pay in a lump sum the aggregate amount of the cash severance payments that Employer would have paid Executive through such date had the payments commenced on the effective date of termination through the Severance Pay Commencement Date, with the balance paid thereafter on the applicable schedules described above. Notwithstanding any other provision of this Employment Agreement to the contrary, it is intended that the payment of severance upon termination for Good Reason by Executive in accordance with Section 3.1.7 satisfy the safe harbor set forth in Treasury Regulation Section 1.409A-1(n)(2)(ii)), and any severance payment made pursuant to this Employment Agreement shall satisfy the exemptions from the application of Section 409A of the Code provided under Treasury Regulation Sections 1.409A-1(b)(4), and 1.409A-1 (b)(9).

SECTION 4.CONFIDENTIALITY, INVENTION RIGHTS, NON-COMPETITION AND NON-SOLICITATION

4.1Confidentiality, Invention Rights, Non-Competition and Non-Solicitation. The parties hereto have entered into a Confidentiality, Invention Rights, Non-Competition, and Non-Solicitation Agreement, which may be amended by the parties from time to time without regard to this Employment Agreement. The Confidentiality, Invention Rights, Non-Competition, and Non-Solicitation Agreement contains provisions that are intended by the parties to survive and do survive termination of this Employment Agreement.

4.2Remedies. Executive acknowledges and agrees that (a) Employer will be irreparably injured in the event of a breach by Executive of any of her obligations under this Article 4; (b) monetary damages will not be an adequate remedy for any such breach; and (c) in the event of any such breach, the Employer will be entitled to injunctive relief, in addition to any other remedy which it may have, and Executive shall not oppose such injunctive relief based upon the extent of the harm or the adequacy of monetary damages.

SECTION 5. MISCELLANEOUS PROVISIONS

5.1Severability. If in any jurisdiction any term or provision hereof is determined to be invalid or unenforceable, (a) the remaining terms and provisions hereof shall be unimpaired, (b) any such invalidity or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction, and (c) the invalid or unenforceable term or provision shall, for purposes of such jurisdiction, be deemed replaced by a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision.

5.2Execution in Counterparts. This Employment Agreement may be executed in one or more counterparts, and by the different parties hereto in separate counterparts, each of which shall be deemed to be an original but all of which taken together shall constitute one and the same agreement (and all signatures need not appear on any one counterpart), and this Employment Agreement shall become effective when one or more counterparts has been signed by each of the parties hereto and delivered to each of the other parties hereto.  Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying

10


with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes.

5.3Notices. All notices, requests, demands and other communications hereunder shall be in writing and shall be deemed duly given when delivered by hand, or when delivered if mailed by registered or certified mail, postage prepaid, return receipt requested, or private courier service or via facsimile (with written confirmation of receipt) or email (with written confirmation of receipt) as follows:

If to Employer, to:

Aclaris Therapeutics, Inc.

640 Lee Road, Suite 200

Wayne, PA 19087

Attention: Neal Walker

E-mail: nwalker@aclaristx.com

If to Executive, to the current address on file with Employer,

or to such other address(es) as a party hereto shall have designated by like notice to the other parties hereto.

5.4Amendment.  No provision of this Employment Agreement may be modified, amended, waived or discharged in any manner except by a written instrument executed by Employer and Executive.

5.5Entire Agreement. This Employment Agreement constitutes the entire agreement of the parties hereto with respect to the subject matter hereof, and supersedes all prior agreements and understandings of the parties hereto, oral or written, with respect to the subject matter hereof, including but not limited to any prior offer letter or written embodiment of the employment relationship between Executive and Employer. No representation, promise or inducement has been made by either party that is not embodied in this Employment Agreement, and neither party shall be bound by or liable for any alleged representation, promise or inducement not so set forth.

5.6Applicable Law. This Employment Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania applicable to contracts made and to be wholly performed therein without regard to its conflicts or choice of law provisions.

5.7Headings. The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the meaning or interpretation of any of the terms or provisions of this Employment Agreement.

5.8Binding Effect; Successors and Assigns. Executive may not delegate her duties or assign her rights hereunder. This Employment Agreement will inure to the benefit of, and be

11


binding upon, the parties hereto and their respective heirs, legal representatives, and successors. Employer may assign this Employment Agreement to any entity purchasing all or substantially all of the assets of Employer.

5.9Waiver, etc. The failure of either of the parties hereto to at any time enforce any of the provisions of this Employment Agreement shall not be deemed or construed to be a waiver of any such provision, nor to in any way affect the validity of this Employment Agreement or any provision hereof or the right of either of the parties hereto to thereafter enforce each and every provision of this Employment Agreement. No waiver of any breach of any of the provisions of this Employment Agreement shall be effective unless set forth in a written instrument executed by the party against whom or which enforcement of such waiver is sought, and no waiver of any such breach shall be construed or deemed to be a waiver of any other or subsequent breach.

5.10 Continuing Effect. Provisions of this Employment Agreement which by their terms must survive the termination of this Employment Agreement in order to effectuate the intent of the parties will survive any such termination, whether by expiration of the term, termination of Executive’s employment, or otherwise, for such period as may be appropriate under the circumstances.

5.11Representations and Warranties of Executive. Executive hereby represents and warrants to Employer that to the knowledge of Executive, Executive is not bound by any non-competition or other agreement which would prevent her performance hereunder.

5.12 Section 409A of the Code. This Employment Agreement is intended to comply with Section 409A of the Code and its corresponding regulations, or an exemption, and payments may only be made under this Employment Agreement upon an event and in a manner permitted by Section 409A of the Code, to the extent applicable. Payment under this Employment Agreement is intended to be exempt from Code Section 409A under the “short-term deferral” exception set forth in Treasury Regulation Section 1.409A-1(b)(4), to the maximum extent applicable, and then under the “separation pay” exception set forth in Treasury Regulation Section 1.409A-1(b)(9), to the maximum extent applicable. All payments to be made upon a termination of employment under this Employment Agreement may only be made upon a “separation from service” within the meaning of Treasury Regulation Section 1.409A-1(h) (or any successor provision) (a “Separation from Service”). For purposes of Code Section 409A, the right to a series of installment payments under this Employment Agreement shall be treated as a right to a series of separate payments. In no event may the Executive, directly or indirectly, designate the calendar year of a payment. If the termination of employment giving rise to the payments described in Section 3.2.1 is not a Separation from Service, then the amounts otherwise payable pursuant to Section 3.2.1 will instead be deferred without interest and paid when Executive experiences a Separation from Service. Notwithstanding anything in this Employment Agreement to the contrary or otherwise, with respect to any expense, reimbursement or in-kind benefit provided pursuant to this Employment Agreement that constitutes a “deferral of compensation” within the meaning of Section 409A of the Code and its implementing regulations and guidance, (a) the expenses eligible for reimbursement or in-kind benefits provided to Executive must be incurred during the Employment Term (or applicable

12


survival period), (b) the amount of expenses eligible for reimbursement or in-kind benefits provided to Executive during any calendar year will not affect the amount of expenses eligible for reimbursement or in-kind benefits provided to Executive in any other calendar year, (c) the reimbursements for expenses for which Executive is entitled to be reimbursed shall be made on or before the last day of the calendar year following the calendar year in which the applicable expense is incurred and (d) the right to payment or reimbursement or in-kind benefits hereunder may not be liquidated or exchanged for any other benefit. Notwithstanding any provision to the contrary in this Employment Agreement, if Executive is deemed by Employer at the time of her Separation from Service to be a “specified employee” for purposes of Section 409A(a)(2)(B)(i) of the Code, and if any of the payments due upon Separation from Service set forth herein and/or under any other agreement with Employer are deemed to be “deferred compensation,” then to the extent delayed commencement of any portion of such payments is required to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code and the related adverse taxation under Section 409A of the Code, such payments will not be provided to Executive prior to the earliest of (i) the expiration of the six (6)-month period measured from the date of Executive’s Separation from Service with Employer, (ii) the date of Executive’s death or (iii) such earlier date as permitted under Section 409A of the Code without the imposition of adverse taxation. Upon the first business day following the expiration of such applicable Code Section 409A(a)(2)(B)(i) period, all payments deferred pursuant to this Section 5.12 will be paid in a lump sum to Executive, and any remaining payments due will be paid as otherwise provided in this Employment Agreement or in the applicable agreement. No interest will be due on any amounts so deferred.

5.13Section 280G. Notwithstanding any other provision of this Employment Agreement or any other plan, arrangement or agreement to the contrary, if any of the payments or benefits provided or to be provided by Employer or its affiliates to Executive or for Executive’s benefit pursuant to the terms of this Employment Agreement or otherwise (the “Covered Payments”) constitute parachute payments (the “Parachute Payments”) within the meaning of Section 280G of the Code and, but for this Section 5.13, would be subject to the excise tax imposed under Section 4999 of the Code (or any successor provision thereto) or any similar tax imposed by state or local law or any interest or penalties with respect to such taxes (collectively, the “Excise Tax”), then prior to making the Covered Payments, a calculation shall be made comparing (i) the Net Benefit (as defined below) to Executive of the Covered Payments after payment of the Excise Tax to (ii) the Net Benefit to Executive if the Covered Payments are limited to the extent necessary to avoid being subject to the Excise Tax. Only if the amount calculated under clause (i) above is less than the amount under clause (ii) above will the Covered Payments be reduced to the minimum extent necessary to ensure that no portion of the Covered Payments is subject to the Excise Tax. “Net Benefit” shall mean the present value of the Covered Payments net of all federal, state, local, foreign income, employment and excise taxes.

(a)Any such reduction shall be made in accordance with Section 409A and the following:

13


(i)the Covered Payments consisting of cash severance benefits that do not constitute nonqualified deferred compensation subject to Section 409A shall be reduced first, in reverse chronological order; and
(ii)all other Covered Payments consisting of cash payments, and Covered Payments consisting of accelerated vesting of equity based awards to which Treas. Reg. §1.280G-1 Q/A-24(c) does not apply, and that in either case do not constitute nonqualified deferred compensation subject to Section 409A, shall be reduced second, in reverse chronological order; and
(iii)all Covered Payments consisting of cash payments that constitute nonqualified deferred compensation subject to Section 409A shall be reduced third, in reverse chronological order; and
(iv)all Covered Payments consisting of accelerated vesting of equity-based awards to which Treas. Reg. § 1.280G-1 Q/A-24(c) applies shall be the last Covered Payments to be reduced.
(b)Any determination required under this Section 5.13 shall be made in writing in good faith by an independent accounting firm selected by Employer and reasonably acceptable to the Executive (the “Accountants”). Employer and Executive shall provide the Accountants with such information and documents as the Accountants may reasonably request in order to make a determination under this Section 5.13. For purposes of making the calculations and determinations required by this Section 5.13, the Accountants may rely on reasonable, good-faith assumptions and approximations concerning the application of Section 280G and Section 4999 of the Code. The Accountants’ determinations shall be final and binding on Employer and Executive. Employer shall be responsible for all fees and expenses incurred by the Accountants in connection with the calculations required by this Section 5.13.
(c)It is possible that after the determinations and selections made pursuant to this Section 5.13. Executive will receive Covered Payments that are in the aggregate more than the amount intended or required to be provided after application of this Section 5.13 (“Overpayment”) or less than the amount intended or required to be provided after application of this Section 5.13 (“Underpayment”).
(i)In the event that: (A) the Accountants determine, based upon the assertion of a deficiency by the Internal Revenue Service against either Employer or Executive that the Accountants believe has a high probability of success, that an Overpayment has been made or (B) it is established pursuant to a final determination of a court or an Internal Revenue Service proceeding that has been finally and conclusively resolved that an Overpayment has been made, then Executive shall pay any such Overpayment to Employer together with interest at the applicable federal rate (as defined in Section 7872(f)(2)(A) of the Code) from the date of Executive’s receipt of the Overpayment until the date of repayment.

14


(ii)In the event that: (A) the Accountants, based upon controlling precedent or substantial authority, determine that an Underpayment has occurred or (B) a court of competent jurisdiction determines that an Underpayment has occurred, any such Underpayment will be paid promptly by Employer to or for the benefit of Executive together with interest at the applicable federal rate (as defined in Section 7872(f)(2)(A) of the Code) from the date the amount should have otherwise been paid to Executive until the payment date.

5.14 Dispute Resolution. The parties recognize that litigation in federal or state courts or before federal or state administrative agencies of disputes arising out of the Executive’s employment with the Employer or out of this Employment Agreement, or the Executive’s termination of employment or termination of this Employment Agreement, may not be in the best interests of either the Executive or Employer, and may result in unnecessary costs, delays, complexities, and uncertainty. The parties agree that any dispute between the parties arising out of or relating to the negotiation, execution, performance or termination of this Employment Agreement or the Executive’s employment, including, but not limited to, any claim arising out of this Employment Agreement, claims under Title VII of the Civil Rights Act of 1964, as amended, the Civil Rights Act of 1991, the Age Discrimination in Employment Act of 1967, the Americans with Disabilities Act of 1990, Section 1981 of the Civil Rights Act of 1966, as amended, the Family Medical Leave Act, the Executive Retirement Income Security Act, and any similar federal, state or local law, statute, regulation, or any common law doctrine, whether that dispute arises during or after employment, shall be settled by binding arbitration in accordance with the National Rules for the Resolution of Employment Disputes of the American Arbitration Association; provided however, that this dispute resolution provision shall not apply to any separate agreements between the parties that do not themselves specify arbitration as an exclusive remedy. The location for the arbitration shall be the Philadelphia, Pennsylvania metropolitan area. Any award made by such panel shall be final, binding and conclusive on the parties for all purposes, and judgment upon the award rendered by the arbitrators may be entered in any court having jurisdiction thereof. The arbitrators’ fees and expenses and all administrative fees and expenses associated with the filing of the arbitration shall be borne by Employer. The parties acknowledge and agree that their obligations to arbitrate under this Section survive the termination of this Employment Agreement and continue after the termination of the employment relationship between Executive and Employer. The parties each further agree that the arbitration provisions of this Employment Agreement shall provide each party with its exclusive remedy, and each party expressly waives any right it might have to seek redress in any other forum, except as otherwise expressly provided in this Employment Agreement. By election arbitration as the means for final settlement of all claims, the parties hereby waive their respective rights to, and agree not to, sue each other in any action in a Federal, State or local court with respect to such claims, but may seek to enforce in court an arbitration award rendered pursuant to this Employment Agreement. The parties specifically agree to waive their respective rights to a trial by jury, and further agree that no demand, request or motion will be made for trial by jury.

[SIGNATURE PAGE FOLLOWS]

15


Background image

Graphic

IN WITNESS WHEREOF the parties have executed this Employment Agreement as of the date first above written.

ACLARIS THERAPEUTICS, INC.


/s/ Neal Walker​ ​​ ​
Name:Neal Walker​ ​
TitlePresident & CEO​ ​

Agreed to and Accepted this 2 day of June , 2022.

EXECUTIVE


/s/ Gail Cawkwell​ ​​ ​
Gail Cawkwell

16


Exhibit A

List of Entities Referenced in Section 1.2.2.

None.

17


EX-31.1 3 acrs-20220630xex31d1.htm EX-31.1

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Neal Walker, certify that:

1.

I have reviewed this Quarterly Report on Form 10-Q for the period ended June 30, 2022 of Aclaris Therapeutics, Inc. (the “registrant”);

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 3, 2022

/s/ Neal Walker

Neal Walker

Chief Executive Officer

(principal executive officer)


EX-31.2 4 acrs-20220630xex31d2.htm EX-31.2

Exhibit 31.2

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Frank Ruffo, certify that:

1.

I have reviewed this Quarterly Report on Form 10-Q for the period ended June 30, 2022 of Aclaris Therapeutics, Inc. (the “registrant”);

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 3, 2022

/s/ Frank Ruffo

Frank Ruffo

Chief Financial Officer

(principal financial officer)


EX-32.1 5 acrs-20220630xex32d1.htm EX-32.1

Exhibit 32.1

CERTIFICATIONS OF

PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Neal Walker, Chief Executive Officer of Aclaris Therapeutics, Inc. (the “Company”), and Frank Ruffo, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:

1.

The Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2022, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

2.

The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 3rd day of August, 2022.

/s/ Neal Walker

/s/ Frank Ruffo

Neal Walker

Frank Ruffo

Chief Executive Officer
(principal executive officer)

Chief Financial Officer
(principal financial officer)

*

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Aclaris Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.


GRAPHIC 6 acrs-20220630xex10d1002.jpg GRAPHIC begin 644 acrs-20220630xex10d1002.jpg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end GRAPHIC 7 acrs-20220630xex10d1001.jpg GRAPHIC begin 644 acrs-20220630xex10d1001.jpg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end EX-101.SCH 8 acrs-20220630.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Fair Value of Financial Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Fair Value of Financial Assets and Liabilities - By Type (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Intangible Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - Intangible Assets - Future Amortization Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 41401 - Disclosure - Discontinued Operations - Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Organization and Nature of Business link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Fair Value of Financial Assets and Liabilities link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Property and Equipment, Net link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Stock-Based Awards link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Net Loss per Share link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Agreements Related to Intellectual Property link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 11401 - Disclosure - Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 11501 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 11601 - Disclosure - Legal Proceedings link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Property and Equipment, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Stock-Based Awards (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Net Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 31503 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Organization and Nature of Business (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Debt (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - Stockholders' Equity - Other Offerings and ATM Facility (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Stock-Based Awards (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - Stock-Based Awards - Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 40903 - Disclosure - Stock-Based Awards - RSUs (Details) link:presentationLink link:calculationLink link:definitionLink 40904 - Disclosure - Stock-Based Awards - Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Net Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 41002 - Disclosure - Net Loss per Share - Anti-dilution (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Agreements Related to Intellectual Property (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 41501 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 41601 - Disclosure - Legal Proceedings (Details) link:presentationLink link:calculationLink link:definitionLink 31403 - Disclosure - Discontinued Operations (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 acrs-20220630_cal.xml EX-101.CAL EX-101.DEF 10 acrs-20220630_def.xml EX-101.DEF EX-101.LAB 11 acrs-20220630_lab.xml EX-101.LAB EX-101.PRE 12 acrs-20220630_pre.xml EX-101.PRE XML 13 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Document and Entity Information - shares
6 Months Ended
Jun. 30, 2022
Jul. 29, 2022
Document and Entity Information    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2022  
Document Transition Report false  
Entity File Number 001-37581  
Entity Registrant Name Aclaris Therapeutics, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 46-0571712  
Entity Address, Address Line One 640 Lee Road, Suite 200  
Entity Address, City or Town Wayne  
Entity Address, State or Province PA  
Entity Address, Postal Zip Code 19087  
City Area Code 484  
Local Phone Number 324-7933  
Title of 12(b) Security Common Stock, $0.00001 par value  
Trading Symbol ACRS  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   66,671,750
Entity Central Index Key 0001557746  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q2  
Amendment Flag false  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.22.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 68,264 $ 27,349
Short-term marketable securities 180,339 164,065
Accounts receivable, net 637 623
Prepaid expenses and other current assets 10,114 12,995
Total current assets 259,354 205,032
Marketable securities 7,221 34,242
Property and equipment, net 1,276 1,335
Intangible assets 7,011 7,048
Other assets 3,114 3,554
Total assets 277,976 251,211
Current liabilities:    
Accounts payable 5,703 9,985
Accrued expenses 7,571 10,051
Current portion of lease liabilities 741 693
Discontinued operations 2,202 2,202
Total current liabilities 16,217 22,931
Other liabilities 1,840 2,172
Contingent consideration 23,800 28,400
Deferred tax liability 367 367
Total liabilities 42,224 53,870
Commitments and contingencies (Note 16)
Stockholders' Equity:    
Preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued or outstanding at June 30, 2022 and December 31, 2021
Common stock, $0.00001 par value; 100,000,000 shares authorized at June 30, 2022 and December 31, 2021; 66,667,580 and 61,228,446 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively 1 1
Additional paid-in capital 871,805 792,971
Accumulated other comprehensive loss (1,326) (224)
Accumulated deficit (634,728) (595,407)
Total stockholders' equity 235,752 197,341
Total liabilities and stockholders' equity $ 277,976 $ 251,211
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.22.2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Jun. 30, 2022
Dec. 31, 2021
CONDENSED CONSOLIDATED BALANCE SHEETS    
Preferred stock, par value (in dollars per share) $ 0.00001 $ 0.00001
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value (in dollars per share) $ 0.00001 $ 0.00001
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 66,667,580 61,228,446
Common stock, shares outstanding 66,667,580 61,228,446
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.22.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Revenues:        
Total revenue $ 1,528 $ 1,824 $ 2,981 $ 3,601
Costs and expenses:        
Cost of revenue 1,068 1,263 2,223 2,465
Research and development 18,779 7,897 33,085 15,735
General and administrative 6,075 5,870 12,174 10,697
Revaluation of contingent consideration (3,400) 4,800 (4,600) 21,239
Total costs and expenses 22,522 19,830 42,882 50,136
Loss from operations (20,994) (18,006) (39,901) (46,535)
Other income (expense), net 462 (155) 580 (380)
Net loss $ (20,532) $ (18,161) $ (39,321) $ (46,915)
Net loss per share, basic $ (0.31) $ (0.34) $ (0.62) $ (0.90)
Net loss per share, diluted $ (0.31) $ (0.34) $ (0.62) $ (0.90)
Weighted average common shares outstanding, basic 65,990,031 53,968,405 63,723,123 52,163,136
Weighted average common shares outstanding, diluted 65,990,031 53,968,405 63,723,123 52,163,136
Other comprehensive loss:        
Unrealized loss on marketable securities, net of tax of $0 $ (354) $ 25 $ (1,101) $ (10)
Foreign currency translation adjustment   (69)   (80)
Total other comprehensive loss (354) (44) (1,101) (90)
Comprehensive loss (20,886) (18,205) (40,422) (47,005)
Contract research        
Revenues:        
Total revenue 1,218 1,606 2,439 3,141
Other revenue        
Revenues:        
Total revenue $ 310 $ 218 $ 542 $ 460
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.22.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS        
Unrealized loss on marketable securities, tax $ 0 $ 0 $ 0 $ 0
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.22.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Common Stock
Public Offering
Common Stock
At The Market Offering
Common Stock
Additional Paid-in Capital
Public Offering
Additional Paid-in Capital
At The Market Offering
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Public Offering
At The Market Offering
Total
Balance at beginning of period at Dec. 31, 2020           $ 542,286 $ (94) $ (504,542)     $ 37,650
Balance at beginning of period (in shares) at Dec. 31, 2020     45,109,314                
Increase (Decrease) in Stockholders' Equity                      
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units           (2,579)         (2,579)
Issuance of common stock in connection with exercise of stock options and warrants and vesting of restricted stock units (in shares)     666,144                
Issuance of common stock, net of offering costs       $ 103,348         $ 103,348    
Issuance of common stock, net of offering costs (in shares) 6,306,271                    
Unrealized gain / loss on marketable securities             (35)       (35)
Foreign currency translation adjustment             (11)       (11)
Stock-based compensation expense           2,675         2,675
Net loss               (28,754)     (28,754)
Balance at end of period at Mar. 31, 2021           645,730 (140) (533,296)     112,294
Balance at end of period (in shares) at Mar. 31, 2021     52,081,729                
Balance at beginning of period at Dec. 31, 2020           542,286 (94) (504,542)     37,650
Balance at beginning of period (in shares) at Dec. 31, 2020     45,109,314                
Increase (Decrease) in Stockholders' Equity                      
Net loss                     (46,915)
Balance at end of period at Jun. 30, 2021     $ 1     785,455 (184) (551,457)     233,815
Balance at end of period (in shares) at Jun. 30, 2021     61,204,987                
Balance at beginning of period at Mar. 31, 2021           645,730 (140) (533,296)     112,294
Balance at beginning of period (in shares) at Mar. 31, 2021     52,081,729                
Increase (Decrease) in Stockholders' Equity                      
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units           1,041         1,041
Issuance of common stock in connection with exercise of stock options and warrants and vesting of restricted stock units (in shares)     1,024,666                
Issuance of common stock, net of offering costs $ 1     $ 134,851         $ 134,852    
Issuance of common stock, net of offering costs (in shares) 8,098,592                    
Unrealized gain / loss on marketable securities             25       25
Foreign currency translation adjustment             (69)       (69)
Stock-based compensation expense           3,833         3,833
Net loss               (18,161)     (18,161)
Balance at end of period at Jun. 30, 2021     $ 1     785,455 (184) (551,457)     233,815
Balance at end of period (in shares) at Jun. 30, 2021     61,204,987                
Balance at beginning of period at Dec. 31, 2021     $ 1     792,971 (224) (595,407)     $ 197,341
Balance at beginning of period (in shares) at Dec. 31, 2021     61,228,446               61,228,446
Increase (Decrease) in Stockholders' Equity                      
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units           49         $ 49
Issuance of common stock in connection with exercise of stock options and warrants and vesting of restricted stock units (in shares)     509,037                
Unrealized gain / loss on marketable securities             (748)       (748)
Stock-based compensation expense           2,346         2,346
Net loss               (18,789)     (18,789)
Balance at end of period at Mar. 31, 2022     $ 1     795,366 (972) (614,196)     180,199
Balance at end of period (in shares) at Mar. 31, 2022     61,737,483                
Balance at beginning of period at Dec. 31, 2021     $ 1     792,971 (224) (595,407)     $ 197,341
Balance at beginning of period (in shares) at Dec. 31, 2021     61,228,446               61,228,446
Increase (Decrease) in Stockholders' Equity                      
Net loss                     $ (39,321)
Balance at end of period at Jun. 30, 2022     $ 1     871,805 (1,326) (634,728)     $ 235,752
Balance at end of period (in shares) at Jun. 30, 2022     66,667,580               66,667,580
Balance at beginning of period at Mar. 31, 2022     $ 1     795,366 (972) (614,196)     $ 180,199
Balance at beginning of period (in shares) at Mar. 31, 2022     61,737,483                
Increase (Decrease) in Stockholders' Equity                      
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units           88         88
Issuance of common stock in connection with exercise of stock options and warrants and vesting of restricted stock units (in shares)     91,388                
Issuance of common stock, net of offering costs         $ 72,659         $ 72,659  
Issuance of common stock, net of offering costs (in shares)   4,838,709                  
Unrealized gain / loss on marketable securities             (354)       (354)
Stock-based compensation expense           3,692         3,692
Net loss               (20,532)     (20,532)
Balance at end of period at Jun. 30, 2022     $ 1     $ 871,805 $ (1,326) $ (634,728)     $ 235,752
Balance at end of period (in shares) at Jun. 30, 2022     66,667,580               66,667,580
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.22.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) - USD ($)
$ in Thousands
3 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Mar. 31, 2021
Public Offering      
Offering costs netted against proceeds   $ 8,899 $ 7,011
At The Market Offering      
Offering costs netted against proceeds $ 2,341    
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.22.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Cash flows from operating activities:    
Net loss $ (39,321) $ (46,915)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 414 535
Stock-based compensation expense 6,038 6,507
Revaluation of contingent consideration (4,600) 21,239
Changes in operating assets and liabilities:    
Accounts receivable (14) (167)
Prepaid expenses and other assets 1,309 (5,223)
Accounts payable (4,283) (1,290)
Accrued expenses (178) 861
Net cash used in operating activities (40,635) (24,453)
Cash flows from investing activities:    
Purchases of property and equipment (350) (52)
Purchases of marketable securities (85,096) (147,289)
Proceeds from sales and maturities of marketable securities 94,155 26,557
Net cash provided by (used in) investing activities 8,709 (120,784)
Cash flows from financing activities:    
Payments of employee withholding taxes related to restricted stock unit award vesting (23) (3,038)
Proceeds from exercise of employee stock options and the issuance of stock 120 1,459
Net cash provided by financing activities 72,841 236,621
Net increase in cash and cash equivalents 40,915 91,384
Cash and cash equivalents at beginning of period 27,349 22,063
Cash and cash equivalents at end of period 68,264 113,447
Supplemental disclosure of non-cash investing and financing activities:    
Additions to property and equipment included in accounts payable 72 37
Offering costs included in accounts payable   28
Public Offering    
Cash flows from financing activities:    
Proceeds from issuance of common stock, net of issuance costs   $ 238,200
At The Market Offering    
Cash flows from financing activities:    
Proceeds from issuance of common stock, net of issuance costs $ 72,744  
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.22.2
Organization and Nature of Business
6 Months Ended
Jun. 30, 2022
Organization and Nature of Business  
Organization and Nature of Business

1. Organization and Nature of Business

Overview

Aclaris Therapeutics, Inc. was incorporated under the laws of the State of Delaware in 2012. In 2015,  Aclaris Therapeutics International Limited (“ATIL”) was established under the laws of the United Kingdom as a wholly-owned subsidiary of Aclaris Therapeutics, Inc. In 2017, Confluence Life Sciences, Inc. (now known as Aclaris Life Sciences, Inc.) (“Confluence”) was acquired by Aclaris Therapeutics, Inc. and became a wholly-owned subsidiary thereof.  Aclaris Therapeutics, Inc., ATIL and Confluence are referred to collectively as the “Company.”  The Company is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases.  In addition to developing its novel drug candidates, the Company is pursuing strategic alternatives, including identifying and consummating transactions with third-party partners, to further develop, obtain marketing approval for and/or commercialize its novel drug candidates.  

Liquidity

The Company’s condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities in the ordinary course of business.  As of June 30, 2022, the Company had cash, cash equivalents and marketable securities of $255.8 million and an accumulated deficit of $634.7 million.  Since inception, the Company has incurred net losses and negative cash flows from its operations.  Prior to the acquisition of Confluence, the Company had never generated revenue.  There can be no assurance that profitable operations will ever be achieved, and, if achieved, will be sustained on a continuing basis. In addition, development activities, including clinical and preclinical testing of the Company’s drug candidates, will require significant additional financing.  The future viability of the Company is dependent on its ability to successfully develop its drug candidates and to generate revenue from identifying and consummating transactions with third-party partners to further develop, obtain marketing approval for and/or commercialize its development assets or to raise additional capital to finance its operations.  The Company will require additional capital to complete the clinical development of zunsemetinib (ATI-450), ATI-1777 and ATI-2138, to develop its preclinical compounds, and to support its discovery efforts.  

Additional funds may not be available on a timely basis, on commercially acceptable terms, or at all, and such funds, if raised, may not be sufficient to enable the Company to continue to implement its long-term business strategy.  The Company’s ability to raise additional capital may be adversely impacted by the potential worsening of global economic conditions, including inflationary pressure, and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the COVID-19 pandemic and geopolitical tensions.  If the Company is unable to raise sufficient additional capital or generate revenue from transactions with potential third-party partners for the development and/or commercialization of its drug candidates, it may need to substantially curtail planned operations. The Company’s failure to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies.  

The Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that its condensed consolidated financial statements are issued.  As of the report date, the Company does not believe that substantial doubt exists about its ability to continue as a going concern.  The Company believes its existing cash, cash equivalents and marketable securities are sufficient to fund its operating and capital expenditure requirements for a period greater than 12 months from the date of issuance of these condensed consolidated financial statements.

XML 22 R10.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies
6 Months Ended
Jun. 30, 2022
Summary of Significant Accounting Policies  
Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Unaudited Interim Financial Information

The accompanying condensed consolidated balance sheet as of June 30, 2022, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2022 and 2021, the condensed consolidated statement of stockholders’ equity for the three and six months ended June 30, 2022 and 2021, and the condensed consolidated statements of cash flows for the six months ended June 30, 2022 and 2021 are unaudited.  The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual financial statements contained in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 24, 2022 and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company’s financial position as of June 30, 2022, the results of its operations and comprehensive loss for the three and six months ended June 30, 2022 and 2021, its changes in stockholders’ equity for the three and six months ended June 30, 2022 and 2021 and its cash flows for the six months ended June 30, 2022 and 2021.  The condensed consolidated balance sheet data as of December 31, 2021 was derived from audited financial statements but does not include all disclosures required by generally accepted accounting principles in the United States (“GAAP”).  The financial data and other information disclosed in these notes related to the three and six months ended June 30, 2022 and 2021 are unaudited. The results for the three and six months ended June 30, 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2022, any other interim periods, or any future year or period.  The unaudited interim financial statements of the Company included herein have been prepared, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K filed with the SEC on February 24, 2022.  

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in conformity with GAAP.  The condensed consolidated financial statements of the Company include the accounts of the operating parent company, Aclaris Therapeutics, Inc., and its wholly-owned subsidiaries, ATIL and Confluence.  All intercompany transactions have been eliminated.  Based upon the Company’s revenue, the Company believes that gross profit does not provide a meaningful measure of profitability and, therefore, has not included a line item for gross profit on the condensed consolidated statement of operations.  

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods.  Significant estimates and assumptions reflected in these financial statements include, but are not limited to, contingent consideration and the valuation of stock-based awards.  Estimates are periodically reviewed in light of changes in circumstances, facts and experience.  As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require an update to its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities.  Actual results could differ from the Company’s estimates.

Significant Accounting Policies

The Company’s significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K filed with the SEC on February 24, 2022.  Except as set forth below, there have been no changes to the Company’s significant accounting policies from those disclosed in the annual report.

Contingent Consideration

The Company initially recorded a contingent consideration liability at fair value on the date of acquisition related to future potential payments resulting from the acquisition of Confluence based upon significant unobservable inputs including the achievement of development, regulatory and commercial milestones, as well as estimated future sales levels and the discount rates applied to calculate the present value of the potential payments. Significant judgement was involved in determining the appropriateness of these assumptions.  These assumptions are considered Level 3 inputs.  Revaluation of the contingent consideration liability can result from changes to one or more of these assumptions.  The Company evaluates the fair value estimate of the contingent consideration liability on a quarterly basis with changes, if any, recorded as income or expense in the condensed consolidated statement of operations.

The fair value of contingent consideration is estimated using a probability-weighted expected payment model for regulatory milestone payments and a Monte Carlo simulation model for commercial milestone and royalty payments and then applying a risk-adjusted discount rate to calculate the present value of the potential payments.  Significant assumptions used in the Company’s estimates include the probability of achieving regulatory milestones and commencing commercialization, which are based on an asset’s current stage of development and a review of existing clinical data. Probability of success assumptions ranged between 10% and 40% at June 30, 2022.  Additionally, estimated future sales levels and the risk-adjusted discount rate applied to the potential payments are also significant assumptions used in calculating the fair value.  The discount rate ranged between 10.2% and 10.9% depending on the year of each potential payment.

XML 23 R11.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value of Financial Assets and Liabilities
6 Months Ended
Jun. 30, 2022
Fair Value of Financial Assets and Liabilities  
Fair Value of Financial Assets and Liabilities

3. Fair Value of Financial Assets and Liabilities

The following tables present information about the fair value measurements of the Company’s financial assets and liabilities which are measured at fair value on a recurring and non-recurring basis, and indicate the level of the fair value hierarchy utilized to determine such fair values:

June 30, 2022

(In thousands)

    

Level 1

    

Level 2

    

Level 3

    

Total

Assets:

    

    

    

    

    

    

    

    

Cash equivalents

$

63,838

$

$

$

63,838

Marketable securities

 

187,560

187,560

Total assets

$

63,838

$

187,560

$

$

251,398

Liabilities:

Contingent consideration

$

$

$

23,800

$

23,800

Total liabilities

$

$

$

23,800

$

23,800

December 31, 2021

(In thousands)

    

Level 1

    

Level 2

    

Level 3

    

Total

Assets:

    

    

    

    

    

    

    

    

Cash equivalents

$

21,678

$

$

$

21,678

Marketable securities

 

198,307

198,307

Total assets

$

21,678

$

198,307

$

$

219,985

Liabilities:

Contingent consideration

$

$

$

28,400

$

28,400

Total liabilities

$

$

$

28,400

$

28,400

As of June 30, 2022 and December 31, 2021, the Company’s cash equivalents consisted of a money market fund, which was valued based upon Level 1 inputs.  The Company’s marketable securities as of June 30, 2022 and December

31, 2021 consisted of commercial paper and corporate, asset-backed and U.S. government agency debt securities, which were all valued based upon Level 2 inputs.  Marketable securities as of December 31, 2021 also included foreign government agency debt securities which were all valued based upon Level 2 inputs.

In determining the fair value of its Level 2 investments, the Company relies on quoted prices for identical securities in markets that are not active. These quoted prices are obtained by the Company with the assistance of a third-party pricing service based on available trade, bid and other observable market data for identical securities.  The Company compares the quoted prices obtained from the third-party pricing service to other available independent pricing information to validate the reasonableness of the quoted prices provided.  The Company evaluates whether adjustments to third-party pricing are necessary and, historically, the Company has not made adjustments to quoted prices obtained from the third-party pricing service.  During the three and six months ended June 30, 2022 and 2021, there were no transfers into or out of Level 3.

A decrease in the fair value of the contingent consideration liability of $4.6 million during the six months ended June 30, 2022 was mainly due to higher discount rates, resulting from higher risk-free rates and wider credit spreads, being applied to potential payments relative to prior periods.  The overall decrease was partially offset by an increase in the contingent consideration liability as a result of the impact of the passage of time.

As of June 30, 2022 and December 31, 2021, the fair value of the Company’s available-for-sale marketable securities by type of security was as follows:

June 30, 2022

Gross

Gross

Amortized

Unrealized

Unrealized

Fair

(In thousands)

Cost

Gain

Loss

Value

Marketable securities:

Corporate debt securities

$

47,201

$

$

(398)

$

46,803

Commercial paper

56,053

56,053

Asset-backed debt securities(1)

28,423

(175)

28,248

U.S. government agency debt securities

57,211

(755)

56,456

Total marketable securities

$

188,888

$

$

(1,328)

$

187,560

(1) Included in Asset-backed debt securities is $7.2 million with maturity dates between one and five years.

December 31, 2021

Gross

Gross

Amortized

Unrealized

Unrealized

Fair

(In thousands)

Cost

Gain

Loss

Value

Marketable securities:

Corporate debt securities(1)

$

40,993

$

6

$

(50)

$

40,949

Commercial paper

71,837

71,837

Asset-backed debt securities

36,166

(43)

36,123

Foreign government agency debt securities

4,073

(13)

4,060

U.S. government agency debt securities(2)

45,465

(127)

45,338

Total marketable securities

$

198,534

$

6

$

(233)

$

198,307

(1) Included in Corporate debt securities is $9.2 million with maturity dates between one and five years.

(2) Included in US government agency debt securities is $25.0 million with maturity dates between one and five years.

XML 24 R12.htm IDEA: XBRL DOCUMENT v3.22.2
Property and Equipment, Net
6 Months Ended
Jun. 30, 2022
Property and Equipment, Net  
Property and Equipment, Net

4. Property and Equipment, Net

Property and equipment, net consisted of the following:

June 30, 

December 31, 

(In thousands)

2022

2021

Computer equipment

    

$

1,355

    

$

1,380

Lab equipment

1,879

1,605

Furniture and fixtures

620

620

Leasehold improvements

1,123

1,123

Property and equipment, gross

 

4,977

 

4,728

Accumulated depreciation

 

(3,701)

 

(3,393)

Property and equipment, net

$

1,276

$

1,335

Depreciation expense was $0.2 million for each of the three months ended June 30, 2022 and 2021, and $0.4 million for each of the six months ended June 30, 2022 and 2021.

XML 25 R13.htm IDEA: XBRL DOCUMENT v3.22.2
Intangible Assets
6 Months Ended
Jun. 30, 2022
Intangible Assets  
Intangible Assets

5. Intangible Assets

Intangible assets consisted of the following:

Gross Cost

Accumulated Amortization

Remaining

June 30, 

December 31, 

June 30, 

December 31, 

(In thousands, except years)

   

Life (years)

   

2022

   

2021

   

2022

   

2021

Other intangible assets

5.1

$

751

$

751

$

369

$

332

In-process research and development

n/a

6,629

6,629

Total intangible assets

$

7,380

$

7,380

$

369

$

332

Amortization expense was $19 thousand for each of the three months ended June 30, 2022 and 2021, and $38 thousand for each of the six months ended June 30, 2022 and 2021.

As of June 30, 2022, estimated future amortization expense was as follows:

Year Ending

(In thousands)

    

December 31,

2022

$

37

2023

 

75

2024

 

75

2025

75

2026

75

Thereafter

45

Total

$

382

XML 26 R14.htm IDEA: XBRL DOCUMENT v3.22.2
Accrued Expenses
6 Months Ended
Jun. 30, 2022
Accrued Expenses  
Accrued Expenses

6. Accrued Expenses

Accrued expenses consisted of the following:

June 30, 

December 31, 

(In thousands)

    

2022

    

2021

Employee compensation expenses

$

2,885

$

4,389

Research and development expenses

2,771

1,278

Litigation settlements (see Note 16)

2,650

Other

 

1,915

 

1,734

Total accrued expenses

$

7,571

$

10,051

XML 27 R15.htm IDEA: XBRL DOCUMENT v3.22.2
Debt
6 Months Ended
Jun. 30, 2022
Debt  
Debt

7. Debt

Loan and Security Agreement – Silicon Valley Bank

In March 2020, the Company entered into a Loan and Security Agreement with Silicon Valley Bank (“SVB”).  The Loan and Security Agreement provided for $11.0 million in term loans, of which the Company borrowed the entire amount on March 30, 2020.  In connection with the Loan and Security Agreement, the Company issued to SVB a warrant to purchase up to 460,251 shares of common stock (the “Warrant”) (see Note 8).  The proceeds of the Loan and Security Agreement were allocated to the term loan and Warrant using a relative fair value approach.  

In July 2021, the Company repaid in full the $11.0 million that was outstanding under the Loan and Security Agreement, together with all accrued and unpaid interest and fees as of the payoff date, for a total payment of $11.7 million.

XML 28 R16.htm IDEA: XBRL DOCUMENT v3.22.2
Stockholders' Equity
6 Months Ended
Jun. 30, 2022
Stockholders' Equity  
Stockholders' Equity

8. Stockholders’ Equity

Preferred Stock

As of June 30, 2022 and December 31, 2021, the Company’s amended and restated certificate of incorporation authorized the Company to issue 10,000,000 shares of undesignated preferred stock.  There were no shares of preferred stock outstanding as of June 30, 2022 or December 31, 2021.

Common Stock

As of June 30, 2022 and December 31, 2021, the Company’s amended and restated certificate of incorporation authorized the Company to issue 100,000,000 shares of $0.00001 par value common stock. There were 66,667,580 and 61,228,446 shares of common stock issued and outstanding as of June 30, 2022 and December 31, 2021, respectively.

Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any, subject to any preferential dividend rights of any series of preferred stock that may be outstanding.  No dividends have been declared through June 30, 2022.  

Warrants

The Warrant issued to SVB in March 2020 had an initial exercise price of $0.956 per share, subject to adjustment as provided in the Warrant.  The Warrant became immediately exercisable in full upon the funding of the term loan facility.  The Company assigned a fair value of $0.4 million to the Warrant using a Black-Scholes valuation methodology, and also concluded that the Warrant was indexed to its own stock and therefore classified the Warrant as an equity instrument.  In January 2021, SVB net exercised the Warrant in full, and the Company issued 388,119 shares of common stock to SVB.  

January 2021 Public Offering

In January 2021, the Company closed a public offering in which it sold 6,306,271 shares of common stock at a price to the public of $17.50 per share, for aggregate gross proceeds of $110.4 million. The Company paid underwriting discounts and commissions of $6.6 million, and also incurred expenses of $0.4 million in connection with the offering.  As a result, the net offering proceeds received by the Company, after deducting underwriting discounts, commissions and offering expenses, were $103.3 million.

June 2021 Public Offering

In June 2021, the Company closed a public offering in which it sold 8,098,592 shares of common stock at a price to the public of $17.75 per share, for aggregate gross proceeds of $143.8 million. The Company paid underwriting discounts and commissions of $8.6 million, and also incurred expenses of $0.3 million in connection with the offering.  As a result, the net offering proceeds received by the Company, after deducting underwriting discounts, commissions and offering expenses, were $134.9 million.

Sales of Common Stock Pursuant to At-The-Market Facility

In April 2022, the Company sold 4,838,709 shares of its common stock at a weighted average price per share of $15.50, for aggregate gross proceeds of $75.0 million, pursuant to a sales agreement with SVB Securities LLC and Cantor Fitzgerald & Co., as sales agents, dated May 20, 2021.  The Company paid selling commissions and other fees of $2.2 million in connection with the sale.

XML 29 R17.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-Based Awards
6 Months Ended
Jun. 30, 2022
Stock-Based Awards  
Stock-Based Awards

9. Stock-Based Awards

2015 Equity Incentive Plan

In September 2015, the Company’s board of directors adopted the 2015 Equity Incentive Plan (the “2015 Plan”), and the Company’s stockholders approved the 2015 Plan. The 2015 Plan became effective in connection with the Company’s initial public offering in October 2015.  Beginning at the time the 2015 Plan became effective, no further grants may be made under the Company’s 2012 Equity Compensation Plan, as amended and restated (the “2012 Plan”).  The 2015 Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock unit (“RSU”) awards, performance stock awards, cash-based awards and other stock-based awards. The number of shares initially reserved for issuance under the 2015 Plan was 1,643,872 shares of common stock. The number of shares of common stock that may be issued under the 2015 Plan will automatically increase on January 1 of each year ending on January 1, 2025, in an amount equal to the lesser of (i) 4.0% of the shares of the Company’s common stock outstanding on December 31st of the preceding calendar year or (ii) an amount determined by the Company’s board of directors. The shares of common stock underlying any awards that expire, are otherwise terminated, settled in cash or repurchased by the Company under the 2015 Plan and the 2012 Plan will be added back to the shares of common stock available for issuance under the 2015 Plan.  As of January 1, 2022, the number of shares of common stock that may be issued under the 2015 Plan was automatically increased by 2,449,137 shares.  As of June 30, 2022, 3,372,766 shares remained available for grant under the 2015 Plan.  The Company had 4,130,376 stock options and 1,454,934 RSUs outstanding as of June 30, 2022 under the 2015 Plan.

2017 Inducement Plan

In July 2017, the Company’s board of directors adopted the 2017 Inducement Plan (the “2017 Inducement Plan”).  The 2017 Inducement Plan is a non-stockholder approved stock plan adopted pursuant to the “inducement exception” provided under Nasdaq listing rules.  The Company had 410,600 stock options and 2,375 RSUs outstanding as of June 30, 2022 under the 2017 Inducement Plan.  All shares of common stock that were eligible for issuance under the 2017 Inducement Plan after October 1, 2018, including any shares underlying any awards that expire or are otherwise terminated, reacquired to satisfy tax withholding obligations, settled in cash or repurchased by the Company in the future that would have been eligible for re-issuance under the 2017 Inducement Plan, were retired.  

2012 Equity Compensation Plan

Upon the 2015 Plan becoming effective, no further grants can be made under the 2012 Plan.  The Company granted stock options to purchase a total of 1,140,524 shares under the 2012 Plan, of which 473,977 were outstanding as of June 30, 2022.  Stock options granted under the 2012 Plan expire after ten years.  

Stock Option Valuation

The weighted average assumptions the Company used to estimate the fair value of stock options granted during the six months ended June 30, 2022 and 2021 were as follows:

    

Six Months Ended

June 30, 

2022

2021

Risk-free interest rate

 

1.90

%

0.91

%

Expected term (in years)

 

6.2

6.2

Expected volatility

 

77.95

%

76.60

%

Expected dividend yield

 

0

%

0

%

The Company recognizes compensation expense for awards over their vesting period.  Compensation expense for awards includes the impact of forfeitures in the period when they occur.  

Stock Options

The following table summarizes stock option activity for the six months ended June 30, 2022:

    

    

    

Weighted

    

Weighted

Average

Average

Remaining

Aggregate

Number

Exercise

Contractual

Intrinsic

(In thousands, except share and per share data and years)

of Shares

Price

Term

Value

(in years)

Outstanding as of December 31, 2021

 

3,792,450

$

17.50

 

6.8

$

13,710

Granted

 

1,891,950

14.40

Exercised

 

(85,672)

1.40

1,115

Forfeited and cancelled

 

(583,775)

15.70

Outstanding as of June 30, 2022

 

5,014,953

$

16.81

 

7.1

$

10,817

Options vested and expected to vest as of June 30, 2022

 

5,014,953

$

16.81

 

7.1

$

10,817

Options exercisable as of June 30, 2022

 

2,519,499

$

18.26

 

4.8

$

7,784

The weighted average grant date fair value of stock options granted during the six months ended June 30, 2022 was $9.89 per share.

Restricted Stock Units

The following table summarizes RSU activity for the six months ended June 30, 2022:

Weighted

Average

Grant Date

Aggregate

Number

Fair Value

Intrinsic

(In thousands, except share and per share data)

of Shares

Per Share

Value

Outstanding as of December 31, 2021

1,496,946

$

12.75

Granted

720,134

14.44

Vested

(513,958)

11.55

$

7,645

Forfeited and cancelled

(245,813)

12.17

Outstanding as of June 30, 2022

1,457,309

$

14.11

Stock-Based Compensation

Stock-based compensation expense included in total costs and expenses on the condensed consolidated statement of operations included the following:

Three Months Ended

Six Months Ended

June 30, 

June 30, 

(In thousands)

    

2022

    

2021

    

2022

    

2021

Cost of revenue

    

$

302

    

$

335

  

$

530

    

$

582

Research and development

941

1,154

828

2,030

General and administrative

 

2,449

 

2,343

 

4,680

 

3,895

Total stock-based compensation expense

$

3,692

$

3,832

$

6,038

$

6,507

As of June 30, 2022, the Company had unrecognized stock-based compensation expense for stock options and RSUs of $23.7 million and $18.3 million, respectively, which is expected to be recognized over weighted average periods of 3.2 years and 3.0 years, respectively.  

XML 30 R18.htm IDEA: XBRL DOCUMENT v3.22.2
Net Loss per Share
6 Months Ended
Jun. 30, 2022
Net Loss per Share  
Net Loss per Share

10. Net Loss per Share

Basic and diluted net loss per share is summarized in the following table:

Three Months Ended

Six Months Ended

June 30, 

June 30, 

(In thousands, except for share and per share data)

2022

2021

    

2022

    

2021

Numerator:

    

    

    

    

    

    

    

Net loss

$

(20,532)

$

(18,161)

$

(39,321)

$

(46,915)

Denominator:

Weighted average shares of common stock outstanding, basic and diluted

 

65,990,031

 

53,968,405

 

63,723,123

 

52,163,136

Net loss per share, basic and diluted

$

(0.31)

$

(0.34)

$

(0.62)

$

(0.90)

The Company’s potentially dilutive securities, which included stock options and RSUs, have been excluded from the computation of diluted net loss per share since the effect would be to reduce the net loss per share. Therefore, the weighted average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share is the same.  The following table presents potential shares of common stock excluded from the calculation of diluted

net loss per share for the three and six months ended June 30, 2022 and 2021.  All share amounts presented in the table below represent the total number outstanding as of June 30, 2022 and 2021.

June 30, 

2022

2021

Options to purchase common stock

5,014,953

3,738,625

Restricted stock unit awards

1,457,309

1,498,716

Total potential shares of common stock

6,472,262

5,237,341

XML 31 R19.htm IDEA: XBRL DOCUMENT v3.22.2
Leases
6 Months Ended
Jun. 30, 2022
Leases  
Leases

11. Leases

Operating Leases

Agreements for Office and Laboratory Space

The Company has a sublease agreement pursuant to which it subleases 33,019 square feet of office space for its headquarters in Wayne, Pennsylvania.  The sublease has a term that runs through October 2023.  If for any reason the lease between the landlord and sublandlord is terminated or expires prior to October 2023, the Company’s sublease will automatically terminate.  In December 2020, the Company entered into a sub-sublease agreement under which it sub-subleased 8,115 square feet to a third party.  The sub-sublease term runs concurrently with the original sublease agreement.

In February 2019, the Company entered into a sublease agreement with a third party for 20,433 square feet of office and laboratory space in St. Louis, Missouri.  The lease commenced in June 2019 and has a term that runs through June 2029.

Supplemental balance sheet information related to operating leases is as follows:  

June 30, 

December 31,

(In thousands)

2022

2021

Operating Leases:

Gross cost

$

5,240

$

5,240

Accumulated amortization

(2,173)

(1,803)

Other assets

$

3,067

$

3,437

Current portion of lease liabilities

$

741

$

693

Other liabilities

1,820

2,151

Total operating lease liabilities

$

2,561

$

2,844

Amortization expense related to operating lease right-of-use assets and accretion of operating lease liabilities totaled $0.3 million for each of the three months ended June 30, 2022 and 2021 and $0.5 million for each of the six months ended June 30, 2022 and 2021.

XML 32 R20.htm IDEA: XBRL DOCUMENT v3.22.2
Agreements Related to Intellectual Property
6 Months Ended
Jun. 30, 2022
Agreements Related to Intellectual Property  
Agreements Related to Intellectual Property

12. Agreements Related to Intellectual Property

Asset Purchase Agreement – EPI Health, LLC

In October 2019, the Company sold RHOFADE (oxymetazoline hydrochloride) cream, 1% (“RHOFADE”) to EPI Health, LLC (“EPI Health”) pursuant to an asset purchase agreement.  EPI Health agreed to pay the Company a high single-digit royalty calculated as a percentage of net sales on a country-by-country basis until the date that the patent rights related to RHOFADE have expired or, if later, ten years from the date of the first commercial sale of RHOFADE in such country.  The Company recorded royalty income under the asset purchase agreement of $0.3 million and $0.2 million

during the three months ended June 30, 2022 and 2021, respectively, and $0.5 million and $0.4 million during the six months ended June 30, 2022 and 2021, respectively.  Royalty income is included in other revenue on the condensed consolidated statements of operations and comprehensive loss.  EPI Health has also agreed to pay the Company potential sales milestone payments of up to $20.0 million in the aggregate upon the achievement of specified levels of net sales of products covered by the asset purchase agreement, and 25% of any upfront, license, milestone, maintenance or fixed payment received by EPI Health in connection with any license or sublicense of the assets transferred in the disposition in any territory outside of the United States, subject to specified exceptions.  

Agreement and Plan of Merger – Confluence

The Company entered into an Agreement and Plan of Merger, pursuant to which it acquired Confluence (the “Confluence Agreement”).  Under the Confluence Agreement, the Company has agreed to pay the former Confluence equity holders aggregate remaining contingent consideration of up to $75.0 million based upon the achievement of specified future regulatory and commercial milestones set forth in the Confluence Agreement.  In addition, the Company has agreed to pay the former Confluence equity holders future royalty payments calculated as a low single-digit percentage of annual net sales, subject to specified reductions, limitations and other adjustments, until the date that all of the patent rights for that product have expired, as determined on a country-by-country and product-by-product basis or, in specified circumstances, ten years from the first commercial sale of such product.  In addition to the payments described above, if the Company sells, licenses or transfers any of the intellectual property acquired from Confluence pursuant to the Confluence Agreement to a third party, the Company will be obligated to pay the former Confluence equity holders a portion of any consideration received from such sale, license or transfer in specified circumstances.

As of June 30, 2022 and December 31, 2021, the balance of the Company’s contingent consideration liability was $23.8 million and $28.4 million, respectively (see Note 3).

XML 33 R21.htm IDEA: XBRL DOCUMENT v3.22.2
Income Taxes
6 Months Ended
Jun. 30, 2022
Income Taxes  
Income Taxes

13. Income Taxes

The Company did not record a federal or state income tax benefit for losses incurred during the three and six months ended June 30, 2022 and 2021.  The Company concluded that it is more likely than not that its deferred tax assets will not be realized which resulted in recording a full valuation allowance during those periods.

XML 34 R22.htm IDEA: XBRL DOCUMENT v3.22.2
Discontinued Operations
6 Months Ended
Jun. 30, 2022
Discontinued Operations.  
Discontinued Operations

14. Discontinued Operations

The following table presents information related to liabilities reported as discontinued operations in the Company’s condensed consolidated balance sheet:  

June 30, 

December 31,

(In thousands)

    

2022

    

2021

Accrued expenses

  

$

2,202

$

2,202

Discontinued operations - current liabilities

$

2,202

$

2,202

 

XML 35 R23.htm IDEA: XBRL DOCUMENT v3.22.2
Segment Information
6 Months Ended
Jun. 30, 2022
Segment Information  
Segment Information

15. Segment Information

The Company has two reportable segments, therapeutics and contract research.  The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.  The contract research segment earns revenue from the provision of laboratory services.  Contract research revenue is generally evidenced by contracts with clients which are on an agreed upon fixed-price, fee-for-service basis.  Corporate and other includes general and administrative expenses as well as eliminations of intercompany transactions.  The Company does not report balance sheet information by segment since it is not reviewed by the chief operating decision maker, and all of the Company’s tangible assets are held in the United States.  

The Company’s results of operations by segment for the three and six months ended June 30, 2022 and 2021 are summarized in the tables below:

(In thousands)

Contract

Corporate

Total

Three Months Ended June 30, 2022

Therapeutics

Research

and Other

Company

Total revenue

$

309

$

4,399

$

(3,180)

$

1,528

Cost of revenue

4,041

(2,973)

1,068

Research and development

18,986

(207)

18,779

General and administrative

854

5,221

6,075

Revaluation of contingent consideration

(3,400)

(3,400)

Loss from operations

$

(15,277)

$

(496)

$

(5,221)

$

(20,994)

(In thousands)

Contract

Corporate

Total

Three Months Ended June 30, 2021

Therapeutics

Research

and Other

Company

Total revenue

$

218

$

3,481

$

(1,875)

$

1,824

Cost of revenue

3,024

(1,761)

1,263

Research and development

8,011

(114)

7,897

Sales and marketing

General and administrative

879

4,991

5,870

Revaluation of contingent consideration

4,800

4,800

Loss from operations

$

(12,593)

$

(422)

$

(4,991)

$

(18,006)

(In thousands)

Contract

Corporate

Total

Six Months Ended June 30, 2022

Therapeutics

Research

and Other

Company

Total revenue

$

541

$

8,495

$

(6,055)

$

2,981

Cost of revenue

7,897

(5,674)

2,223

Research and development

33,466

(381)

33,085

General and administrative

1,695

10,479

12,174

Revaluation of contingent consideration

(4,600)

(4,600)

Loss from operations

$

(28,325)

$

(1,097)

$

(10,479)

$

(39,901)

(In thousands)

Contract

Corporate

Total

Six Months Ended June 30, 2021

Therapeutics

Research

and Other

Company

Total revenue

$

460

$

6,681

$

(3,540)

$

3,601

Cost of revenue

5,793

(3,328)

2,465

Research and development

15,946

(211)

15,735

General and administrative

1,507

9,190

10,697

Revaluation of contingent consideration

21,239

21,239

Loss from operations

$

(36,725)

$

(619)

$

(9,191)

$

(46,535)

Intersegment Revenue

Revenue for the contract research segment included $3.2 million and $1.9 million for services performed on behalf of the therapeutics segment for the three months ended June 30, 2022 and 2021, respectively, and $6.1 million and $3.5 million for the six months ended June 30, 2022 and 2021, respectively.  All intersegment revenue has been eliminated in the Company’s condensed consolidated statement of operations.  

XML 36 R24.htm IDEA: XBRL DOCUMENT v3.22.2
Legal Proceedings
6 Months Ended
Jun. 30, 2022
Legal Proceedings  
Legal Proceedings

16. Legal Proceedings

Securities Class Action

On July 30, 2019, plaintiff Linda Rosi (“Rosi”) filed a putative class action complaint captioned Rosi v. Aclaris Therapeutics, Inc., et al. in the U.S. District Court for the Southern District of New York against the Company and certain of its executive officers.  The complaint alleged that the defendants violated federal securities laws by, among other things, failing to disclose an alleged likelihood that regulators would scrutinize advertising materials related to ESKATA (hydrogen peroxide) topical solution, 40% (w/w) (“ESKATA”) and find that the materials minimized the risks or overstated the efficacy of the product.  The complaint sought unspecified compensatory damages on behalf of Rosi and all

other persons and entities that purchased or otherwise acquired the Company’s securities between May 8, 2018 and June 20, 2019. 

On September 5, 2019, an additional plaintiff, Robert Fulcher (“Fulcher”), filed a substantially identical putative class action complaint captioned Fulcher v. Aclaris Therapeutics, Inc., et al. in the same court against the same defendants.

On November 6, 2019, the court consolidated the Rosi and Fulcher actions (together, the “Consolidated Securities Action”) and appointed Fulcher “lead plaintiff” for the putative class. 

On January 24, 2020, Fulcher filed a consolidated amended complaint in the Consolidated Securities Action, naming two additional executive officers as defendants, extending the putative class period to August 12, 2019, and adding allegations concerning, among other things, alleged statements and omissions throughout the putative class period concerning ESKATA’s risks, tolerability and effectiveness. The defendants filed a motion to dismiss the consolidated amended complaint on April 17, 2020. Following briefing and oral argument on February 25, 2021, the motion was granted in part and denied in part on March 29, 2021, and the issues in dispute significantly narrowed. The defendants filed an answer to the remaining aspects of the consolidated amended complaint on April 19, 2021.

In June 2021, the defendants and the plaintiffs agreed to settle the Consolidated Securities Action. The parties signed and filed a settlement agreement in July 2021. On August 18, 2021, the court preliminarily approved the proposed settlement, directed that notice be given to the putative class and scheduled the final approval settlement hearing for November 30, 2021. Notice was subsequently given to the putative class. The court granted final approval of the settlement on December 9, 2021.

The Company’s financial obligation under the settlement was $2.7 million, which was within the limits of its insurance coverage.

XML 37 R25.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies (Policies)
6 Months Ended
Jun. 30, 2022
Summary of Significant Accounting Policies  
Unaudited Interim Financial Information

Unaudited Interim Financial Information

The accompanying condensed consolidated balance sheet as of June 30, 2022, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2022 and 2021, the condensed consolidated statement of stockholders’ equity for the three and six months ended June 30, 2022 and 2021, and the condensed consolidated statements of cash flows for the six months ended June 30, 2022 and 2021 are unaudited.  The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual financial statements contained in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 24, 2022 and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company’s financial position as of June 30, 2022, the results of its operations and comprehensive loss for the three and six months ended June 30, 2022 and 2021, its changes in stockholders’ equity for the three and six months ended June 30, 2022 and 2021 and its cash flows for the six months ended June 30, 2022 and 2021.  The condensed consolidated balance sheet data as of December 31, 2021 was derived from audited financial statements but does not include all disclosures required by generally accepted accounting principles in the United States (“GAAP”).  The financial data and other information disclosed in these notes related to the three and six months ended June 30, 2022 and 2021 are unaudited. The results for the three and six months ended June 30, 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2022, any other interim periods, or any future year or period.  The unaudited interim financial statements of the Company included herein have been prepared, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K filed with the SEC on February 24, 2022.  

Basis of Presentation

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in conformity with GAAP.  The condensed consolidated financial statements of the Company include the accounts of the operating parent company, Aclaris Therapeutics, Inc., and its wholly-owned subsidiaries, ATIL and Confluence.  All intercompany transactions have been eliminated.  Based upon the Company’s revenue, the Company believes that gross profit does not provide a meaningful measure of profitability and, therefore, has not included a line item for gross profit on the condensed consolidated statement of operations.  

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods.  Significant estimates and assumptions reflected in these financial statements include, but are not limited to, contingent consideration and the valuation of stock-based awards.  Estimates are periodically reviewed in light of changes in circumstances, facts and experience.  As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require an update to its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities.  Actual results could differ from the Company’s estimates.

Significant Accounting Policies

Significant Accounting Policies

The Company’s significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K filed with the SEC on February 24, 2022.  Except as set forth below, there have been no changes to the Company’s significant accounting policies from those disclosed in the annual report.

Contingent Consideration

Contingent Consideration

The Company initially recorded a contingent consideration liability at fair value on the date of acquisition related to future potential payments resulting from the acquisition of Confluence based upon significant unobservable inputs including the achievement of development, regulatory and commercial milestones, as well as estimated future sales levels and the discount rates applied to calculate the present value of the potential payments. Significant judgement was involved in determining the appropriateness of these assumptions.  These assumptions are considered Level 3 inputs.  Revaluation of the contingent consideration liability can result from changes to one or more of these assumptions.  The Company evaluates the fair value estimate of the contingent consideration liability on a quarterly basis with changes, if any, recorded as income or expense in the condensed consolidated statement of operations.

The fair value of contingent consideration is estimated using a probability-weighted expected payment model for regulatory milestone payments and a Monte Carlo simulation model for commercial milestone and royalty payments and then applying a risk-adjusted discount rate to calculate the present value of the potential payments.  Significant assumptions used in the Company’s estimates include the probability of achieving regulatory milestones and commencing commercialization, which are based on an asset’s current stage of development and a review of existing clinical data. Probability of success assumptions ranged between 10% and 40% at June 30, 2022.  Additionally, estimated future sales levels and the risk-adjusted discount rate applied to the potential payments are also significant assumptions used in calculating the fair value.  The discount rate ranged between 10.2% and 10.9% depending on the year of each potential payment.

XML 38 R26.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value of Financial Assets and Liabilities (Tables)
6 Months Ended
Jun. 30, 2022
Fair Value of Financial Assets and Liabilities  
Schedule of assets and liabilities measured at fair value on a recurring basis

June 30, 2022

(In thousands)

    

Level 1

    

Level 2

    

Level 3

    

Total

Assets:

    

    

    

    

    

    

    

    

Cash equivalents

$

63,838

$

$

$

63,838

Marketable securities

 

187,560

187,560

Total assets

$

63,838

$

187,560

$

$

251,398

Liabilities:

Contingent consideration

$

$

$

23,800

$

23,800

Total liabilities

$

$

$

23,800

$

23,800

December 31, 2021

(In thousands)

    

Level 1

    

Level 2

    

Level 3

    

Total

Assets:

    

    

    

    

    

    

    

    

Cash equivalents

$

21,678

$

$

$

21,678

Marketable securities

 

198,307

198,307

Total assets

$

21,678

$

198,307

$

$

219,985

Liabilities:

Contingent consideration

$

$

$

28,400

$

28,400

Total liabilities

$

$

$

28,400

$

28,400

Schedule of the fair value of available for sale marketable securities

June 30, 2022

Gross

Gross

Amortized

Unrealized

Unrealized

Fair

(In thousands)

Cost

Gain

Loss

Value

Marketable securities:

Corporate debt securities

$

47,201

$

$

(398)

$

46,803

Commercial paper

56,053

56,053

Asset-backed debt securities(1)

28,423

(175)

28,248

U.S. government agency debt securities

57,211

(755)

56,456

Total marketable securities

$

188,888

$

$

(1,328)

$

187,560

(1) Included in Asset-backed debt securities is $7.2 million with maturity dates between one and five years.

December 31, 2021

Gross

Gross

Amortized

Unrealized

Unrealized

Fair

(In thousands)

Cost

Gain

Loss

Value

Marketable securities:

Corporate debt securities(1)

$

40,993

$

6

$

(50)

$

40,949

Commercial paper

71,837

71,837

Asset-backed debt securities

36,166

(43)

36,123

Foreign government agency debt securities

4,073

(13)

4,060

U.S. government agency debt securities(2)

45,465

(127)

45,338

Total marketable securities

$

198,534

$

6

$

(233)

$

198,307

(1) Included in Corporate debt securities is $9.2 million with maturity dates between one and five years.

(2) Included in US government agency debt securities is $25.0 million with maturity dates between one and five years.

XML 39 R27.htm IDEA: XBRL DOCUMENT v3.22.2
Property and Equipment, Net (Tables)
6 Months Ended
Jun. 30, 2022
Property and Equipment, Net  
Schedule of property and equipment, net

June 30, 

December 31, 

(In thousands)

2022

2021

Computer equipment

    

$

1,355

    

$

1,380

Lab equipment

1,879

1,605

Furniture and fixtures

620

620

Leasehold improvements

1,123

1,123

Property and equipment, gross

 

4,977

 

4,728

Accumulated depreciation

 

(3,701)

 

(3,393)

Property and equipment, net

$

1,276

$

1,335

XML 40 R28.htm IDEA: XBRL DOCUMENT v3.22.2
Intangible Assets (Tables)
6 Months Ended
Jun. 30, 2022
Intangible Assets  
Schedule of intangible assets

Gross Cost

Accumulated Amortization

Remaining

June 30, 

December 31, 

June 30, 

December 31, 

(In thousands, except years)

   

Life (years)

   

2022

   

2021

   

2022

   

2021

Other intangible assets

5.1

$

751

$

751

$

369

$

332

In-process research and development

n/a

6,629

6,629

Total intangible assets

$

7,380

$

7,380

$

369

$

332

Schedule of estimated future amortization expenses

Year Ending

(In thousands)

    

December 31,

2022

$

37

2023

 

75

2024

 

75

2025

75

2026

75

Thereafter

45

Total

$

382

XML 41 R29.htm IDEA: XBRL DOCUMENT v3.22.2
Accrued Expenses (Tables)
6 Months Ended
Jun. 30, 2022
Accrued Expenses  
Schedule of accrued expenses

June 30, 

December 31, 

(In thousands)

    

2022

    

2021

Employee compensation expenses

$

2,885

$

4,389

Research and development expenses

2,771

1,278

Litigation settlements (see Note 16)

2,650

Other

 

1,915

 

1,734

Total accrued expenses

$

7,571

$

10,051

XML 42 R30.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-Based Awards (Tables)
6 Months Ended
Jun. 30, 2022
Stock-Based Awards  
Assumptions used to determine fair value of stock options granted

    

Six Months Ended

June 30, 

2022

2021

Risk-free interest rate

 

1.90

%

0.91

%

Expected term (in years)

 

6.2

6.2

Expected volatility

 

77.95

%

76.60

%

Expected dividend yield

 

0

%

0

%

Summary of stock option activity

    

    

    

Weighted

    

Weighted

Average

Average

Remaining

Aggregate

Number

Exercise

Contractual

Intrinsic

(In thousands, except share and per share data and years)

of Shares

Price

Term

Value

(in years)

Outstanding as of December 31, 2021

 

3,792,450

$

17.50

 

6.8

$

13,710

Granted

 

1,891,950

14.40

Exercised

 

(85,672)

1.40

1,115

Forfeited and cancelled

 

(583,775)

15.70

Outstanding as of June 30, 2022

 

5,014,953

$

16.81

 

7.1

$

10,817

Options vested and expected to vest as of June 30, 2022

 

5,014,953

$

16.81

 

7.1

$

10,817

Options exercisable as of June 30, 2022

 

2,519,499

$

18.26

 

4.8

$

7,784

Summary of restricted stock units activity

Weighted

Average

Grant Date

Aggregate

Number

Fair Value

Intrinsic

(In thousands, except share and per share data)

of Shares

Per Share

Value

Outstanding as of December 31, 2021

1,496,946

$

12.75

Granted

720,134

14.44

Vested

(513,958)

11.55

$

7,645

Forfeited and cancelled

(245,813)

12.17

Outstanding as of June 30, 2022

1,457,309

$

14.11

Stock-based compensation expense

Three Months Ended

Six Months Ended

June 30, 

June 30, 

(In thousands)

    

2022

    

2021

    

2022

    

2021

Cost of revenue

    

$

302

    

$

335

  

$

530

    

$

582

Research and development

941

1,154

828

2,030

General and administrative

 

2,449

 

2,343

 

4,680

 

3,895

Total stock-based compensation expense

$

3,692

$

3,832

$

6,038

$

6,507

XML 43 R31.htm IDEA: XBRL DOCUMENT v3.22.2
Net Loss per Share (Tables)
6 Months Ended
Jun. 30, 2022
Net Loss per Share  
Basic and diluted net loss per share

Three Months Ended

Six Months Ended

June 30, 

June 30, 

(In thousands, except for share and per share data)

2022

2021

    

2022

    

2021

Numerator:

    

    

    

    

    

    

    

Net loss

$

(20,532)

$

(18,161)

$

(39,321)

$

(46,915)

Denominator:

Weighted average shares of common stock outstanding, basic and diluted

 

65,990,031

 

53,968,405

 

63,723,123

 

52,163,136

Net loss per share, basic and diluted

$

(0.31)

$

(0.34)

$

(0.62)

$

(0.90)

Potential common shares excluded from the calculation of diluted net loss per share attributable to common stockholders

June 30, 

2022

2021

Options to purchase common stock

5,014,953

3,738,625

Restricted stock unit awards

1,457,309

1,498,716

Total potential shares of common stock

6,472,262

5,237,341

XML 44 R32.htm IDEA: XBRL DOCUMENT v3.22.2
Leases (Tables)
6 Months Ended
Jun. 30, 2022
Leases  
Schedule of supplemental balance sheet information related to operating leases

June 30, 

December 31,

(In thousands)

2022

2021

Operating Leases:

Gross cost

$

5,240

$

5,240

Accumulated amortization

(2,173)

(1,803)

Other assets

$

3,067

$

3,437

Current portion of lease liabilities

$

741

$

693

Other liabilities

1,820

2,151

Total operating lease liabilities

$

2,561

$

2,844

XML 45 R33.htm IDEA: XBRL DOCUMENT v3.22.2
Discontinued Operations (Tables)
6 Months Ended
Jun. 30, 2022
Discontinued Operations.  
Schedule of discontinued operations

June 30, 

December 31,

(In thousands)

    

2022

    

2021

Accrued expenses

  

$

2,202

$

2,202

Discontinued operations - current liabilities

$

2,202

$

2,202

XML 46 R34.htm IDEA: XBRL DOCUMENT v3.22.2
Segment Information (Tables)
6 Months Ended
Jun. 30, 2022
Segment Information  
Summary of results of operations by segment

(In thousands)

Contract

Corporate

Total

Three Months Ended June 30, 2022

Therapeutics

Research

and Other

Company

Total revenue

$

309

$

4,399

$

(3,180)

$

1,528

Cost of revenue

4,041

(2,973)

1,068

Research and development

18,986

(207)

18,779

General and administrative

854

5,221

6,075

Revaluation of contingent consideration

(3,400)

(3,400)

Loss from operations

$

(15,277)

$

(496)

$

(5,221)

$

(20,994)

(In thousands)

Contract

Corporate

Total

Three Months Ended June 30, 2021

Therapeutics

Research

and Other

Company

Total revenue

$

218

$

3,481

$

(1,875)

$

1,824

Cost of revenue

3,024

(1,761)

1,263

Research and development

8,011

(114)

7,897

Sales and marketing

General and administrative

879

4,991

5,870

Revaluation of contingent consideration

4,800

4,800

Loss from operations

$

(12,593)

$

(422)

$

(4,991)

$

(18,006)

(In thousands)

Contract

Corporate

Total

Six Months Ended June 30, 2022

Therapeutics

Research

and Other

Company

Total revenue

$

541

$

8,495

$

(6,055)

$

2,981

Cost of revenue

7,897

(5,674)

2,223

Research and development

33,466

(381)

33,085

General and administrative

1,695

10,479

12,174

Revaluation of contingent consideration

(4,600)

(4,600)

Loss from operations

$

(28,325)

$

(1,097)

$

(10,479)

$

(39,901)

(In thousands)

Contract

Corporate

Total

Six Months Ended June 30, 2021

Therapeutics

Research

and Other

Company

Total revenue

$

460

$

6,681

$

(3,540)

$

3,601

Cost of revenue

5,793

(3,328)

2,465

Research and development

15,946

(211)

15,735

General and administrative

1,507

9,190

10,697

Revaluation of contingent consideration

21,239

21,239

Loss from operations

$

(36,725)

$

(619)

$

(9,191)

$

(46,535)

XML 47 R35.htm IDEA: XBRL DOCUMENT v3.22.2
Organization and Nature of Business (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Organization and Nature of Business    
Cash, cash equivalents and marketable securities $ 255,800  
Accumulated deficit $ 634,728 $ 595,407
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies (Details)
6 Months Ended
Jun. 30, 2022
Minimum  
Contingent Consideration [Abstract]  
Probability of success assumptions 10.00%
Discount range 10.20%
Maximum  
Contingent Consideration [Abstract]  
Probability of success assumptions 40.00%
Discount range 10.90%
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value of Financial Assets and Liabilities (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Assets:          
Marketable securities $ 187,560   $ 187,560   $ 198,307
Liabilities:          
Transfers into or out of Level 3     0 $ 0  
Revaluation of contingent consideration (3,400) $ 4,800 (4,600) $ 21,239  
Confluence          
Liabilities:          
Revaluation of contingent consideration     (4,600)    
Recurring          
Assets:          
Cash equivalents 63,838   63,838   21,678
Marketable securities 187,560   187,560   198,307
Total assets measured at fair value 251,398   251,398   219,985
Liabilities:          
Contingent consideration 23,800   23,800   28,400
Total liabilities measured at fair value 23,800   23,800   28,400
Recurring | Level 1          
Assets:          
Cash equivalents 63,838   63,838   21,678
Total assets measured at fair value 63,838   63,838   21,678
Recurring | Level 2          
Assets:          
Marketable securities 187,560   187,560   198,307
Total assets measured at fair value 187,560   187,560   198,307
Recurring | Level 3          
Liabilities:          
Contingent consideration 23,800   23,800   28,400
Total liabilities measured at fair value $ 23,800   $ 23,800   $ 28,400
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value of Financial Assets and Liabilities - By Type (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Marketable securities:    
Amortized Cost $ 188,888 $ 198,534
Gross Unrealized Gain   6
Gross Unrealized Loss (1,328) (233)
Fair Value 187,560 198,307
Corporate debt securities    
Marketable securities:    
Amortized Cost 47,201 40,993
Gross Unrealized Gain   6
Gross Unrealized Loss (398) (50)
Fair Value 46,803 40,949
Debt securities, maturity dates between one and five years   9,200
Commercial paper    
Marketable securities:    
Amortized Cost 56,053 71,837
Fair Value 56,053 71,837
Asset-backed securities    
Marketable securities:    
Amortized Cost 28,423 36,166
Gross Unrealized Loss (175) (43)
Fair Value 28,248 36,123
Debt securities, maturity dates between one and five years 7,200  
Foreign Government Agency Debt Securities    
Marketable securities:    
Amortized Cost   4,073
Gross Unrealized Loss   (13)
Fair Value   4,060
U.S. government agency debt securities    
Marketable securities:    
Amortized Cost 57,211 45,465
Gross Unrealized Loss (755) (127)
Fair Value $ 56,456 45,338
Debt securities, maturity dates between one and five years   $ 25,000
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.22.2
Property and Equipment, Net (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Property and Equipment, Net          
Property and equipment, gross $ 4,977   $ 4,977   $ 4,728
Accumulated depreciation (3,701)   (3,701)   (3,393)
Property and equipment, net 1,276   1,276   1,335
Depreciation expense 200 $ 200 400 $ 400  
Computer equipment          
Property and Equipment, Net          
Property and equipment, gross 1,355   1,355   1,380
Lab equipment          
Property and Equipment, Net          
Property and equipment, gross 1,879   1,879   1,605
Furniture and fixtures          
Property and Equipment, Net          
Property and equipment, gross 620   620   620
Leasehold improvements          
Property and Equipment, Net          
Property and equipment, gross $ 1,123   $ 1,123   $ 1,123
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.22.2
Intangible Assets (Details) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2022
Dec. 31, 2021
Definite-lived intangible assets    
Accumulated Amortization $ 369 $ 332
Intangible assets, net    
Gross cost 7,380 7,380
In-process research and development    
Indefinite-lived intangible assets    
Gross cost $ 6,629 6,629
Other intangible assets    
Finite Lived And Indefinite Lived Intangible Assets By Major Class [Line Items]    
Remaining life 5 years 1 month 6 days  
Definite-lived intangible assets    
Gross Cost $ 751 751
Accumulated Amortization $ 369 $ 332
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.22.2
Intangible Assets - Future Amortization Expenses (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]        
Amortization expense $ 19 $ 19 $ 38,000 $ 38,000
Future amortization expenses        
2022 37   37  
2023 75   75  
2024 75   75  
2025 75   75  
2026 75   75  
Thereafter 45   45  
Total $ 382   $ 382  
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.22.2
Accrued Expenses (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Accrued Expenses    
Employee compensation expenses $ 2,885 $ 4,389
Research and development expenses 2,771 1,278
Litigation settlements (see Note 16)   2,650
Other 1,915 1,734
Total accrued expenses $ 7,571 $ 10,051
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.22.2
Debt (Details) - USD ($)
$ in Millions
1 Months Ended
Jul. 31, 2021
Jan. 31, 2021
Mar. 31, 2020
SVB      
Debt Instrument [Line Items]      
Common stock warrants   388,119 460,251
Term Loan Facility      
Debt Instrument [Line Items]      
Loan borrowed     $ 11.0
Term Loan Facility | SVB      
Debt Instrument [Line Items]      
Loan borrowed $ 11.0    
Loan repaid $ 11.7    
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.22.2
Stockholders' Equity (Details)
$ / shares in Units, $ in Thousands
6 Months Ended
Jun. 30, 2022
USD ($)
Vote
$ / shares
shares
Dec. 31, 2021
$ / shares
shares
Jan. 31, 2021
shares
Mar. 31, 2020
USD ($)
$ / shares
shares
Class of Stock [Line Items]        
Preferred stock, shares authorized 10,000,000 10,000,000    
Preferred stock, shares outstanding 0 0    
Common stock, shares authorized 100,000,000 100,000,000    
Common stock, par value (in dollars per share) | $ / shares $ 0.00001 $ 0.00001    
Common stock, shares issued 66,667,580 61,228,446    
Common stock, shares outstanding 66,667,580 61,228,446    
Dividend declared | $ $ 0      
Number of votes per share | Vote 1      
SVB        
Class of Stock [Line Items]        
Common stock warrants     388,119 460,251
Initial exercise price | $ / shares       $ 0.956
Fair value of warrants | $       $ 400
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.22.2
Stockholders' Equity - Other Offerings and ATM Facility (Details) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended
Apr. 30, 2022
Jun. 30, 2021
Jan. 31, 2021
January 2021 Public Offering      
Subsidiary, Sale of Stock [Line Items]      
Common stock, sold     6,306,271
Common stock, price per share     $ 17.50
Aggregate gross proceeds     $ 110.4
Underwriting discounts and commissions     6.6
Payments of stock offering costs     0.4
Proceeds from common stock     $ 103.3
June 2021 Public Offering      
Subsidiary, Sale of Stock [Line Items]      
Common stock, sold   8,098,592  
Common stock, price per share   $ 17.75  
Aggregate gross proceeds   $ 143.8  
Underwriting discounts and commissions   8.6  
Payments of stock offering costs   0.3  
Proceeds from common stock   $ 134.9  
At The Market Offering | Silicon Valley Bank Securities LLC and Cantor Fitzgerald & Co.      
Subsidiary, Sale of Stock [Line Items]      
Common stock, sold 4,838,709    
Common stock, price per share $ 15.50    
Payments of stock offering costs $ 2.2    
Proceeds from common stock $ 75.0    
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-Based Awards (Details) - shares
6 Months Ended 44 Months Ended
Jan. 01, 2022
Jun. 30, 2022
Jun. 30, 2021
Sep. 14, 2015
Dec. 31, 2021
Sep. 30, 2015
Stock-based awards            
Options granted (in shares)   1,891,950        
Options outstanding   5,014,953     3,792,450  
Stock Option Valuation            
Risk-free interest rate (as a percent)   1.90% 0.91%      
Expected term (in years)   6 years 2 months 12 days 6 years 2 months 12 days      
Expected volatility (as a percent)   77.95% 76.60%      
Expected dividend yield (as a percent)   0.00% 0.00%      
2017 Inducement Plan            
Stock-based awards            
Options outstanding   410,600        
2017 Inducement Plan | Restricted stock unit awards            
Stock-based awards            
Number of shares outstanding   2,375        
2015 Equity Incentive Plan            
Stock-based awards            
Number of shares authorized           1,643,872
Number of shares available for grant   3,372,766        
Percentage increase to shares available for grant from common outstanding as of preceding December 31 (as a percent)   4.00%        
Additional shares available 2,449,137          
Options outstanding   4,130,376        
2015 Equity Incentive Plan | Restricted stock unit awards            
Stock-based awards            
Number of shares outstanding   1,454,934        
2012 Equity Compensation Plan            
Stock-based awards            
Number of shares available for grant   0        
Options granted (in shares)       1,140,524    
Options outstanding   473,977        
Term of award (in years)   10 years        
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-Based Awards - Option Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
6 Months Ended 12 Months Ended
Jun. 30, 2022
Dec. 31, 2021
Options, Number of Shares    
Number of Shares, beginning balance 3,792,450  
Number of Shares, Granted 1,891,950  
Number of Shares, Exercised (85,672)  
Number of Shares, Forfeited and cancelled (583,775)  
Number of Shares, ending balance 5,014,953 3,792,450
Number of Shares, Options vested and expected to vest 5,014,953  
Number of Shares, Options exercisable 2,519,499  
Options, Weighted Average Exercise Price    
Weighted Average Exercise Price, beginning balance (in dollars per share) $ 17.50  
Weighted Average Exercise Price, Granted (in dollars per share) 14.40  
Weighted Average Exercise Price, Exercised (in dollars per share) 1.40  
Weighted Average Exercise Price, Forfeited and cancelled (in dollars per share) 15.70  
Weighted Average Exercise Price, ending balance (in dollars per share) 16.81 $ 17.50
Weighted Average Exercise Price, Options vested and expected to vest (in dollars per share) 16.81  
Weighted Average Exercise Price, Options exercisable (in dollars per share) $ 18.26  
Options, Weighted Average Remaining Contractual Term    
Weighted Average Remaining Contractual Term (in years) 7 years 1 month 6 days 6 years 9 months 18 days
Weighted Average Remaining Contractual Term, Options vested and expected to vest (in years) 7 years 1 month 6 days  
Weighted Average Remaining Contractual Term, Options exercisable (in years) 4 years 9 months 18 days  
Aggregate Intrinsic Value    
Aggregate Intrinsic Value $ 10,817 $ 13,710
Aggregate Intrinsic Value, Exercised 1,115  
Aggregate Intrinsic Value, Options vested and expected to vest 10,817  
Aggregate Intrinsic Value, Options exercisable $ 7,784  
Weighted average grant-date fair value of stock options granted (in dollars per share) $ 9.89  
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-Based Awards - RSUs (Details) - Restricted stock unit awards
$ / shares in Units, $ in Thousands
6 Months Ended
Jun. 30, 2022
USD ($)
$ / shares
shares
RSU, Number of Units  
Units outstanding, beginning of period | shares 1,496,946
Granted | shares 720,134
Vested | shares (513,958)
Forfeited and cancelled | shares (245,813)
Units outstanding, end of period | shares 1,457,309
RSU, Weighted Average Grant Date Fair Value Per Unit  
Weighted average grant date fair value, beginning balance (in dollars per share) | $ / shares $ 12.75
Weighted average grant date fair value, granted (in dollars per share) | $ / shares 14.44
Weighted average grant date fair value, vested (in dollars per share) | $ / shares 11.55
Weighted average grant date fair value, forfeited and cancelled (in dollars per share) | $ / shares 12.17
Weighted average grant date fair value, ending balance (in dollars per share) | $ / shares $ 14.11
Aggregate intrinsic value of awards that vested during the period | $ $ 7,645
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-Based Awards - Compensation (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Jun. 30, 2022
Jun. 30, 2021
Stock-based compensation expense        
Stock-based compensation expense $ 3,692 $ 3,832 $ 6,038 $ 6,507
Unrecognized stock-based compensation expense, options     23,700  
Unrecognized stock-based compensation expense, RSUs     18,300  
Cost of revenue.        
Stock-based compensation expense        
Stock-based compensation expense 302 335 530 582
Research and development        
Stock-based compensation expense        
Stock-based compensation expense 941 1,154 828 2,030
General and administrative        
Stock-based compensation expense        
Stock-based compensation expense $ 2,449 $ 2,343 $ 4,680 $ 3,895
Options to purchase common stock        
Stock-based compensation expense        
Weighted average recognition period unrecognized stock-based compensation cost (in years)     3 years 2 months 12 days  
Restricted stock unit awards        
Stock-based compensation expense        
Weighted average recognition period unrecognized stock-based compensation cost (in years)     3 years  
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.22.2
Net Loss per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2022
Jun. 30, 2021
Numerator:            
Net loss $ (20,532) $ (18,789) $ (18,161) $ (28,754) $ (39,321) $ (46,915)
Denominator:            
Weighted average common shares outstanding, basic 65,990,031   53,968,405   63,723,123 52,163,136
Weighted average common shares outstanding, diluted 65,990,031   53,968,405   63,723,123 52,163,136
Net loss per share, basic $ (0.31)   $ (0.34)   $ (0.62) $ (0.90)
Net loss per share, diluted $ (0.31)   $ (0.34)   $ (0.62) $ (0.90)
XML 63 R51.htm IDEA: XBRL DOCUMENT v3.22.2
Net Loss per Share - Anti-dilution (Details) - shares
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potential common shares excluded from the calculation of diluted net loss per share attributable to common stockholders 6,472,262 5,237,341
Options to purchase common stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potential common shares excluded from the calculation of diluted net loss per share attributable to common stockholders 5,014,953 3,738,625
Restricted stock unit awards    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potential common shares excluded from the calculation of diluted net loss per share attributable to common stockholders 1,457,309 1,498,716
XML 64 R52.htm IDEA: XBRL DOCUMENT v3.22.2
Leases (Details)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Dec. 31, 2020
ft²
Jun. 30, 2022
USD ($)
ft²
Jun. 30, 2021
USD ($)
Jun. 30, 2022
USD ($)
ft²
Jun. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
Feb. 28, 2019
ft²
Lessee, Lease, Description [Line Items]              
Area leased, sublease agreement | ft²   33,019   33,019     20,433
Sub-subleased | ft² 8,115            
Amortization expense   $ 300 $ 300 $ 500 $ 500    
Operating Leases:              
Accumulated amortization   369   369   $ 332  
Other assets   7,011   7,011   7,048  
Current portion of lease liabilities   741   741   693  
Other liabilities   $ 1,820   $ 1,820   $ 2,151  
Financial position   Other liabilities   Other liabilities   Other liabilities  
Total operating lease liabilities   $ 2,561   $ 2,561   $ 2,844  
Operating Leases              
Operating Leases:              
Gross cost   5,240   5,240   5,240  
Accumulated amortization   2,173   2,173   1,803  
Other assets   $ 3,067   $ 3,067   $ 3,437  
XML 65 R53.htm IDEA: XBRL DOCUMENT v3.22.2
Agreements Related to Intellectual Property (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Oct. 31, 2019
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Agreements Related to Intellectual Property            
Revenue, Net   $ 1,528 $ 1,824 $ 2,981 $ 3,601  
Contingent consideration   23,800   $ 23,800   $ 28,400
Agreement and Plan of Merger            
Agreements Related to Intellectual Property            
Term of agreement       10 years    
Additional contingent consideration based on milestones, maximum, per Agreement   75,000   $ 75,000    
APA            
Agreements Related to Intellectual Property            
Potential milestone payments   20,000   20,000    
Percentage of upfront and license fees 25.00%          
Term of agreement 10 years          
APA | Royalty            
Agreements Related to Intellectual Property            
Revenue, Net   $ 300 $ 200 $ 500 $ 400  
XML 66 R54.htm IDEA: XBRL DOCUMENT v3.22.2
Income Taxes (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Income Taxes        
Federal income tax benefit $ 0 $ 0 $ 0 $ 0
State income tax benefit $ 0 $ 0 $ 0 $ 0
XML 67 R55.htm IDEA: XBRL DOCUMENT v3.22.2
Discontinued Operations - Assets and Liabilities (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]    
Accrued expenses $ 2,202 $ 2,202
Discontinued operations - current liabilities $ 2,202 $ 2,202
XML 68 R56.htm IDEA: XBRL DOCUMENT v3.22.2
Segment Information (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2022
USD ($)
segment
Jun. 30, 2021
USD ($)
Segment Reporting Information [Line Items]        
Number of reportable segments | segment     2  
Total revenue $ 1,528 $ 1,824 $ 2,981 $ 3,601
Cost of revenue 1,068 1,263 2,223 2,465
Research and development 18,779 7,897 33,085 15,735
General and administrative 6,075 5,870 12,174 10,697
Revaluation of contingent consideration (3,400) 4,800 (4,600) 21,239
Loss from operations (20,994) (18,006) (39,901) (46,535)
Dermatology Therapeutics Segment        
Segment Reporting Information [Line Items]        
Total revenue 309 218 541 460
Research and development 18,986 8,011 33,466 15,946
Revaluation of contingent consideration (3,400) 4,800 (4,600) 21,239
Loss from operations (15,277) (12,593) (28,325) (36,725)
Contract Research Segment        
Segment Reporting Information [Line Items]        
Total revenue 4,399 3,481 8,495 6,681
Cost of revenue 4,041 3,024 7,897 5,793
General and administrative 854 879 1,695 1,507
Loss from operations (496) (422) (1,097) (619)
Corporate and Other        
Segment Reporting Information [Line Items]        
Total revenue (3,180) (1,875) (6,055) (3,540)
Cost of revenue (2,973) (1,761) (5,674) (3,328)
Research and development (207) (114) (381) (211)
General and administrative 5,221 4,991 10,479 9,190
Loss from operations (5,221) (4,991) (10,479) (9,191)
Intersegment Eliminations | Contract Research Segment        
Segment Reporting Information [Line Items]        
Total revenue $ 3,200 $ 1,900 $ 6,100 $ 3,500
XML 69 R57.htm IDEA: XBRL DOCUMENT v3.22.2
Legal Proceedings (Details)
$ in Thousands
Jan. 24, 2020
item
Jun. 30, 2022
USD ($)
Dec. 31, 2021
USD ($)
Other Commitments [Line Items]      
Accrual for estimated financial obligation     $ 2,650
Consolidated Securities Action      
Other Commitments [Line Items]      
Accrual for estimated financial obligation   $ 2,700  
Consolidated Securities Action | Executive officer      
Other Commitments [Line Items]      
Number of defendants | item 2    
XML 70 acrs-20220630x10q_htm.xml IDEA: XBRL DOCUMENT 0001557746 us-gaap:AdditionalPaidInCapitalMember acrs:AtMarketOfferingMember 2022-04-01 2022-06-30 0001557746 us-gaap:AdditionalPaidInCapitalMember acrs:FollowOnPublicOfferingMember 2021-04-01 2021-06-30 0001557746 us-gaap:AdditionalPaidInCapitalMember acrs:FollowOnPublicOfferingMember 2021-01-01 2021-03-31 0001557746 us-gaap:CommonStockMember acrs:AtMarketOfferingMember 2022-04-01 2022-06-30 0001557746 us-gaap:CommonStockMember acrs:FollowOnPublicOfferingMember 2021-04-01 2021-06-30 0001557746 us-gaap:CommonStockMember acrs:FollowOnPublicOfferingMember 2021-01-01 2021-03-31 0001557746 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001557746 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001557746 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001557746 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001557746 us-gaap:RetainedEarningsMember 2022-06-30 0001557746 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001557746 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001557746 us-gaap:RetainedEarningsMember 2022-03-31 0001557746 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001557746 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001557746 2022-03-31 0001557746 us-gaap:RetainedEarningsMember 2021-12-31 0001557746 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001557746 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001557746 us-gaap:RetainedEarningsMember 2021-06-30 0001557746 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001557746 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001557746 us-gaap:RetainedEarningsMember 2021-03-31 0001557746 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001557746 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001557746 2021-03-31 0001557746 us-gaap:RetainedEarningsMember 2020-12-31 0001557746 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001557746 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001557746 acrs:SiliconValleyBankSecuritiesLlcAndCantorFitzgeraldAndCo.Member acrs:AtMarketOfferingMember 2022-04-30 0001557746 acrs:June2021PublicOfferingMember 2021-06-30 0001557746 acrs:January2021PublicOfferingMember 2021-01-31 0001557746 2021-01-01 2021-12-31 0001557746 acrs:EquityCompensation2017InducementPlanMember 2022-06-30 0001557746 acrs:EquityCompensationPlan2012Member 2012-01-01 2015-09-14 0001557746 acrs:EquityCompensationPlan2012Member 2022-06-30 0001557746 acrs:EquityIncentivePlan2015Member 2015-09-30 0001557746 acrs:EquityIncentivePlan2015Member 2022-01-01 2022-01-01 0001557746 acrs:EquityCompensationPlan2012Member 2022-01-01 2022-06-30 0001557746 us-gaap:RestrictedStockUnitsRSUMember 2022-06-30 0001557746 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001557746 us-gaap:RestrictedStockUnitsRSUMember acrs:EquityIncentivePlan2015Member 2022-06-30 0001557746 us-gaap:RestrictedStockUnitsRSUMember acrs:EquityCompensation2017InducementPlanMember 2022-06-30 0001557746 acrs:AtMarketOfferingMember 2022-01-01 2022-06-30 0001557746 acrs:FollowOnPublicOfferingMember 2021-01-01 2021-06-30 0001557746 us-gaap:RoyaltyMember acrs:AssetPurchaseAgreementEncompassingWorldwideRightsToOxymetazolineHydrochlorideCreamPlusIntellectualPropertyMember 2022-04-01 2022-06-30 0001557746 us-gaap:IntersegmentEliminationMember acrs:ContractResearchSegmentMember 2022-04-01 2022-06-30 0001557746 acrs:OtherRevenueMember 2022-04-01 2022-06-30 0001557746 acrs:LaboratoryResearchRevenueMember 2022-04-01 2022-06-30 0001557746 us-gaap:RoyaltyMember acrs:AssetPurchaseAgreementEncompassingWorldwideRightsToOxymetazolineHydrochlorideCreamPlusIntellectualPropertyMember 2022-01-01 2022-06-30 0001557746 us-gaap:IntersegmentEliminationMember acrs:ContractResearchSegmentMember 2022-01-01 2022-06-30 0001557746 acrs:OtherRevenueMember 2022-01-01 2022-06-30 0001557746 acrs:LaboratoryResearchRevenueMember 2022-01-01 2022-06-30 0001557746 us-gaap:RoyaltyMember acrs:AssetPurchaseAgreementEncompassingWorldwideRightsToOxymetazolineHydrochlorideCreamPlusIntellectualPropertyMember 2021-04-01 2021-06-30 0001557746 us-gaap:IntersegmentEliminationMember acrs:ContractResearchSegmentMember 2021-04-01 2021-06-30 0001557746 acrs:OtherRevenueMember 2021-04-01 2021-06-30 0001557746 acrs:LaboratoryResearchRevenueMember 2021-04-01 2021-06-30 0001557746 us-gaap:RoyaltyMember acrs:AssetPurchaseAgreementEncompassingWorldwideRightsToOxymetazolineHydrochlorideCreamPlusIntellectualPropertyMember 2021-01-01 2021-06-30 0001557746 us-gaap:IntersegmentEliminationMember acrs:ContractResearchSegmentMember 2021-01-01 2021-06-30 0001557746 acrs:OtherRevenueMember 2021-01-01 2021-06-30 0001557746 acrs:LaboratoryResearchRevenueMember 2021-01-01 2021-06-30 0001557746 acrs:SiliconValleyBankMember acrs:TermLoanFacilityMember 2021-07-01 2021-07-31 0001557746 us-gaap:LeaseholdImprovementsMember 2022-06-30 0001557746 us-gaap:FurnitureAndFixturesMember 2022-06-30 0001557746 us-gaap:ComputerEquipmentMember 2022-06-30 0001557746 acrs:LaboratoryEquipmentMember 2022-06-30 0001557746 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001557746 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001557746 us-gaap:ComputerEquipmentMember 2021-12-31 0001557746 acrs:LaboratoryEquipmentMember 2021-12-31 0001557746 acrs:SiliconValleyBankSecuritiesLlcAndCantorFitzgeraldAndCo.Member acrs:AtMarketOfferingMember 2022-04-01 2022-04-30 0001557746 2019-02-28 0001557746 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001557746 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001557746 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001557746 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001557746 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001557746 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001557746 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001557746 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001557746 acrs:RosiAndFulcherVs.AclarisTherapeuticsInc.Member srt:ExecutiveOfficerMember 2020-01-24 2020-01-24 0001557746 acrs:RosiAndFulcherVs.AclarisTherapeuticsInc.Member 2022-06-30 0001557746 acrs:SiliconValleyBankMember acrs:TermLoanFacilityMember 2021-07-31 0001557746 acrs:TermLoanFacilityMember 2020-03-31 0001557746 us-gaap:InProcessResearchAndDevelopmentMember 2022-06-30 0001557746 us-gaap:InProcessResearchAndDevelopmentMember 2021-12-31 0001557746 us-gaap:OtherIntangibleAssetsMember 2022-01-01 2022-06-30 0001557746 us-gaap:OtherIntangibleAssetsMember 2022-06-30 0001557746 acrs:OperatingLeasesMember 2022-06-30 0001557746 us-gaap:OtherIntangibleAssetsMember 2021-12-31 0001557746 acrs:OperatingLeasesMember 2021-12-31 0001557746 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-06-30 0001557746 acrs:EmployeeConsultantsAndDirectorsStockOptionsMember 2022-01-01 2022-06-30 0001557746 us-gaap:CorporateNonSegmentMember 2022-04-01 2022-06-30 0001557746 acrs:ContractResearchSegmentMember 2022-04-01 2022-06-30 0001557746 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-06-30 0001557746 acrs:ContractResearchSegmentMember 2022-01-01 2022-06-30 0001557746 us-gaap:CorporateNonSegmentMember 2021-04-01 2021-06-30 0001557746 acrs:ContractResearchSegmentMember 2021-04-01 2021-06-30 0001557746 us-gaap:CorporateNonSegmentMember 2021-01-01 2021-06-30 0001557746 acrs:ContractResearchSegmentMember 2021-01-01 2021-06-30 0001557746 us-gaap:CommonStockMember 2022-06-30 0001557746 us-gaap:CommonStockMember 2022-03-31 0001557746 us-gaap:CommonStockMember 2021-12-31 0001557746 us-gaap:CommonStockMember 2021-06-30 0001557746 us-gaap:CommonStockMember 2021-03-31 0001557746 us-gaap:CommonStockMember 2020-12-31 0001557746 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001557746 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001557746 acrs:SiliconValleyBankMember 2021-01-31 0001557746 2021-06-30 0001557746 2020-12-31 0001557746 acrs:DermatologyTherapeuticsSegmentMember 2022-04-01 2022-06-30 0001557746 acrs:DermatologyTherapeuticsSegmentMember 2022-01-01 2022-06-30 0001557746 acrs:ConfluenceMember 2022-01-01 2022-06-30 0001557746 acrs:DermatologyTherapeuticsSegmentMember 2021-04-01 2021-06-30 0001557746 acrs:DermatologyTherapeuticsSegmentMember 2021-01-01 2021-06-30 0001557746 us-gaap:FixedIncomeSecuritiesMember 2022-06-30 0001557746 us-gaap:FixedIncomeSecuritiesMember 2021-12-31 0001557746 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-06-30 0001557746 us-gaap:CorporateDebtSecuritiesMember 2022-06-30 0001557746 us-gaap:AssetBackedSecuritiesMember 2021-12-31 0001557746 acrs:ForeignGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001557746 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001557746 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001557746 us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001557746 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001557746 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001557746 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001557746 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-06-30 0001557746 acrs:EmployeeConsultantsAndDirectorsStockOptionsMember 2022-01-01 2022-06-30 0001557746 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-06-30 0001557746 acrs:EmployeeConsultantsAndDirectorsStockOptionsMember 2021-01-01 2021-06-30 0001557746 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-06-30 0001557746 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-06-30 0001557746 us-gaap:CostOfSalesMember 2022-01-01 2022-06-30 0001557746 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0001557746 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-03-31 0001557746 us-gaap:CostOfSalesMember 2022-01-01 2022-03-31 0001557746 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-06-30 0001557746 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-06-30 0001557746 us-gaap:CostOfSalesMember 2021-01-01 2021-06-30 0001557746 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001557746 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001557746 us-gaap:CostOfSalesMember 2021-01-01 2021-03-31 0001557746 acrs:AtMarketOfferingMember 2022-04-01 2022-06-30 0001557746 acrs:FollowOnPublicOfferingMember 2021-04-01 2021-06-30 0001557746 acrs:FollowOnPublicOfferingMember 2021-01-01 2021-03-31 0001557746 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001557746 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001557746 2022-01-01 2022-03-31 0001557746 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001557746 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001557746 2021-01-01 2021-03-31 0001557746 2022-07-29 0001557746 acrs:EquityIncentivePlan2015Member 2022-06-30 0001557746 srt:MinimumMember 2022-01-01 2022-06-30 0001557746 srt:MaximumMember 2022-01-01 2022-06-30 0001557746 acrs:June2021PublicOfferingMember 2021-06-01 2021-06-30 0001557746 acrs:January2021PublicOfferingMember 2021-01-01 2021-01-31 0001557746 2022-04-01 2022-06-30 0001557746 2021-04-01 2021-06-30 0001557746 acrs:SiliconValleyBankMember 2020-03-31 0001557746 2021-01-01 2021-06-30 0001557746 us-gaap:AssetBackedSecuritiesMember 2022-06-30 0001557746 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001557746 us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001557746 acrs:AgreementAndPlanOfMergerMember 2022-06-30 0001557746 acrs:AssetPurchaseAgreementEncompassingWorldwideRightsToOxymetazolineHydrochlorideCreamPlusIntellectualPropertyMember 2022-06-30 0001557746 2020-12-01 2020-12-31 0001557746 acrs:AgreementAndPlanOfMergerMember 2022-01-01 2022-06-30 0001557746 acrs:AssetPurchaseAgreementEncompassingWorldwideRightsToOxymetazolineHydrochlorideCreamPlusIntellectualPropertyMember 2019-10-01 2019-10-31 0001557746 2022-06-30 0001557746 2021-12-31 0001557746 2022-01-01 2022-06-30 iso4217:USD utr:sqft acrs:Vote pure shares iso4217:USD shares acrs:item acrs:segment -0.31 -0.34 -0.62 -0.90 65990031 53968405 63723123 52163136 65990031 53968405 63723123 52163136 -0.31 -0.34 -0.62 -0.90 0 0 0 0 66667580 http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent 61228446 0 0 0001557746 --12-31 2022 Q2 false 61228446 66667580 10-Q true 2022-06-30 false 001-37581 Aclaris Therapeutics, Inc. DE 46-0571712 640 Lee Road, Suite 200 Wayne PA 19087 484 324-7933 Common Stock, $0.00001 par value ACRS NASDAQ Yes Yes Large Accelerated Filer false false false 66671750 68264000 27349000 180339000 164065000 637000 623000 10114000 12995000 259354000 205032000 7221000 34242000 1276000 1335000 7011000 7048000 3114000 3554000 277976000 251211000 5703000 9985000 7571000 10051000 741000 693000 2202000 2202000 16217000 22931000 1840000 2172000 23800000 28400000 367000 367000 42224000 53870000 0.00001 0.00001 10000000 10000000 0 0 0.00001 0.00001 100000000 100000000 66667580 61228446 1000 1000 871805000 792971000 -1326000 -224000 -634728000 -595407000 235752000 197341000 277976000 251211000 1218000 1606000 2439000 3141000 310000 218000 542000 460000 1528000 1824000 2981000 3601000 1068000 1263000 2223000 2465000 18779000 7897000 33085000 15735000 6075000 5870000 12174000 10697000 -3400000 4800000 -4600000 21239000 22522000 19830000 42882000 50136000 -20994000 -18006000 -39901000 -46535000 462000 -155000 580000 -380000 -20532000 -18161000 -39321000 -46915000 -0.31 -0.34 -0.62 -0.90 65990031 53968405 63723123 52163136 0 0 0 0 -354000 25000 -1101000 -10000 -69000 -80000 -354000 -44000 -1101000 -90000 -20886000 -18205000 -40422000 -47005000 61228446 1000 792971000 -224000 -595407000 197341000 509037 49000 49000 -748000 -748000 2346000 2346000 -18789000 -18789000 61737483 1000 795366000 -972000 -614196000 180199000 91388 88000 88000 2341000 4838709 72659000 72659000 -354000 -354000 3692000 3692000 -20532000 -20532000 66667580 1000 871805000 -1326000 -634728000 235752000 45109314 542286000 -94000 -504542000 37650000 666144 -2579000 -2579000 7011000 6306271 103348000 103348000 -35000 -35000 -11000 -11000 2675000 2675000 -28754000 -28754000 52081729 645730000 -140000 -533296000 112294000 1024666 1041000 1041000 8899000 8098592 1000 134851000 134852000 25000 25000 -69000 -69000 3833000 3833000 -18161000 -18161000 61204987 1000 785455000 -184000 -551457000 233815000 -39321000 -46915000 414000 535000 6038000 6507000 -4600000 21239000 14000 167000 -1309000 5223000 -4283000 -1290000 -178000 861000 -40635000 -24453000 350000 52000 85096000 147289000 94155000 26557000 8709000 -120784000 238200000 72744000 23000 3038000 120000 1459000 72841000 236621000 40915000 91384000 27349000 22063000 68264000 113447000 72000 37000 28000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">1. Organization and Nature of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Aclaris Therapeutics, Inc. was incorporated under the laws of the State of Delaware in 2012. In 2015,  Aclaris Therapeutics International Limited (“ATIL”) was established under the laws of the United Kingdom as a wholly-owned subsidiary of Aclaris Therapeutics, Inc. In 2017, Confluence Life Sciences, Inc. (now known as Aclaris Life Sciences, Inc.) (“Confluence”) was acquired by Aclaris Therapeutics, Inc. and became a wholly-owned subsidiary thereof.  Aclaris Therapeutics, Inc., ATIL and Confluence are referred to collectively as the “Company.”  The Company is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases.  In addition to developing its novel drug candidates, the Company is pursuing strategic alternatives, including identifying and consummating transactions with third-party partners, to further develop, obtain marketing approval for and/or commercialize its novel drug candidates.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Liquidity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company’s condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities in the ordinary course of business.  As of June 30, 2022, the Company had cash, cash equivalents and marketable securities of $255.8 million and an accumulated deficit of $634.7 million.  Since inception, the Company has incurred net losses and negative cash flows from its operations.  Prior to the acquisition of Confluence, the Company had never generated revenue.  There can be no assurance that profitable operations will ever be achieved, and, if achieved, will be sustained on a continuing basis. In addition, development activities, including clinical and preclinical testing of the Company’s drug candidates, will require significant additional financing.  The future viability of the Company is dependent on its ability to successfully develop its drug candidates and to generate revenue from identifying and consummating transactions with third-party partners to further develop, obtain marketing approval for and/or commercialize its development assets or to raise additional capital to finance its operations.  The Company will require additional capital to complete the clinical development of zunsemetinib (ATI-450), ATI-1777 and ATI-2138, to develop its preclinical compounds, and to support its discovery efforts.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Additional funds may not be available on a timely basis, on commercially acceptable terms, or at all, and such funds, if raised, may not be sufficient to enable the Company to continue to implement its long-term business strategy.  The Company’s ability to raise additional capital may be adversely impacted by the potential worsening of global economic conditions, including inflationary pressure, and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the COVID-19 pandemic and geopolitical tensions.  If the Company is unable to raise sufficient additional capital or generate revenue from transactions with potential third-party partners for the development and/or commercialization of its drug candidates, it may need to substantially curtail planned operations. The Company’s failure to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that its condensed consolidated financial statements are issued.  As of the report date, the Company does not believe that substantial doubt exists about its ability to continue as a going concern.  The Company believes its existing cash, cash equivalents and marketable securities are sufficient to fund its operating and capital expenditure requirements for a period greater than 12 months from the date of issuance of these condensed consolidated financial statements.</p> 255800000 -634700000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">2. Summary of Significant Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Unaudited Interim Financial Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The accompanying condensed consolidated balance sheet as of June 30, 2022, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2022 and 2021, the condensed consolidated statement of stockholders’ equity for the three and six months ended June 30, 2022 and 2021, and the condensed consolidated statements of cash flows for the six months ended June 30, 2022 and 2021 are unaudited.  The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual financial statements contained in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 24, 2022 and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company’s financial position as of June 30, 2022, the results of its operations and comprehensive loss for the three and six months ended June 30, 2022 and 2021, its changes in stockholders’ equity for the three and six months ended June 30, 2022 and 2021 and its cash flows for the six months ended June 30, 2022 and 2021.  The condensed consolidated balance sheet data as of December 31, 2021 was derived from audited financial statements but does not include all disclosures required by generally accepted accounting principles in the United States (“GAAP”).  The financial data and other information disclosed in these notes related to the three and six months ended June 30, 2022 and 2021 are unaudited. The results for the three and six months ended June 30, 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2022, any other interim periods, or any future year or period.  The unaudited interim financial statements of the Company included herein have been prepared, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K filed with the SEC on February 24, 2022.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Basis of Presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The accompanying condensed consolidated financial statements have been prepared in conformity with GAAP.  The condensed consolidated financial statements of the Company include the accounts of the operating parent company, Aclaris Therapeutics, Inc., and its wholly-owned subsidiaries, ATIL and Confluence.  All intercompany transactions have been eliminated.  Based upon the Company’s revenue, the Company believes that gross profit does not provide a meaningful measure of profitability and, therefore, has not included a line item for gross profit on the condensed consolidated statement of operations.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods.  Significant estimates and assumptions reflected in these financial statements include, but are not limited to, contingent consideration and the valuation of stock-based awards.  Estimates are periodically reviewed in light of changes in circumstances, facts and experience.  As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require an update to its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities.  Actual results could differ from the Company’s estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Significant Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company’s significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K filed with the SEC on February 24, 2022.  Except as set forth below, there have been no changes to the Company’s significant accounting policies from those disclosed in the annual report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Contingent Consideration</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company initially recorded a contingent consideration liability at fair value on the date of acquisition related to future potential payments resulting from the acquisition of Confluence based upon significant unobservable inputs including the achievement of development, regulatory and commercial milestones, as well as estimated future sales levels and the discount rates applied to calculate the present value of the potential payments. <span style="background:#ffffff;">Significant judgement was involved in determining the appropriateness of these assumptions.  These assumptions are considered Level 3 inputs.  Revaluation of the contingent consideration liability can result from changes to one or more of these assumptions.  The Company evaluates the fair value estimate of the contingent consideration liability on a quarterly basis with changes, if any, recorded as income or expense in the condensed consolidated statement of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">The fair value of contingent consideration is estimated using a probability-weighted expected payment model for regulatory milestone payments and a Monte Carlo simulation model for commercial milestone and royalty payments and then applying a risk-adjusted discount rate to calculate the present value of the potential payments.  </span><span style="background:#ffffff;">Significant assumptions used in the Company’s estimates include the probability of achieving regulatory milestones and commencing commercialization, which are based on an asset’s current stage of development and a review of existing clinical data. Probability of success </span>assumptions ranged between 10% and 40% at June 30, 2022.  Additionally, estimated future sales levels and the risk-adjusted discount rate applied to the potential payments are also significant assumptions used in calculating the fair value.  The discount rate ranged between 10.2% and 10.9% depending<span style="background:#ffffff;"> on the year of each potential payment</span><span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Unaudited Interim Financial Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The accompanying condensed consolidated balance sheet as of June 30, 2022, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2022 and 2021, the condensed consolidated statement of stockholders’ equity for the three and six months ended June 30, 2022 and 2021, and the condensed consolidated statements of cash flows for the six months ended June 30, 2022 and 2021 are unaudited.  The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited annual financial statements contained in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 24, 2022 and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company’s financial position as of June 30, 2022, the results of its operations and comprehensive loss for the three and six months ended June 30, 2022 and 2021, its changes in stockholders’ equity for the three and six months ended June 30, 2022 and 2021 and its cash flows for the six months ended June 30, 2022 and 2021.  The condensed consolidated balance sheet data as of December 31, 2021 was derived from audited financial statements but does not include all disclosures required by generally accepted accounting principles in the United States (“GAAP”).  The financial data and other information disclosed in these notes related to the three and six months ended June 30, 2022 and 2021 are unaudited. The results for the three and six months ended June 30, 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2022, any other interim periods, or any future year or period.  The unaudited interim financial statements of the Company included herein have been prepared, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K filed with the SEC on February 24, 2022.  </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Basis of Presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The accompanying condensed consolidated financial statements have been prepared in conformity with GAAP.  The condensed consolidated financial statements of the Company include the accounts of the operating parent company, Aclaris Therapeutics, Inc., and its wholly-owned subsidiaries, ATIL and Confluence.  All intercompany transactions have been eliminated.  Based upon the Company’s revenue, the Company believes that gross profit does not provide a meaningful measure of profitability and, therefore, has not included a line item for gross profit on the condensed consolidated statement of operations.  </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods.  Significant estimates and assumptions reflected in these financial statements include, but are not limited to, contingent consideration and the valuation of stock-based awards.  Estimates are periodically reviewed in light of changes in circumstances, facts and experience.  As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require an update to its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities.  Actual results could differ from the Company’s estimates.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Significant Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company’s significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K filed with the SEC on February 24, 2022.  Except as set forth below, there have been no changes to the Company’s significant accounting policies from those disclosed in the annual report.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Contingent Consideration</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company initially recorded a contingent consideration liability at fair value on the date of acquisition related to future potential payments resulting from the acquisition of Confluence based upon significant unobservable inputs including the achievement of development, regulatory and commercial milestones, as well as estimated future sales levels and the discount rates applied to calculate the present value of the potential payments. <span style="background:#ffffff;">Significant judgement was involved in determining the appropriateness of these assumptions.  These assumptions are considered Level 3 inputs.  Revaluation of the contingent consideration liability can result from changes to one or more of these assumptions.  The Company evaluates the fair value estimate of the contingent consideration liability on a quarterly basis with changes, if any, recorded as income or expense in the condensed consolidated statement of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">The fair value of contingent consideration is estimated using a probability-weighted expected payment model for regulatory milestone payments and a Monte Carlo simulation model for commercial milestone and royalty payments and then applying a risk-adjusted discount rate to calculate the present value of the potential payments.  </span><span style="background:#ffffff;">Significant assumptions used in the Company’s estimates include the probability of achieving regulatory milestones and commencing commercialization, which are based on an asset’s current stage of development and a review of existing clinical data. Probability of success </span>assumptions ranged between 10% and 40% at June 30, 2022.  Additionally, estimated future sales levels and the risk-adjusted discount rate applied to the potential payments are also significant assumptions used in calculating the fair value.  The discount rate ranged between 10.2% and 10.9% depending<span style="background:#ffffff;"> on the year of each potential payment</span><span style="background:#ffffff;">.</span></p> 0.10 0.40 0.102 0.109 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">3. Fair Value of Financial Assets and Liabilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following tables present information about the fair value measurements of the Company’s financial assets and liabilities which are measured at fair value on a recurring and non-recurring basis, and indicate the level of the fair value hierarchy utilized to determine such fair values:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td></tr><tr><td style="vertical-align:bottom;width:57.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 63,838</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 63,838</p></td></tr><tr><td style="vertical-align:bottom;width:57.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 187,560</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 187,560</p></td></tr><tr><td style="vertical-align:bottom;width:57.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 63,838</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 187,560</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 251,398</p></td></tr><tr><td style="vertical-align:bottom;width:57.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 23,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 23,800</p></td></tr><tr><td style="vertical-align:bottom;width:57.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 23,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 23,800</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td></tr><tr><td style="vertical-align:bottom;width:57.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21,678</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21,678</p></td></tr><tr><td style="vertical-align:bottom;width:57.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 198,307</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 198,307</p></td></tr><tr><td style="vertical-align:bottom;width:57.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21,678</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 198,307</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 219,985</p></td></tr><tr><td style="vertical-align:bottom;width:57.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 28,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 28,400</p></td></tr><tr><td style="vertical-align:bottom;width:57.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 28,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 28,400</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of June 30, 2022 and December 31, 2021, the Company’s cash equivalents consisted of a money market fund, which was valued based upon Level 1 inputs.  The Company’s marketable securities as of June 30, 2022 and December </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">31, 2021 consisted of commercial paper and corporate, asset-backed and U.S. government agency debt securities, which were all valued based upon Level 2 inputs.  Marketable securities as of December 31, 2021 also included foreign government agency debt securities which were all valued based upon Level 2 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In determining the fair value of its Level 2 investments, the Company relies on quoted prices for identical securities in markets that are not active. These quoted prices are obtained by the Company with the assistance of a third-party pricing service based on available trade, bid and other observable market data for identical securities.  The Company compares the quoted prices obtained from the third-party pricing service to other available independent pricing information to validate the reasonableness of the quoted prices provided.  The Company evaluates whether adjustments to third-party pricing are necessary and, historically, the Company has not made adjustments to quoted prices obtained from the third-party pricing service.  During the three and six months ended June 30, 2022 and 2021, there were no transfers into or out of Level 3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">A decrease in the fair value of the contingent consideration liability of $4.6 million during the six months ended June 30, 2022 was mainly due to higher discount rates, resulting from higher risk-free rates and wider credit spreads, being applied to potential payments relative to prior periods.  The overall decrease was partially offset by an increase in the contingent consideration liability as a result of the impact of the passage of time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of June 30, 2022 and December 31, 2021, the fair value of the Company’s available-for-sale marketable securities by type of security was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:38.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gain</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:middle;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 47,201</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (398)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 46,803</p></td></tr><tr><td style="vertical-align:middle;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 56,053</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 56,053</p></td></tr><tr><td style="vertical-align:middle;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;">Asset-backed debt securities</span><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 28,423</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (175)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 28,248</p></td></tr><tr><td style="vertical-align:middle;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">U.S. government agency debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 57,211</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (755)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 56,456</p></td></tr><tr><td style="vertical-align:middle;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 188,888</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,328)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 187,560</p></td></tr><tr><td style="vertical-align:middle;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 6pt;"><sup style="font-size:4.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup> Included in Asset-backed debt securities is $7.2 million with maturity dates between one and five years.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:6pt;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:59.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:38.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gain</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:middle;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;">Corporate debt securities</span><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 40,993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (50)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 40,949</p></td></tr><tr><td style="vertical-align:middle;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 71,837</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 71,837</p></td></tr><tr><td style="vertical-align:middle;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Asset-backed debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 36,166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (43)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 36,123</p></td></tr><tr><td style="vertical-align:middle;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Foreign government agency debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,073</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,060</p></td></tr><tr><td style="vertical-align:middle;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;">U.S. government agency debt securities</span><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 45,465</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (127)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 45,338</p></td></tr><tr><td style="vertical-align:middle;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 198,534</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (233)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 198,307</p></td></tr><tr><td style="vertical-align:middle;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 6pt;"><sup style="font-size:4.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup> Included in Corporate debt securities is $9.2 million with maturity dates between one and five years.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 6pt;"><sup style="font-size:4.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup> Included in US government agency debt securities is $25.0 million with maturity dates between one and five years.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td></tr><tr><td style="vertical-align:bottom;width:57.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 63,838</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 63,838</p></td></tr><tr><td style="vertical-align:bottom;width:57.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 187,560</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 187,560</p></td></tr><tr><td style="vertical-align:bottom;width:57.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 63,838</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 187,560</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 251,398</p></td></tr><tr><td style="vertical-align:bottom;width:57.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 23,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 23,800</p></td></tr><tr><td style="vertical-align:bottom;width:57.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 23,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 23,800</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td></tr><tr><td style="vertical-align:bottom;width:57.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21,678</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21,678</p></td></tr><tr><td style="vertical-align:bottom;width:57.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 198,307</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 198,307</p></td></tr><tr><td style="vertical-align:bottom;width:57.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21,678</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 198,307</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 219,985</p></td></tr><tr><td style="vertical-align:bottom;width:57.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 28,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 28,400</p></td></tr><tr><td style="vertical-align:bottom;width:57.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 28,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 28,400</p></td></tr></table> 63838000 63838000 187560000 187560000 63838000 187560000 251398000 23800000 23800000 23800000 23800000 21678000 21678000 198307000 198307000 21678000 198307000 219985000 28400000 28400000 28400000 28400000 0 0 -4600000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:38.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gain</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:middle;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 47,201</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (398)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 46,803</p></td></tr><tr><td style="vertical-align:middle;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 56,053</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 56,053</p></td></tr><tr><td style="vertical-align:middle;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;">Asset-backed debt securities</span><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 28,423</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (175)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 28,248</p></td></tr><tr><td style="vertical-align:middle;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">U.S. government agency debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 57,211</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (755)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 56,456</p></td></tr><tr><td style="vertical-align:middle;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 188,888</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,328)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 187,560</p></td></tr><tr><td style="vertical-align:middle;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 6pt;"><sup style="font-size:4.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup> Included in Asset-backed debt securities is $7.2 million with maturity dates between one and five years.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:6pt;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:59.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:38.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gain</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:middle;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;">Corporate debt securities</span><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 40,993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (50)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 40,949</p></td></tr><tr><td style="vertical-align:middle;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 71,837</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 71,837</p></td></tr><tr><td style="vertical-align:middle;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Asset-backed debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 36,166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (43)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 36,123</p></td></tr><tr><td style="vertical-align:middle;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Foreign government agency debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,073</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,060</p></td></tr><tr><td style="vertical-align:middle;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:10pt;">U.S. government agency debt securities</span><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 45,465</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (127)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 45,338</p></td></tr><tr><td style="vertical-align:middle;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 198,534</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (233)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 198,307</p></td></tr><tr><td style="vertical-align:middle;width:59.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 6pt;"><sup style="font-size:4.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup> Included in Corporate debt securities is $9.2 million with maturity dates between one and five years.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:59.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0pt 6pt;"><sup style="font-size:4.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup> Included in US government agency debt securities is $25.0 million with maturity dates between one and five years.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td></tr></table> 47201000 398000 46803000 56053000 56053000 28423000 175000 28248000 57211000 755000 56456000 188888000 1328000 187560000 7200000 40993000 6000 50000 40949000 71837000 71837000 36166000 43000 36123000 4073000 13000 4060000 45465000 127000 45338000 198534000 6000 233000 198307000 9200000 25000000.0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">4. Property and Equipment, Net</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Property and equipment, net consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:middle;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,355</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,380</p></td></tr><tr><td style="vertical-align:middle;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Lab equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,879</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,605</p></td></tr><tr><td style="vertical-align:middle;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 620</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 620</p></td></tr><tr><td style="vertical-align:middle;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,123</p></td></tr><tr><td style="vertical-align:middle;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,977</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,728</p></td></tr><tr><td style="vertical-align:middle;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,701)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,393)</p></td></tr><tr><td style="vertical-align:middle;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,276</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,335</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Depreciation expense was $0.2 million for each of the three months ended June 30, 2022 and 2021, and $0.4 million for each of the six months ended June 30, 2022 and 2021.</p> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:middle;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,355</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,380</p></td></tr><tr><td style="vertical-align:middle;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Lab equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,879</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,605</p></td></tr><tr><td style="vertical-align:middle;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 620</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 620</p></td></tr><tr><td style="vertical-align:middle;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,123</p></td></tr><tr><td style="vertical-align:middle;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,977</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,728</p></td></tr><tr><td style="vertical-align:middle;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,701)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,393)</p></td></tr><tr><td style="vertical-align:middle;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,276</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,335</p></td></tr></table> 1355000 1380000 1879000 1605000 620000 620000 1123000 1123000 4977000 4728000 3701000 3393000 1276000 1335000 200000 200000 400000 400000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">5. Intangible Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">Intangible assets consisted of the following: </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated Amortization</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:43.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands, except years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">   </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life (years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">   </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">   </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">   </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">   </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:middle;width:43.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Other intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5.1 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 751</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 751</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 369</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 332</p></td></tr><tr><td style="vertical-align:middle;width:43.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">In-process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">n/a</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,629</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,629</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:43.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 369</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 332</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Amortization expense was $19 thousand for each of the three months ended June 30, 2022 and 2021, and $38 thousand for each of the six months ended June 30, 2022 and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of June 30, 2022, estimated future amortization expense was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:79.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ending</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 37</p></td></tr><tr><td style="vertical-align:bottom;width:79.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 75</p></td></tr><tr><td style="vertical-align:bottom;width:79.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 75</p></td></tr><tr><td style="vertical-align:bottom;width:79.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 75</p></td></tr><tr><td style="vertical-align:bottom;width:79.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 75</p></td></tr><tr><td style="vertical-align:bottom;width:79.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 45</p></td></tr><tr><td style="vertical-align:bottom;width:79.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 382</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated Amortization</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:43.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands, except years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">   </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life (years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">   </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">   </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">   </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">   </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:middle;width:43.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Other intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5.1 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 751</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 751</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 369</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 332</p></td></tr><tr><td style="vertical-align:middle;width:43.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">In-process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">n/a</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,629</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,629</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:43.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 369</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 332</p></td></tr></table> P5Y1M6D 751000 751000 369000 332000 6629000 6629000 7380000 7380000 369000 332000 19000 19000 38000000 38000000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:79.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ending</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:79.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 37</p></td></tr><tr><td style="vertical-align:bottom;width:79.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 75</p></td></tr><tr><td style="vertical-align:bottom;width:79.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 75</p></td></tr><tr><td style="vertical-align:bottom;width:79.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 75</p></td></tr><tr><td style="vertical-align:bottom;width:79.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 75</p></td></tr><tr><td style="vertical-align:bottom;width:79.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 45</p></td></tr><tr><td style="vertical-align:bottom;width:79.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 382</p></td></tr></table> 37000 75000 75000 75000 75000 45000 382000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">6. Accrued Expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Accrued expenses consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:74.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:middle;width:74.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Employee compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,885</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,389</p></td></tr><tr><td style="vertical-align:middle;width:74.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,771</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,278</p></td></tr><tr><td style="vertical-align:middle;width:74.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Litigation settlements (see Note 16)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,650</p></td></tr><tr><td style="vertical-align:middle;width:74.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,915</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,734</p></td></tr><tr><td style="vertical-align:bottom;width:74.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,051</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"> <span style="visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:74.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:middle;width:74.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Employee compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,885</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,389</p></td></tr><tr><td style="vertical-align:middle;width:74.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,771</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,278</p></td></tr><tr><td style="vertical-align:middle;width:74.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Litigation settlements (see Note 16)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,650</p></td></tr><tr><td style="vertical-align:middle;width:74.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,915</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,734</p></td></tr><tr><td style="vertical-align:bottom;width:74.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,051</p></td></tr></table> 2885000 4389000 2771000 1278000 2650000 1915000 1734000 7571000 10051000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">7. Debt</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Loan and Security Agreement – Silicon Valley Bank</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In March 2020, the Company entered into a Loan and Security Agreement with Silicon Valley Bank (“SVB”).  The Loan and Security Agreement provided for $11.0 million in term loans, of which the Company borrowed the entire amount on March 30, 2020.  In connection with the Loan and Security Agreement, the Company issued to SVB a warrant to purchase up to 460,251 shares of common stock (the “Warrant”) (see Note 8).  The proceeds of the Loan and Security Agreement were allocated to the term loan and Warrant using a relative fair value approach.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In July 2021, the Company repaid in full the $11.0 million that was outstanding under the Loan and Security Agreement, together with all accrued and unpaid interest and fees as of the payoff date, for a total payment of $11.7 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p> 11000000.0 460251 11000000.0 11700000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">8. Stockholders’ Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Preferred Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of June 30, 2022 and December 31, 2021, the Company’s amended and restated certificate of incorporation authorized the Company to issue 10,000,000 shares of undesignated preferred stock.  There were no shares of preferred stock outstanding as of June 30, 2022 or December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of June 30, 2022 and December 31, 2021, the Company’s amended and restated certificate of incorporation authorized the Company to issue 100,000,000 shares of $0.00001 par value common stock. There were 66,667,580 and 61,228,446 shares of common stock <span style="-sec-ix-hidden:Hidden_vHrjvMk0mEK4aLRXkOso4Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_FcktSZ33I0at1P2asKsO2w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> as of June 30, 2022 and December 31, 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any, subject to any preferential dividend rights of any series of preferred stock that may be outstanding.  No dividends have been declared through June 30, 2022.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Warrants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Warrant issued to SVB in March 2020 had an initial exercise price of $0.956 per share, subject to adjustment as provided in the Warrant.  The Warrant became immediately exercisable in full upon the funding of the term loan facility.  The Company assigned a fair value of $0.4 million to the Warrant using a Black-Scholes valuation methodology, and also concluded that the Warrant was indexed to its own stock and therefore classified the Warrant as an equity instrument.  In January 2021, SVB net exercised the Warrant in full, and the Company issued 388,119 shares of common stock to SVB.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">January 2021 Public Offering</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In January 2021, the Company closed a public offering in which it sold 6,306,271 shares of common stock at a price to the public of $17.50 per share, for aggregate gross proceeds of $110.4 million. The Company paid underwriting discounts and commissions of $6.6 million, and also incurred expenses of $0.4 million in connection with the offering.  As a result, the net offering proceeds received by the Company, after deducting underwriting discounts, commissions and offering expenses, were $103.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;background:#ffffff;">June 2021 Public Offering</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;background:#ffffff;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">In June 2021, the Company closed a public offering in which it sold </span><span style="background:#ffffff;">8,098,592</span><span style="background:#ffffff;"> shares of common stock at a price to the public of </span><span style="background:#ffffff;">$17.75</span><span style="background:#ffffff;"> per share, for aggregate gross proceeds of </span><span style="background:#ffffff;">$143.8</span><span style="background:#ffffff;"> million. The Company paid underwriting discounts and commissions of </span><span style="background:#ffffff;">$8.6</span><span style="background:#ffffff;"> million, and also incurred expenses of </span><span style="background:#ffffff;">$0.3</span><span style="background:#ffffff;"> million in connection with the offering.  As a result, the net offering proceeds received by the Company, after deducting underwriting discounts, commissions and offering expenses, were </span><span style="background:#ffffff;">$134.9</span><span style="background:#ffffff;"> million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;background:#ffffff;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;background:#ffffff;">Sales of Common Stock Pursuant to At-The-Market Facility</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/><span style="font-size:10pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;background:#ffffff;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">In April 2022, the Company sold </span><span style="background:#ffffff;">4,838,709</span><span style="background:#ffffff;"> shares of its common stock at a weighted average price per share of </span><span style="background:#ffffff;">$15.50</span><span style="background:#ffffff;">, for aggregate gross proceeds of </span><span style="background:#ffffff;">$75.0</span><span style="background:#ffffff;"> million, pursuant to a sales agreement with SVB Securities LLC and Cantor Fitzgerald &amp; Co., as sales agents, dated May 20, 2021.  The Company paid selling commissions and other fees of </span><span style="background:#ffffff;">$2.2</span><span style="background:#ffffff;"> million in connection with the sale.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p> 10000000 10000000 0 0 100000000 100000000 0.00001 0.00001 66667580 61228446 1 0 0.956 400000 388119 6306271 17.50 110400000 6600000 400000 103300000 8098592 17.75 143800000 8600000 300000 134900000 4838709 15.50 75000000.0 2200000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">9. Stock-Based Awards</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">2015 Equity Incentive Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In September 2015, the Company’s board of directors adopted the 2015 Equity Incentive Plan (the “2015 Plan”), and the Company’s stockholders approved the 2015 Plan. The 2015 Plan became effective in connection with the Company’s initial public offering in October 2015.  Beginning at the time the 2015 Plan became effective, no further grants may be made under the Company’s 2012 Equity Compensation Plan, as amended and restated (the “2012 Plan”).  The 2015 Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock unit (“RSU”) awards, performance stock awards, cash-based awards and other stock-based awards. The number of shares initially reserved for issuance under the 2015 Plan was 1,643,872 shares of common stock. The number of shares of common stock that may be issued under the 2015 Plan will automatically increase on January 1 of each year ending on January 1, 2025, in an amount equal to the lesser of (i) 4.0% of the shares of the Company’s common stock outstanding on December 31st of the preceding calendar year or (ii) an amount determined by the Company’s board of directors. The shares of common stock underlying any awards that expire, are otherwise terminated, settled in cash or repurchased by the Company under the 2015 Plan and the 2012 Plan will be added back to the shares of common stock available for issuance under the 2015 Plan.  As of January 1, 2022, the number of shares of common stock that may be issued under the 2015 Plan was automatically increased by 2,449,137 shares.  As of June 30, 2022, 3,372,766 shares remained available for grant under the 2015 Plan.  The Company had 4,130,376 stock options and 1,454,934 RSUs outstanding as of June 30, 2022 under the 2015 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">2017 Inducement Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In July 2017, the Company’s board of directors adopted the 2017 Inducement Plan (the “2017 Inducement Plan”).  The 2017 Inducement Plan is a non-stockholder approved stock plan adopted pursuant to the “inducement exception” provided under Nasdaq listing rules.  The Company had 410,600 stock options and 2,375 RSUs outstanding as of June 30, 2022 under the 2017 Inducement Plan.  All shares of common stock that were eligible for issuance under the 2017 Inducement Plan after October 1, 2018, including any shares underlying any awards that expire or are otherwise terminated, reacquired to satisfy tax withholding obligations, settled in cash or repurchased by the Company in the future that would have been eligible for re-issuance under the 2017 Inducement Plan, were retired.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">2012 Equity Compensation Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Upon the 2015 Plan becoming effective, no further grants can be made under the 2012 Plan.  The Company granted stock options to purchase a total of 1,140,524 shares under the 2012 Plan, of which 473,977 were outstanding as of June 30, 2022.  Stock options granted under the 2012 Plan expire after ten years.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Stock Option Valuation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The weighted average assumptions the Company used to estimate the fair value of stock options granted during the six months ended June 30, 2022 and 2021 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 77.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 76.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company recognizes compensation expense for awards over their vesting period.  Compensation expense for awards includes the impact of forfeitures in the period when they occur.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Stock Options</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes stock option activity for the six months ended June 30, 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.499691%;padding-left:0pt;padding-right:0pt;width:100.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share and per share data and years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,792,450</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 17.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 13,710</p></td></tr><tr><td style="vertical-align:bottom;width:58.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,891,950</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (85,672)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,115</p></td></tr><tr><td style="vertical-align:bottom;width:58.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited and cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (583,775)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 15.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,014,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,817</p></td></tr><tr><td style="vertical-align:bottom;width:58.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options vested and expected to vest as of June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,014,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,817</p></td></tr><tr><td style="vertical-align:bottom;width:58.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options exercisable as of June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,519,499</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 18.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,784</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The weighted average grant date fair value of stock options granted during the six months ended June 30, 2022 was $9.89 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Restricted Stock Units</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes RSU activity for the six months ended June 30, 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:62.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share and per share data)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Per Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,496,946</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 720,134</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Vested </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (513,958)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,645</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited and cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (245,813)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,457,309</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Stock-Based Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Stock-based compensation expense included in total costs and expenses on the condensed consolidated statement of operations included the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:59.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">     </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">     </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:middle;width:59.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 302</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 335</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 530</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 582</p></td></tr><tr><td style="vertical-align:middle;width:59.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 941</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,154</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 828</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,030</p></td></tr><tr><td style="vertical-align:middle;width:59.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,449</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,343</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,895</p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,692</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,832</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,038</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,507</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of June 30, 2022, the Company had unrecognized stock-based compensation expense for stock options and RSUs of $23.7 million and $18.3 million, respectively, which is expected to be recognized over weighted average periods of 3.2 years and 3.0 years, respectively.  </p> 1643872 0.040 2449137 3372766 4130376 1454934 410600 2375 0 1140524 473977 P10Y <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 77.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 76.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table> 0.0190 0.0091 P6Y2M12D P6Y2M12D 0.7795 0.7660 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.499691%;padding-left:0pt;padding-right:0pt;width:100.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share and per share data and years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,792,450</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 17.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 13,710</p></td></tr><tr><td style="vertical-align:bottom;width:58.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,891,950</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (85,672)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,115</p></td></tr><tr><td style="vertical-align:bottom;width:58.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited and cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (583,775)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 15.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,014,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,817</p></td></tr><tr><td style="vertical-align:bottom;width:58.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options vested and expected to vest as of June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,014,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,817</p></td></tr><tr><td style="vertical-align:bottom;width:58.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options exercisable as of June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,519,499</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 18.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,784</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div> 3792450 17.50 P6Y9M18D 13710000 1891950 14.40 85672 1.40 1115000 583775 15.70 5014953 16.81 P7Y1M6D 10817000 5014953 16.81 P7Y1M6D 10817000 2519499 18.26 P4Y9M18D 7784000 9.89 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:62.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share and per share data)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Per Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,496,946</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 720,134</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Vested </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (513,958)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,645</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited and cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (245,813)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,457,309</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 1496946 12.75 720134 14.44 513958 11.55 7645000 245813 12.17 1457309 14.11 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:59.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">     </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">     </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:middle;width:59.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 302</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 335</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 530</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 582</p></td></tr><tr><td style="vertical-align:middle;width:59.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 941</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,154</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 828</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,030</p></td></tr><tr><td style="vertical-align:middle;width:59.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,449</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,343</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,895</p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,692</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,832</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,038</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,507</p></td></tr></table> 302000 335000 530000 582000 941000 1154000 828000 2030000 2449000 2343000 4680000 3895000 3692000 3832000 6038000 6507000 23700000 18300000 P3Y2M12D P3Y <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">10. Net Loss per Share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Basic and diluted net loss per share is summarized in the following table:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:46.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:46.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands, except for share and per share data)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td></tr><tr><td style="vertical-align:bottom;width:46.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (20,532)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,161)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39,321)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (46,915)</p></td></tr><tr><td style="vertical-align:bottom;width:46.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Weighted average shares of common stock outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 65,990,031</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 53,968,405</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 63,723,123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 52,163,136</p></td></tr><tr><td style="vertical-align:bottom;width:46.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_PyF8VGINCUylOsFfNHPo3A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.31)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_iZFFZBMhiUapitav7r8YBw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.34)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_KB-whsSXu0219dmQzkte5g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.62)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_3YZUbB1NmUq7Y-Q6yokKPQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.90)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company’s potentially dilutive securities, which included stock options and RSUs, have been excluded from the computation of diluted net loss per share since the effect would be to reduce the net loss per share. Therefore, the weighted average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share is the same.  The following table presents potential shares of common stock excluded from the calculation of diluted </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">net loss per share for the three and six months ended June 30, 2022 and 2021.  All share amounts presented in the table below represent the total number outstanding as of June 30, 2022 and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;width:22.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;width:22.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:75.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:middle;width:75.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,014,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,738,625</p></td></tr><tr><td style="vertical-align:middle;width:75.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Restricted stock unit awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,457,309</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,498,716</p></td></tr><tr><td style="vertical-align:bottom;width:75.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total potential shares of common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,472,262</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,237,341</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:46.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:46.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands, except for share and per share data)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td></tr><tr><td style="vertical-align:bottom;width:46.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (20,532)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,161)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39,321)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (46,915)</p></td></tr><tr><td style="vertical-align:bottom;width:46.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Weighted average shares of common stock outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 65,990,031</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 53,968,405</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 63,723,123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 52,163,136</p></td></tr><tr><td style="vertical-align:bottom;width:46.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_PyF8VGINCUylOsFfNHPo3A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.31)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_iZFFZBMhiUapitav7r8YBw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.34)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_KB-whsSXu0219dmQzkte5g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.62)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_3YZUbB1NmUq7Y-Q6yokKPQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.90)</p></td></tr></table> -20532000 -18161000 -39321000 -46915000 65990031 53968405 63723123 52163136 -0.31 -0.34 -0.62 -0.90 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;width:22.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;width:22.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:75.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:middle;width:75.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,014,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,738,625</p></td></tr><tr><td style="vertical-align:middle;width:75.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Restricted stock unit awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,457,309</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,498,716</p></td></tr><tr><td style="vertical-align:bottom;width:75.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total potential shares of common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,472,262</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,237,341</p></td></tr></table> 5014953 3738625 1457309 1498716 6472262 5237341 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">11. Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Operating Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Agreements for Office and Laboratory Space</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company has a sublease agreement pursuant to which it subleases 33,019 square feet of office space for its headquarters in Wayne, Pennsylvania.  The sublease has a term that runs through October 2023.  If for any reason the lease between the landlord and sublandlord is terminated or expires prior to October 2023, the Company’s sublease will automatically terminate.  In December 2020, the Company entered into a sub-sublease agreement under which it sub-subleased 8,115 square feet to a third party.  The sub-sublease term runs concurrently with the original sublease agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In February 2019, the Company entered into a sublease agreement with a third party for 20,433 square feet of office and laboratory space in St. Louis, Missouri.  The lease commenced in June 2019 and has a term that runs through June 2029.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Supplemental balance sheet information related to operating leases is as follows:  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating Leases:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:71.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Gross cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,240</p></td></tr><tr><td style="vertical-align:middle;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,173)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,803)</p></td></tr><tr><td style="vertical-align:bottom;width:71.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,067</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,437</p></td></tr><tr><td style="vertical-align:bottom;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:71.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Current portion of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 741</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 693</p></td></tr><tr><td style="vertical-align:middle;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="-sec-ix-hidden:Hidden_ZBa1fnJL-0GUr42YV2Jbmg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,820</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,151</p></td></tr><tr><td style="vertical-align:bottom;width:71.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,561</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,844</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Amortization expense related to operating lease right-of-use assets and accretion of operating lease liabilities totaled $0.3 million for each of the three months ended June 30, 2022 and 2021 and $0.5 million for each of the six months ended June 30, 2022 and 2021.</p> 33019 8115 20433 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating Leases:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:71.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Gross cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,240</p></td></tr><tr><td style="vertical-align:middle;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,173)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,803)</p></td></tr><tr><td style="vertical-align:bottom;width:71.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,067</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,437</p></td></tr><tr><td style="vertical-align:bottom;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:71.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Current portion of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 741</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 693</p></td></tr><tr><td style="vertical-align:middle;width:71.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="-sec-ix-hidden:Hidden_ZBa1fnJL-0GUr42YV2Jbmg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,820</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,151</p></td></tr><tr><td style="vertical-align:bottom;width:71.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,561</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,844</p></td></tr></table> 5240000 5240000 2173000 1803000 3067000 3437000 741000 693000 1820000 2151000 2561000 2844000 300000 300000 500000 500000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">12.</b><span style="font-style:italic;font-weight:bold;"> </span><b style="font-weight:bold;">Agreements Related to Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Asset Purchase Agreement – </b><b style="font-weight:bold;">EPI Health, </b><b style="font-weight:bold;">LLC</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In October 2019, the Company sold RHOFADE (oxymetazoline hydrochloride) cream, 1% (“RHOFADE”) to EPI Health, LLC (“EPI Health”) pursuant to an asset purchase agreement.  EPI Health agreed to pay the Company a high single-digit royalty calculated as a percentage of net sales on a country-by-country basis until the date that the patent rights related to RHOFADE have expired or, if later, ten years from the date of the first commercial sale of RHOFADE in such country.  The Company recorded royalty income under the asset purchase agreement of $0.3 million and $0.2 million </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">during the three months ended June 30, 2022 and 2021, respectively, and $0.5 million and $0.4 million during the six months ended June 30, 2022 and 2021, respectively.  Royalty income is included in other revenue on the condensed consolidated statements of operations and comprehensive loss.  EPI Health has also agreed to pay the Company potential sales milestone payments of up to $20.0 million in the aggregate upon the achievement of specified levels of net sales of products covered by the asset purchase agreement, and 25% of any upfront, license, milestone, maintenance or fixed payment received by EPI Health in connection with any license or sublicense of the assets transferred in the disposition in any territory outside of the United States, subject to specified exceptions.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Agreement and Plan of Merger – Confluence</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company entered into an Agreement and Plan of Merger, pursuant to which it acquired Confluence (the “Confluence Agreement”).  Under the Confluence Agreement, the Company has agreed to pay the former Confluence equity holders aggregate remaining contingent consideration of up to $75.0 million based upon the achievement of specified future regulatory and commercial milestones set forth in the Confluence Agreement.  In addition, the Company has agreed to pay the former Confluence equity holders future royalty payments calculated as a low single-digit percentage of annual net sales, subject to specified reductions, limitations and other adjustments, until the date that all of the patent rights for that product have expired, as determined on a country-by-country and product-by-product basis or, in specified circumstances, ten years from the first commercial sale of such product.  In addition to the payments described above, if the Company sells, licenses or transfers any of the intellectual property acquired from Confluence pursuant to the Confluence Agreement to a third party, the Company will be obligated to pay the former Confluence equity holders a portion of any consideration received from such sale, license or transfer in specified circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of June 30, 2022 and December 31, 2021, the balance of the Company’s contingent consideration liability was $23.8 million and $28.4 million, respectively (see Note 3).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> P10Y 300000 200000 500000 400000 20000000.0 0.25 75000000.0 P10Y 23800000 28400000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">13. Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company did not record a federal or state income tax benefit for losses incurred during the three and six months ended June 30, 2022 and 2021.  The Company concluded that it is more likely than not that its deferred tax assets will not be realized which resulted in recording a full valuation allowance during those periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 0 0 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">14. Discontinued Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table presents information related to liabilities reported as discontinued operations in the Company’s condensed consolidated balance sheet:  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,202</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,202</p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;"> Discontinued operations - current liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,202</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,202</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">  <span style="visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="font-family:'Arial','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,202</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,202</p></td></tr><tr><td style="vertical-align:bottom;width:66.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;"> Discontinued operations - current liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,202</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,202</p></td></tr></table> 2202000 2202000 2202000 2202000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">15. Segment Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company has two reportable segments, therapeutics and contract research.  The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.  The contract research segment earns revenue from the provision of laboratory services.  Contract research revenue is generally evidenced by contracts with clients which are on an agreed upon fixed-price, fee-for-service basis.  Corporate and other includes general and administrative expenses as well as eliminations of intercompany transactions.  The Company does not report balance sheet information by segment since it is not reviewed by the chief operating decision maker, and all of the Company’s tangible assets are held in the United States.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company’s results of operations by segment for the three and six months ended June 30, 2022 and 2021 are summarized in the tables below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contract</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Corporate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Three Months Ended June 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Therapeutics</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Research</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Company</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 309</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (3,180)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,528</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,041</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (2,973)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,068</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,986</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (207)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,779</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 854</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,221</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,075</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Revaluation of contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (3,400)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (3,400)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (15,277)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (496)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (5,221)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (20,994)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contract</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Corporate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Three Months Ended June 30, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Therapeutics</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Research</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Company</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,481</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (1,875)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,824</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (1,761)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,263</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,011</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (114)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,897</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Sales and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 879</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,991</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,870</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Revaluation of contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,800</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (12,593)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (422)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (4,991)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (18,006)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contract</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Corporate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Six Months Ended June 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Therapeutics</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Research</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Company</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 541</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (6,055)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,981</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,897</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (5,674)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,223</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,466</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (381)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,085</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,695</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,479</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,174</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Revaluation of contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (4,600)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (4,600)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (28,325)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (1,097)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (10,479)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (39,901)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contract</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Corporate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Six Months Ended June 30, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Therapeutics</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Research</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Company</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 460</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,681</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (3,540)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,601</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (3,328)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,465</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,946</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (211)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,735</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,507</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,697</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Revaluation of contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,239</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,239</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (36,725)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (619)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (9,191)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (46,535)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Intersegment Revenue</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Revenue for the contract research segment included $3.2 million and $1.9 million for services performed on behalf of the therapeutics segment for the three months ended June 30, 2022 and 2021, respectively, and $6.1 million and $3.5 million for the six months ended June 30, 2022 and 2021, respectively.  All intersegment revenue has been eliminated in the Company’s condensed consolidated statement of operations.  </p> 2 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contract</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Corporate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Three Months Ended June 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Therapeutics</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Research</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Company</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 309</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (3,180)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,528</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,041</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (2,973)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,068</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,986</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (207)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,779</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 854</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,221</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,075</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Revaluation of contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (3,400)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (3,400)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (15,277)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (496)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (5,221)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (20,994)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contract</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Corporate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Three Months Ended June 30, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Therapeutics</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Research</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Company</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,481</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (1,875)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,824</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (1,761)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,263</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,011</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (114)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,897</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Sales and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 879</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,991</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,870</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Revaluation of contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,800</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (12,593)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (422)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (4,991)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (18,006)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contract</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Corporate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Six Months Ended June 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Therapeutics</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Research</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Company</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 541</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (6,055)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,981</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,897</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (5,674)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,223</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,466</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (381)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,085</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,695</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,479</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,174</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Revaluation of contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (4,600)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (4,600)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (28,325)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (1,097)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (10,479)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (39,901)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contract</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Corporate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Six Months Ended June 30, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Therapeutics</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Research</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Company</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 460</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,681</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (3,540)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,601</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (3,328)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,465</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,946</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (211)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,735</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,507</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,697</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Revaluation of contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,239</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,239</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (36,725)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (619)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (9,191)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (46,535)</p></td></tr></table> 309000 4399000 -3180000 1528000 4041000 -2973000 1068000 18986000 -207000 18779000 854000 5221000 6075000 -3400000 -3400000 -15277000 -496000 -5221000 -20994000 218000 3481000 -1875000 1824000 3024000 -1761000 1263000 8011000 -114000 7897000 879000 4991000 5870000 4800000 4800000 -12593000 -422000 -4991000 -18006000 541000 8495000 -6055000 2981000 7897000 -5674000 2223000 33466000 -381000 33085000 1695000 10479000 12174000 -4600000 -4600000 -28325000 -1097000 -10479000 -39901000 460000 6681000 -3540000 3601000 5793000 -3328000 2465000 15946000 -211000 15735000 1507000 9190000 10697000 21239000 21239000 -36725000 -619000 -9191000 -46535000 3200000 1900000 6100000 3500000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">16. Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Securities Class Action</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On July 30, 2019, plaintiff Linda Rosi (“Rosi”) filed a putative class action complaint captioned <i style="font-style:italic;">Rosi v. Aclaris Therapeutics, Inc., et al.</i> in the U.S. District Court for the Southern District of New York against the Company and certain of its executive officers.  The complaint alleged that the defendants violated federal securities laws by, among other things, failing to disclose an alleged likelihood that regulators would scrutinize advertising materials related to ESKATA (hydrogen peroxide) topical solution, 40% (w/w) (“ESKATA”) and find that the materials minimized the risks or overstated the efficacy of the product.  The complaint sought unspecified compensatory damages on behalf of Rosi and all </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">other persons and entities that purchased or otherwise acquired the Company’s securities between May 8, 2018 and June 20, 2019. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On September 5, 2019, an additional plaintiff, Robert Fulcher (“Fulcher”), filed a substantially identical putative class action complaint captioned <i style="font-style:italic;">Fulcher v. Aclaris Therapeutics, Inc., et al.</i> in the same court against the same defendants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On November 6, 2019, the court consolidated the Rosi and Fulcher actions (together, the “Consolidated Securities Action”) and appointed Fulcher “lead plaintiff” for the putative class. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On January 24, 2020, Fulcher filed a consolidated amended complaint in the Consolidated Securities Action, naming two additional executive officers as defendants, extending the putative class period to August 12, 2019, and adding allegations concerning, among other things, alleged statements and omissions throughout the putative class period concerning ESKATA’s risks, tolerability and effectiveness. The defendants filed a motion to dismiss the consolidated amended complaint on April 17, 2020. Following briefing and oral argument on February 25, 2021, the motion was granted in part and denied in part on March 29, 2021, and the issues in dispute significantly narrowed. The defendants filed an answer to the remaining aspects of the consolidated amended complaint on April 19, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">In June 2021, the defendants and the plaintiffs agreed to settle the Consolidated Securities Action. The parties signed and filed a settlement agreement in July 2021. On August 18, 2021, the court preliminarily approved the proposed settlement, directed that notice be given to the putative class and scheduled the final approval settlement hearing for November 30, 2021. Notice was subsequently given to the putative class. The court granted final approval of the settlement on December 9, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company’s financial obligation under the settlement was $2.7 million, which was within the limits of its insurance coverage. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;background:#ffff00;">​</span></p> 2 2700000 EXCEL 71 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 72 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 73 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 74 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 176 252 1 false 51 0 false 8 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sheet http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Statements 4 false false R5.htm 00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) Sheet http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) Statements 5 false false R6.htm 00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 6 false false R7.htm 00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Sheet http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Statements 7 false false R8.htm 00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 8 false false R9.htm 10101 - Disclosure - Organization and Nature of Business Sheet http://www.aclaristx.com/role/DisclosureOrganizationAndNatureOfBusiness Organization and Nature of Business Notes 9 false false R10.htm 10201 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 10301 - Disclosure - Fair Value of Financial Assets and Liabilities Sheet http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilities Fair Value of Financial Assets and Liabilities Notes 11 false false R12.htm 10401 - Disclosure - Property and Equipment, Net Sheet http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNet Property and Equipment, Net Notes 12 false false R13.htm 10501 - Disclosure - Intangible Assets Sheet http://www.aclaristx.com/role/DisclosureIntangibleAssets Intangible Assets Notes 13 false false R14.htm 10601 - Disclosure - Accrued Expenses Sheet http://www.aclaristx.com/role/DisclosureAccruedExpenses Accrued Expenses Notes 14 false false R15.htm 10701 - Disclosure - Debt Sheet http://www.aclaristx.com/role/DisclosureDebt Debt Notes 15 false false R16.htm 10801 - Disclosure - Stockholders' Equity Sheet http://www.aclaristx.com/role/DisclosureStockholdersEquity Stockholders' Equity Notes 16 false false R17.htm 10901 - Disclosure - Stock-Based Awards Sheet http://www.aclaristx.com/role/DisclosureStockBasedAwards Stock-Based Awards Notes 17 false false R18.htm 11001 - Disclosure - Net Loss per Share Sheet http://www.aclaristx.com/role/DisclosureNetLossPerShare Net Loss per Share Notes 18 false false R19.htm 11101 - Disclosure - Leases Sheet http://www.aclaristx.com/role/DisclosureLeases Leases Notes 19 false false R20.htm 11201 - Disclosure - Agreements Related to Intellectual Property Sheet http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualProperty Agreements Related to Intellectual Property Notes 20 false false R21.htm 11301 - Disclosure - Income Taxes Sheet http://www.aclaristx.com/role/DisclosureIncomeTaxes Income Taxes Notes 21 false false R22.htm 11401 - Disclosure - Discontinued Operations Sheet http://www.aclaristx.com/role/DisclosureDiscontinuedOperations Discontinued Operations Notes 22 false false R23.htm 11501 - Disclosure - Segment Information Sheet http://www.aclaristx.com/role/DisclosureSegmentInformation Segment Information Notes 23 false false R24.htm 11601 - Disclosure - Legal Proceedings Sheet http://www.aclaristx.com/role/DisclosureLegalProceedings Legal Proceedings Notes 24 false false R25.htm 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPolicies 25 false false R26.htm 30303 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables) Sheet http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables Fair Value of Financial Assets and Liabilities (Tables) Tables http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilities 26 false false R27.htm 30403 - Disclosure - Property and Equipment, Net (Tables) Sheet http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetTables Property and Equipment, Net (Tables) Tables http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNet 27 false false R28.htm 30503 - Disclosure - Intangible Assets (Tables) Sheet http://www.aclaristx.com/role/DisclosureIntangibleAssetsTables Intangible Assets (Tables) Tables http://www.aclaristx.com/role/DisclosureIntangibleAssets 28 false false R29.htm 30603 - Disclosure - Accrued Expenses (Tables) Sheet http://www.aclaristx.com/role/DisclosureAccruedExpensesTables Accrued Expenses (Tables) Tables http://www.aclaristx.com/role/DisclosureAccruedExpenses 29 false false R30.htm 30903 - Disclosure - Stock-Based Awards (Tables) Sheet http://www.aclaristx.com/role/DisclosureStockBasedAwardsTables Stock-Based Awards (Tables) Tables http://www.aclaristx.com/role/DisclosureStockBasedAwards 30 false false R31.htm 31003 - Disclosure - Net Loss per Share (Tables) Sheet http://www.aclaristx.com/role/DisclosureNetLossPerShareTables Net Loss per Share (Tables) Tables http://www.aclaristx.com/role/DisclosureNetLossPerShare 31 false false R32.htm 31103 - Disclosure - Leases (Tables) Sheet http://www.aclaristx.com/role/DisclosureLeasesTables Leases (Tables) Tables http://www.aclaristx.com/role/DisclosureLeases 32 false false R33.htm 31403 - Disclosure - Discontinued Operations (Tables) Sheet http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsTables Discontinued Operations (Tables) Tables http://www.aclaristx.com/role/DisclosureDiscontinuedOperations 33 false false R34.htm 31503 - Disclosure - Segment Information (Tables) Sheet http://www.aclaristx.com/role/DisclosureSegmentInformationTables Segment Information (Tables) Tables http://www.aclaristx.com/role/DisclosureSegmentInformation 34 false false R35.htm 40101 - Disclosure - Organization and Nature of Business (Details) Sheet http://www.aclaristx.com/role/DisclosureOrganizationAndNatureOfBusinessDetails Organization and Nature of Business (Details) Details http://www.aclaristx.com/role/DisclosureOrganizationAndNatureOfBusiness 35 false false R36.htm 40201 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies 36 false false R37.htm 40301 - Disclosure - Fair Value of Financial Assets and Liabilities (Details) Sheet http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails Fair Value of Financial Assets and Liabilities (Details) Details http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables 37 false false R38.htm 40302 - Disclosure - Fair Value of Financial Assets and Liabilities - By Type (Details) Sheet http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails Fair Value of Financial Assets and Liabilities - By Type (Details) Details http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables 38 false false R39.htm 40401 - Disclosure - Property and Equipment, Net (Details) Sheet http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetDetails Property and Equipment, Net (Details) Details http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetTables 39 false false R40.htm 40501 - Disclosure - Intangible Assets (Details) Sheet http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetails Intangible Assets (Details) Details http://www.aclaristx.com/role/DisclosureIntangibleAssetsTables 40 false false R41.htm 40502 - Disclosure - Intangible Assets - Future Amortization Expenses (Details) Sheet http://www.aclaristx.com/role/DisclosureIntangibleAssetsFutureAmortizationExpensesDetails Intangible Assets - Future Amortization Expenses (Details) Details 41 false false R42.htm 40601 - Disclosure - Accrued Expenses (Details) Sheet http://www.aclaristx.com/role/DisclosureAccruedExpensesDetails Accrued Expenses (Details) Details http://www.aclaristx.com/role/DisclosureAccruedExpensesTables 42 false false R43.htm 40701 - Disclosure - Debt (Details) Sheet http://www.aclaristx.com/role/DisclosureDebtDetails Debt (Details) Details http://www.aclaristx.com/role/DisclosureDebt 43 false false R44.htm 40801 - Disclosure - Stockholders' Equity (Details) Sheet http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails Stockholders' Equity (Details) Details http://www.aclaristx.com/role/DisclosureStockholdersEquity 44 false false R45.htm 40802 - Disclosure - Stockholders' Equity - Other Offerings and ATM Facility (Details) Sheet http://www.aclaristx.com/role/DisclosureStockholdersEquityOtherOfferingsAndAtmFacilityDetails Stockholders' Equity - Other Offerings and ATM Facility (Details) Details 45 false false R46.htm 40901 - Disclosure - Stock-Based Awards (Details) Sheet http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails Stock-Based Awards (Details) Details http://www.aclaristx.com/role/DisclosureStockBasedAwardsTables 46 false false R47.htm 40902 - Disclosure - Stock-Based Awards - Option Activity (Details) Sheet http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails Stock-Based Awards - Option Activity (Details) Details 47 false false R48.htm 40903 - Disclosure - Stock-Based Awards - RSUs (Details) Sheet http://www.aclaristx.com/role/DisclosureStockBasedAwardsRsusDetails Stock-Based Awards - RSUs (Details) Details 48 false false R49.htm 40904 - Disclosure - Stock-Based Awards - Compensation (Details) Sheet http://www.aclaristx.com/role/DisclosureStockBasedAwardsCompensationDetails Stock-Based Awards - Compensation (Details) Details 49 false false R50.htm 41001 - Disclosure - Net Loss per Share (Details) Sheet http://www.aclaristx.com/role/DisclosureNetLossPerShareDetails Net Loss per Share (Details) Details http://www.aclaristx.com/role/DisclosureNetLossPerShareTables 50 false false R51.htm 41002 - Disclosure - Net Loss per Share - Anti-dilution (Details) Sheet http://www.aclaristx.com/role/DisclosureNetLossPerShareAntiDilutionDetails Net Loss per Share - Anti-dilution (Details) Details 51 false false R52.htm 41101 - Disclosure - Leases (Details) Sheet http://www.aclaristx.com/role/DisclosureLeasesDetails Leases (Details) Details http://www.aclaristx.com/role/DisclosureLeasesTables 52 false false R53.htm 41201 - Disclosure - Agreements Related to Intellectual Property (Details) Sheet http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails Agreements Related to Intellectual Property (Details) Details http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualProperty 53 false false R54.htm 41301 - Disclosure - Income Taxes (Details) Sheet http://www.aclaristx.com/role/DisclosureIncomeTaxesDetails Income Taxes (Details) Details http://www.aclaristx.com/role/DisclosureIncomeTaxes 54 false false R55.htm 41401 - Disclosure - Discontinued Operations - Assets and Liabilities (Details) Sheet http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails Discontinued Operations - Assets and Liabilities (Details) Details 55 false false R56.htm 41501 - Disclosure - Segment Information (Details) Sheet http://www.aclaristx.com/role/DisclosureSegmentInformationDetails Segment Information (Details) Details http://www.aclaristx.com/role/DisclosureSegmentInformationTables 56 false false R57.htm 41601 - Disclosure - Legal Proceedings (Details) Sheet http://www.aclaristx.com/role/DisclosureLegalProceedingsDetails Legal Proceedings (Details) Details http://www.aclaristx.com/role/DisclosureLegalProceedings 57 false false All Reports Book All Reports acrs-20220630x10q.htm acrs-20220630.xsd acrs-20220630_cal.xml acrs-20220630_def.xml acrs-20220630_lab.xml acrs-20220630_pre.xml acrs-20220630xex10d1.htm acrs-20220630xex31d1.htm acrs-20220630xex31d2.htm acrs-20220630xex32d1.htm http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 77 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "acrs-20220630x10q.htm": { "axisCustom": 0, "axisStandard": 22, "contextCount": 176, "dts": { "calculationLink": { "local": [ "acrs-20220630_cal.xml" ] }, "definitionLink": { "local": [ "acrs-20220630_def.xml" ] }, "inline": { "local": [ "acrs-20220630x10q.htm" ] }, "labelLink": { "local": [ "acrs-20220630_lab.xml" ] }, "presentationLink": { "local": [ "acrs-20220630_pre.xml" ] }, "schema": { "local": [ "acrs-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 434, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 32, "http://xbrl.sec.gov/dei/2021q4": 5, "total": 37 }, "keyCustom": 23, "keyStandard": 229, "memberCustom": 22, "memberStandard": 27, "nsprefix": "acrs", "nsuri": "http://www.aclaristx.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - Fair Value of Financial Assets and Liabilities", "role": "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilities", "shortName": "Fair Value of Financial Assets and Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Property and Equipment, Net", "role": "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNet", "shortName": "Property and Equipment, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Intangible Assets", "role": "http://www.aclaristx.com/role/DisclosureIntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "acrs:AccruedLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Accrued Expenses", "role": "http://www.aclaristx.com/role/DisclosureAccruedExpenses", "shortName": "Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "acrs:AccruedLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Debt", "role": "http://www.aclaristx.com/role/DisclosureDebt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Stockholders' Equity", "role": "http://www.aclaristx.com/role/DisclosureStockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - Stock-Based Awards", "role": "http://www.aclaristx.com/role/DisclosureStockBasedAwards", "shortName": "Stock-Based Awards", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - Net Loss per Share", "role": "http://www.aclaristx.com/role/DisclosureNetLossPerShare", "shortName": "Net Loss per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "acrs:LesseeOperatingAndFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - Leases", "role": "http://www.aclaristx.com/role/DisclosureLeases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "acrs:LesseeOperatingAndFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_Oq-yHLOFykieiYrfaiBUvA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "role": "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_Oq-yHLOFykieiYrfaiBUvA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11201 - Disclosure - Agreements Related to Intellectual Property", "role": "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualProperty", "shortName": "Agreements Related to Intellectual Property", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11301 - Disclosure - Income Taxes", "role": "http://www.aclaristx.com/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11401 - Disclosure - Discontinued Operations", "role": "http://www.aclaristx.com/role/DisclosureDiscontinuedOperations", "shortName": "Discontinued Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11501 - Disclosure - Segment Information", "role": "http://www.aclaristx.com/role/DisclosureSegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11601 - Disclosure - Legal Proceedings", "role": "http://www.aclaristx.com/role/DisclosureLegalProceedings", "shortName": "Legal Proceedings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "acrs:UnauditedInterimFinancialInformationPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "acrs:UnauditedInterimFinancialInformationPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30303 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)", "role": "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables", "shortName": "Fair Value of Financial Assets and Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30403 - Disclosure - Property and Equipment, Net (Tables)", "role": "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetTables", "shortName": "Property and Equipment, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "acrs:ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - Intangible Assets (Tables)", "role": "http://www.aclaristx.com/role/DisclosureIntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "acrs:ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30603 - Disclosure - Accrued Expenses (Tables)", "role": "http://www.aclaristx.com/role/DisclosureAccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_Oq-yHLOFykieiYrfaiBUvA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_hYaLwLakZU658wysTJAHXw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_Oq-yHLOFykieiYrfaiBUvA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_hYaLwLakZU658wysTJAHXw", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30903 - Disclosure - Stock-Based Awards (Tables)", "role": "http://www.aclaristx.com/role/DisclosureStockBasedAwardsTables", "shortName": "Stock-Based Awards (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31003 - Disclosure - Net Loss per Share (Tables)", "role": "http://www.aclaristx.com/role/DisclosureNetLossPerShareTables", "shortName": "Net Loss per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "acrs:LesseeOperatingAndFinanceLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31103 - Disclosure - Leases (Tables)", "role": "http://www.aclaristx.com/role/DisclosureLeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "acrs:LesseeOperatingAndFinanceLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31403 - Disclosure - Discontinued Operations (Tables)", "role": "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsTables", "shortName": "Discontinued Operations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31503 - Disclosure - Segment Information (Tables)", "role": "http://www.aclaristx.com/role/DisclosureSegmentInformationTables", "shortName": "Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "us-gaap:NatureOfOperations", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_Oq-yHLOFykieiYrfaiBUvA", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - Organization and Nature of Business (Details)", "role": "http://www.aclaristx.com/role/DisclosureOrganizationAndNatureOfBusinessDetails", "shortName": "Organization and Nature of Business (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:NatureOfOperations", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_Oq-yHLOFykieiYrfaiBUvA", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "acrs:ContingentConsiderationPolicyPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_srt_RangeAxis_srt_MinimumMember_wBnOXDyLrkegsoRdvU6fpw", "decimals": "2", "first": true, "lang": null, "name": "acrs:PercentageOfAssetsCurrentStageOfDevelopmentAndReview", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_EVHanOnFQU6ReGJuBRq3jw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40201 - Disclosure - Summary of Significant Accounting Policies (Details)", "role": "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "acrs:ContingentConsiderationPolicyPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_srt_RangeAxis_srt_MinimumMember_wBnOXDyLrkegsoRdvU6fpw", "decimals": "2", "first": true, "lang": null, "name": "acrs:PercentageOfAssetsCurrentStageOfDevelopmentAndReview", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_EVHanOnFQU6ReGJuBRq3jw", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_Oq-yHLOFykieiYrfaiBUvA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - Fair Value of Financial Assets and Liabilities (Details)", "role": "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails", "shortName": "Fair Value of Financial Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": "-3", "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_Oq-yHLOFykieiYrfaiBUvA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40302 - Disclosure - Fair Value of Financial Assets and Liabilities - By Type (Details)", "role": "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails", "shortName": "Fair Value of Financial Assets and Liabilities - By Type (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_Oq-yHLOFykieiYrfaiBUvA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_Oq-yHLOFykieiYrfaiBUvA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - Property and Equipment, Net (Details)", "role": "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetDetails", "shortName": "Property and Equipment, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "As_Of_12_31_2021_fsx-f5QZiU6vWsW90sR6qA", "decimals": "-3", "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_8fqtuW3OekiboLOzW6CIaw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "role": "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_8fqtuW3OekiboLOzW6CIaw", "decimals": "-3", "lang": null, "name": "us-gaap:CostsAndExpenses", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "acrs:ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_Oq-yHLOFykieiYrfaiBUvA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Intangible Assets (Details)", "role": "http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetails", "shortName": "Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "acrs:ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_Oq-yHLOFykieiYrfaiBUvA", "decimals": "-3", "lang": null, "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "us-gaap:AmortizationOfIntangibleAssets", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_8fqtuW3OekiboLOzW6CIaw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40502 - Disclosure - Intangible Assets - Future Amortization Expenses (Details)", "role": "http://www.aclaristx.com/role/DisclosureIntangibleAssetsFutureAmortizationExpensesDetails", "shortName": "Intangible Assets - Future Amortization Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:AmortizationOfIntangibleAssets", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_8fqtuW3OekiboLOzW6CIaw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_Oq-yHLOFykieiYrfaiBUvA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - Accrued Expenses (Details)", "role": "http://www.aclaristx.com/role/DisclosureAccruedExpensesDetails", "shortName": "Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_Oq-yHLOFykieiYrfaiBUvA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "As_Of_1_31_2021_srt_CounterpartyNameAxis_acrs_SiliconValleyBankMember_g8YK-ZfwPECFAuoTFfES4g", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unitRef": "Unit_Standard_shares_Vcs4S45AxEyF4XSsDexLzA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Debt (Details)", "role": "http://www.aclaristx.com/role/DisclosureDebtDetails", "shortName": "Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_acrs_TermLoanFacilityMember_A0CEC-gai0GJfOjhyzhR4A", "decimals": "-5", "lang": null, "name": "us-gaap:LineOfCredit", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_Oq-yHLOFykieiYrfaiBUvA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Unit_Standard_shares_Vcs4S45AxEyF4XSsDexLzA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - Stockholders' Equity (Details)", "role": "http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails", "shortName": "Stockholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_Oq-yHLOFykieiYrfaiBUvA", "decimals": "-3", "lang": null, "name": "us-gaap:DividendsPayableCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "As_Of_1_31_2021_us-gaap_SubsidiarySaleOfStockAxis_acrs_January2021PublicOfferingMember_A-chqy3A80mF3f169qfn3A", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_Vcs4S45AxEyF4XSsDexLzA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40802 - Disclosure - Stockholders' Equity - Other Offerings and ATM Facility (Details)", "role": "http://www.aclaristx.com/role/DisclosureStockholdersEquityOtherOfferingsAndAtmFacilityDetails", "shortName": "Stockholders' Equity - Other Offerings and ATM Facility (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "As_Of_1_31_2021_us-gaap_SubsidiarySaleOfStockAxis_acrs_January2021PublicOfferingMember_A-chqy3A80mF3f169qfn3A", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_Vcs4S45AxEyF4XSsDexLzA", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "Unit_Standard_shares_Vcs4S45AxEyF4XSsDexLzA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - Stock-Based Awards (Details)", "role": "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails", "shortName": "Stock-Based Awards (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": "4", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_EVHanOnFQU6ReGJuBRq3jw", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "As_Of_12_31_2021_fsx-f5QZiU6vWsW90sR6qA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_Standard_shares_Vcs4S45AxEyF4XSsDexLzA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40902 - Disclosure - Stock-Based Awards - Option Activity (Details)", "role": "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails", "shortName": "Stock-Based Awards - Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_Vcs4S45AxEyF4XSsDexLzA", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_dpJswDsUNECwr_kwY1fNjA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_Vcs4S45AxEyF4XSsDexLzA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40903 - Disclosure - Stock-Based Awards - RSUs (Details)", "role": "http://www.aclaristx.com/role/DisclosureStockBasedAwardsRsusDetails", "shortName": "Stock-Based Awards - RSUs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_dpJswDsUNECwr_kwY1fNjA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_Vcs4S45AxEyF4XSsDexLzA", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_stM3CtTgqUOrIv6htJdQBA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40904 - Disclosure - Stock-Based Awards - Compensation (Details)", "role": "http://www.aclaristx.com/role/DisclosureStockBasedAwardsCompensationDetails", "shortName": "Stock-Based Awards - Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_stM3CtTgqUOrIv6htJdQBA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_8fqtuW3OekiboLOzW6CIaw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)", "role": "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_8fqtuW3OekiboLOzW6CIaw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_8fqtuW3OekiboLOzW6CIaw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - Net Loss per Share (Details)", "role": "http://www.aclaristx.com/role/DisclosureNetLossPerShareDetails", "shortName": "Net Loss per Share (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_Vcs4S45AxEyF4XSsDexLzA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41002 - Disclosure - Net Loss per Share - Anti-dilution (Details)", "role": "http://www.aclaristx.com/role/DisclosureNetLossPerShareAntiDilutionDetails", "shortName": "Net Loss per Share - Anti-dilution (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_Vcs4S45AxEyF4XSsDexLzA", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "acrs:LesseeOperatingAndFinanceLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_Oq-yHLOFykieiYrfaiBUvA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NetRentableArea", "reportCount": 1, "unitRef": "Unit_Standard_sqft_l3Bzh-hJCkaaQWbGOllZWg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41101 - Disclosure - Leases (Details)", "role": "http://www.aclaristx.com/role/DisclosureLeasesDetails", "shortName": "Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "acrs:LesseeOperatingAndFinanceLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "As_Of_2_28_2019_ph2chBS1LEeb-l3cdgSI-Q", "decimals": "INF", "lang": null, "name": "us-gaap:NetRentableArea", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_sqft_l3Bzh-hJCkaaQWbGOllZWg", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_8fqtuW3OekiboLOzW6CIaw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41201 - Disclosure - Agreements Related to Intellectual Property (Details)", "role": "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails", "shortName": "Agreements Related to Intellectual Property (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_us-gaap_TypeOfArrangementAxis_acrs_AgreementAndPlanOfMergerMember_rz9aXv0Xck6urgPPBp1bmQ", "decimals": null, "lang": "en-US", "name": "acrs:AgreementTermDuration", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_8fqtuW3OekiboLOzW6CIaw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41301 - Disclosure - Income Taxes (Details)", "role": "http://www.aclaristx.com/role/DisclosureIncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_8fqtuW3OekiboLOzW6CIaw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_Oq-yHLOFykieiYrfaiBUvA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41401 - Disclosure - Discontinued Operations - Assets and Liabilities (Details)", "role": "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails", "shortName": "Discontinued Operations - Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_Oq-yHLOFykieiYrfaiBUvA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_segment_xgHyAFjJS02yh-UNJzDPfw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41501 - Disclosure - Segment Information (Details)", "role": "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails", "shortName": "Segment Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_segment_xgHyAFjJS02yh-UNJzDPfw", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "As_Of_12_31_2021_fsx-f5QZiU6vWsW90sR6qA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LossContingencyAccrualCarryingValueCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41601 - Disclosure - Legal Proceedings (Details)", "role": "http://www.aclaristx.com/role/DisclosureLegalProceedingsDetails", "shortName": "Legal Proceedings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "As_Of_6_30_2022_srt_LitigationCaseAxis_acrs_RosiAndFulcherVs.AclarisTherapeuticsInc.Member_Lsq6NYerLUuqa0sWrEyrLg", "decimals": "-4", "lang": null, "name": "us-gaap:LossContingencyAccrualCarryingValueCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WdLKCE8cckahcVj22l4V2w", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "role": "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9drtx8_SQEa9WLOzaz9jlQ", "decimals": "-3", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_us-gaap_SubsidiarySaleOfStockAxis_acrs_FollowOnPublicOfferingMember_YcxPHX6zjUuspu02tX3e_g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)", "role": "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_us-gaap_SubsidiarySaleOfStockAxis_acrs_FollowOnPublicOfferingMember_YcxPHX6zjUuspu02tX3e_g", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_L2AzrlcKek2RVaTVIV4mbg", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - Organization and Nature of Business", "role": "http://www.aclaristx.com/role/DisclosureOrganizationAndNatureOfBusiness", "shortName": "Organization and Nature of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "acrs-20220630x10q.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_MYQgC5oFpEC-zKTN1iBkQA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 51, "tag": { "acrs_AccruedLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accrued expenses and other liabilities that are classified as current at the end of the reporting period.", "label": "Accrued Liabilities Disclosure Current [Text Block]", "terseLabel": "Accrued Expenses" } } }, "localname": "AccruedLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureAccruedExpenses" ], "xbrltype": "textBlockItemType" }, "acrs_AccruedResearchAndDevelopmentCostsCurrent": { "auth_ref": [], "calculation": { "http://www.aclaristx.com/role/DisclosureAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The liability for the aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. This is the portion of that liability expected to be paid within one year of the date of the statement of financial position.", "label": "Accrued Research And Development Costs, Current", "terseLabel": "Research and development expenses" } } }, "localname": "AccruedResearchAndDevelopmentCostsCurrent", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "acrs_AgreementAndPlanOfMergerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Agreement and Plan of Merger.", "label": "Agreement and Plan of Merger" } } }, "localname": "AgreementAndPlanOfMergerMember", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "domainItemType" }, "acrs_AgreementTermDuration": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The term of agreement.", "label": "Agreement Term, Duration", "terseLabel": "Term of agreement" } } }, "localname": "AgreementTermDuration", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "durationItemType" }, "acrs_AreaOfPropertySubSubleased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The area of property sub-subleased during the period.", "label": "Area Of Property Sub Subleased", "terseLabel": "Sub-subleased" } } }, "localname": "AreaOfPropertySubSubleased", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeasesDetails" ], "xbrltype": "areaItemType" }, "acrs_AssetPurchaseAgreementEncompassingWorldwideRightsToOxymetazolineHydrochlorideCreamPlusIntellectualPropertyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to asset purchase agreement encompassing worldwide rights to oxymetazoline hydrochloride cream plus intellectual property.", "label": "APA" } } }, "localname": "AssetPurchaseAgreementEncompassingWorldwideRightsToOxymetazolineHydrochlorideCreamPlusIntellectualPropertyMember", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "domainItemType" }, "acrs_AssetPurchaseAgreementThresholdConditionalPotentialSalesMilestoneReceivable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of threshold potential sales milestone payments receivable upon the achievement of specified levels of net sales of products.", "label": "Asset Purchase Agreement, Threshold Conditional Potential Sales Milestone Receivable", "terseLabel": "Potential milestone payments" } } }, "localname": "AssetPurchaseAgreementThresholdConditionalPotentialSalesMilestoneReceivable", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "monetaryItemType" }, "acrs_AtMarketOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to an at the market offering of the entity's stock.", "label": "At The Market Offering" } } }, "localname": "AtMarketOfferingMember", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityOtherOfferingsAndAtmFacilityDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "acrs_BusinessCombinationMaximumContingentConsiderationMilestonePaymentsPerAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "In a business combination, the maximum contingent consideration to be paid based upon achievement of certain milestones as set forth in the Agreement and Plan of Merger.", "label": "Business Combination Maximum Contingent Consideration Milestone Payments Per Agreement", "terseLabel": "Additional contingent consideration based on milestones, maximum, per Agreement" } } }, "localname": "BusinessCombinationMaximumContingentConsiderationMilestonePaymentsPerAgreement", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "monetaryItemType" }, "acrs_CollaborativeArrangementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Agreements Related to Intellectual Property" } } }, "localname": "CollaborativeArrangementDisclosureAbstract", "nsuri": "http://www.aclaristx.com/20220630", "xbrltype": "stringItemType" }, "acrs_CommonStockNumberOfVotesPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of votes for each share of common stock.", "label": "Common Stock Number Of Votes Per Share", "terseLabel": "Number of votes per share" } } }, "localname": "CommonStockNumberOfVotesPerShare", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails" ], "xbrltype": "integerItemType" }, "acrs_ConfluenceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Confluence, an entity acquired by the entity.", "label": "Confluence" } } }, "localname": "ConfluenceMember", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "acrs_ContingentConsiderationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Contingent Consideration [Abstract]" } } }, "localname": "ContingentConsiderationAbstract", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "acrs_ContingentConsiderationPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for contingent consideration.", "label": "Contingent Consideration, Policy [Policy Text Block]", "terseLabel": "Contingent Consideration" } } }, "localname": "ContingentConsiderationPolicyPolicyTextBlock", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "acrs_ContractResearchSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to segment that earns revenue from the provision of laboratory services to clients through Confluence, the Company's wholly-owned subsidiary. Laboratory service revenue is generally evidenced by contracts with clients which are on an agreed upon fixed-price, fee-for-service basis.", "label": "Contract Research Segment" } } }, "localname": "ContractResearchSegmentMember", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "acrs_DebtSecuritiesAvailableForSaleOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with maturity dates of a certain range.", "label": "Debt Securities, Available-for-sale, Other", "terseLabel": "Debt securities, maturity dates between one and five years" } } }, "localname": "DebtSecuritiesAvailableForSaleOther", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails" ], "xbrltype": "monetaryItemType" }, "acrs_DeferredOfferingCostsIncurredButNotYetPaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for deferred offering costs that have occurred.", "label": "Deferred Offering Costs Incurred but Not yet Paid", "terseLabel": "Offering costs included in accounts payable" } } }, "localname": "DeferredOfferingCostsIncurredButNotYetPaid", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "acrs_DermatologyTherapeuticsSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to dermatology therapeutics segment, which is focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology.", "label": "Dermatology Therapeutics Segment" } } }, "localname": "DermatologyTherapeuticsSegmentMember", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "acrs_EmployeeConsultantsAndDirectorsStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An arrangement whereby an employee, consultant, or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.", "label": "Options to purchase common stock" } } }, "localname": "EmployeeConsultantsAndDirectorsStockOptionsMember", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureNetLossPerShareAntiDilutionDetails", "http://www.aclaristx.com/role/DisclosureStockBasedAwardsCompensationDetails" ], "xbrltype": "domainItemType" }, "acrs_EquityCompensation2017InducementPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the 2017 Inducement Plan, a non-shareholder approved stock plan adopted pursuant to the \"inducement exception\" provided under NASDAQ listing rules. The only persons eligible to receive grants of awards under the 2017 Inducement Plan are individuals who satisfy the standards for inducement grants under NASDAQ rules, generally including individuals who were not previously an employee or director of the Company. Under the terms of the 2017 Inducement Plan, the Company may grant up to 1,000,000 shares of common stock pursuant to nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock unit (\"RSU\") awards, and other stock awards. The shares of common stock underlying any awards that expire, are otherwise terminated, settled in cash or repurchased by the Company under the 2017 Inducement Plan will be added back to the shares of common stock available for issuance under the 2017 Inducement Plan.", "label": "2017 Inducement Plan" } } }, "localname": "EquityCompensation2017InducementPlanMember", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails" ], "xbrltype": "domainItemType" }, "acrs_EquityCompensationPlan2012Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The 2012 Equity Compensation Plan, as amended and restated, providing for the sale or issuance of common stock or restricted stock, or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the board of directors and consultants.", "label": "2012 Equity Compensation Plan" } } }, "localname": "EquityCompensationPlan2012Member", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails" ], "xbrltype": "domainItemType" }, "acrs_EquityIncentivePlan2015Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The 2015 Equity Incentive Plan provides for the grant of incentive stock options, non statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, cash-based awards and other stock-based awards.", "label": "2015 Equity Incentive Plan" } } }, "localname": "EquityIncentivePlan2015Member", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails" ], "xbrltype": "domainItemType" }, "acrs_FairValueOfWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The fair value of warrants.", "label": "Fair Value of Warrants", "terseLabel": "Fair value of warrants" } } }, "localname": "FairValueOfWarrants", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "acrs_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite Lived And Indefinite Lived Intangible Assets By Major Class [Line Items]" } } }, "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassLineItems", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "acrs_FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of finite-lived and indefinite-lived intangible assets, excluding goodwill, in total and by major class.", "label": "Finite Lived And Indefinite Lived Intangible Assets By Major Class [Table]" } } }, "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "acrs_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour": { "auth_ref": [], "calculation": { "http://www.aclaristx.com/role/DisclosureIntangibleAssetsFutureAmortizationExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, after Year Four", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsFutureAmortizationExpensesDetails" ], "xbrltype": "monetaryItemType" }, "acrs_FollowOnPublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to sale or issuance of stock in a follow-on public offering.", "label": "Public Offering" } } }, "localname": "FollowOnPublicOfferingMember", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "acrs_ForeignGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by Foreign government agencies.", "label": "Foreign Government Agency Debt Securities" } } }, "localname": "ForeignGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails" ], "xbrltype": "domainItemType" }, "acrs_IntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NA", "label": "Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureAbstract", "nsuri": "http://www.aclaristx.com/20220630", "xbrltype": "stringItemType" }, "acrs_January2021PublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to stock issued through public offering in January 2021.", "label": "January 2021 Public Offering" } } }, "localname": "January2021PublicOfferingMember", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityOtherOfferingsAndAtmFacilityDetails" ], "xbrltype": "domainItemType" }, "acrs_June2021PublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to stock issued through public offering in June 2021.", "label": "June 2021 Public Offering" } } }, "localname": "June2021PublicOfferingMember", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityOtherOfferingsAndAtmFacilityDetails" ], "xbrltype": "domainItemType" }, "acrs_LaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to laboratory equipment.", "label": "Lab equipment" } } }, "localname": "LaboratoryEquipmentMember", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "acrs_LaboratoryResearchRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Laboratory service revenue is generally evidenced by contracts with clients which are on an agreed upon fixed-price, fee-for-service basis and are generally billed on a monthly basis in arrears for services rendered. Revenue related to these contracts is generally recognized as the laboratory services are performed, based upon the rates specified in the contracts.", "label": "Contract research" } } }, "localname": "LaboratoryResearchRevenueMember", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "domainItemType" }, "acrs_LesseeOperatingAndFinanceLeasesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of operating and finance leases.", "label": "Lessee Operating And Finance Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingAndFinanceLeasesTextBlock", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeases" ], "xbrltype": "textBlockItemType" }, "acrs_OperatingLeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Operating Leases [Abstract]", "terseLabel": "Operating Leases:" } } }, "localname": "OperatingLeasesAbstract", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeasesDetails" ], "xbrltype": "stringItemType" }, "acrs_OperatingLeasesAmortizationExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of amortization expenses in connection with operating leases.", "label": "Operating Leases Amortization Expense", "terseLabel": "Amortization expense" } } }, "localname": "OperatingLeasesAmortizationExpense", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "acrs_OperatingLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Representing information pertaining to operating leases.", "label": "Operating Leases" } } }, "localname": "OperatingLeasesMember", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeasesDetails" ], "xbrltype": "domainItemType" }, "acrs_OtherRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to revenue not otherwise specified.", "label": "Other revenue" } } }, "localname": "OtherRevenueMember", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "domainItemType" }, "acrs_PaymentsOfUnderwritingDiscountsAndCommissions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow from payments of underwriting discounts and commissions.", "label": "Payments Of Underwriting Discounts And Commissions", "terseLabel": "Underwriting discounts and commissions" } } }, "localname": "PaymentsOfUnderwritingDiscountsAndCommissions", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails", "http://www.aclaristx.com/role/DisclosureStockholdersEquityOtherOfferingsAndAtmFacilityDetails" ], "xbrltype": "monetaryItemType" }, "acrs_PercentageOfAssetsCurrentStageOfDevelopmentAndReview": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of assets current stage of development and review.", "label": "Percentage of Assets Current Stage of Development and Review", "terseLabel": "Probability of success assumptions" } } }, "localname": "PercentageOfAssetsCurrentStageOfDevelopmentAndReview", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "acrs_PercentageOfDiscountRatesAppliedToContingentPayment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of discount rates applied to contingent payment.", "label": "Percentage of Discount Rates Applied to Contingent Payment", "terseLabel": "Discount range" } } }, "localname": "PercentageOfDiscountRatesAppliedToContingentPayment", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "acrs_PercentageOfUpfrontAndLicenseFees": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of upfront and license fees.", "label": "Percentage of Upfront and License Fees", "terseLabel": "Percentage of upfront and license fees" } } }, "localname": "PercentageOfUpfrontAndLicenseFees", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "percentItemType" }, "acrs_ProceedsFromIssuanceOfCommonStockGross": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of common stock, gross before deducting underwriting discounts, commissions and offering expenses.", "label": "Proceeds From Issuance Of Common Stock, Gross", "terseLabel": "Aggregate gross proceeds" } } }, "localname": "ProceedsFromIssuanceOfCommonStockGross", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails", "http://www.aclaristx.com/role/DisclosureStockholdersEquityOtherOfferingsAndAtmFacilityDetails" ], "xbrltype": "monetaryItemType" }, "acrs_RosiAndFulcherVs.AclarisTherapeuticsInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Rosi and Fulcher Vs. Aclaris Therapeutics, Inc., litigation case.", "label": "Consolidated Securities Action" } } }, "localname": "RosiAndFulcherVs.AclarisTherapeuticsInc.Member", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureLegalProceedingsDetails" ], "xbrltype": "domainItemType" }, "acrs_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of amortizable finite-lived intangible assets, in total and by major class, including the gross carrying amount and accumulated amortization, and indefinite-lived intangible assets not subject to amortization, excluding goodwill, in total and by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Schedule Of Finite Lived And Indefinite Lived Intangible Assets By Major Class [Table Text Block]", "terseLabel": "Schedule of intangible assets" } } }, "localname": "ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTableTextBlock", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "acrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "N/A.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Aggregate Intrinsic Value [Abstract]", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "stringItemType" }, "acrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Abstract]", "terseLabel": "Options, Weighted Average Remaining Contractual Term" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "stringItemType" }, "acrs_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageIncreaseToSharesAvailableForGrantFromCommonStockOutstandingAtEndOfPrecedingCalendarYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of increase to the number of shares available for grant from the common stock outstanding as of the end of the preceding calendar year.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Percentage Increase To Shares Available For Grant From Common Stock Outstanding At End Of Preceding Calendar Year", "terseLabel": "Percentage increase to shares available for grant from common outstanding as of preceding December 31 (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageIncreaseToSharesAvailableForGrantFromCommonStockOutstandingAtEndOfPrecedingCalendarYear", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails" ], "xbrltype": "percentItemType" }, "acrs_SignificantAccountingPoliciesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for presentation of accounting policies in interim reports.", "label": "Significant Accounting Policies [Policy Text Block]", "terseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesPolicyTextBlock", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "acrs_SiliconValleyBankMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Silicon Valley Bank.", "label": "SVB" } } }, "localname": "SiliconValleyBankMember", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureDebtDetails", "http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "acrs_SiliconValleyBankSecuritiesLlcAndCantorFitzgeraldAndCo.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Silicon Valley Bank Securities LLC and Cantor Fitzgerald & Co.", "label": "Silicon Valley Bank Securities LLC and Cantor Fitzgerald & Co." } } }, "localname": "SiliconValleyBankSecuritiesLlcAndCantorFitzgeraldAndCo.Member", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityOtherOfferingsAndAtmFacilityDetails" ], "xbrltype": "domainItemType" }, "acrs_SummaryOfAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Summary Of Accounting Policies [Line Items]" } } }, "localname": "SummaryOfAccountingPoliciesLineItems", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "acrs_SummaryOfAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting details about accounting policies.", "label": "Summary Of Accounting Policies [Table]" } } }, "localname": "SummaryOfAccountingPoliciesTable", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "acrs_TermLoanFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to term loan facility with Silicon Valley Bank.", "label": "Term Loan Facility" } } }, "localname": "TermLoanFacilityMember", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureDebtDetails" ], "xbrltype": "domainItemType" }, "acrs_UnauditedInterimFinancialInformationPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of unaudited interim financial information.", "label": "Unaudited Interim Financial Information Policy [Policy Text Block]", "terseLabel": "Unaudited Interim Financial Information" } } }, "localname": "UnauditedInterimFinancialInformationPolicyPolicyTextBlock", "nsuri": "http://www.aclaristx.com/20220630", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r542" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r550" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r539" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r538" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r540" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.aclaristx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r114", "r159", "r172", "r173", "r174", "r175", "r177", "r179", "r183", "r253", "r254", "r255", "r256", "r257", "r258", "r260", "r261", "r263", "r265", "r266" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r114", "r159", "r172", "r173", "r174", "r175", "r177", "r179", "r183", "r253", "r254", "r255", "r256", "r257", "r258", "r260", "r261", "r263", "r265", "r266" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r57", "r59", "r112", "r113", "r272", "r307" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDebtDetails", "http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails", "http://www.aclaristx.com/role/DisclosureStockholdersEquityOtherOfferingsAndAtmFacilityDetails" ], "xbrltype": "stringItemType" }, "srt_ExecutiveOfficerMember": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "label": "Executive officer" } } }, "localname": "ExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLegalProceedingsDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLegalProceedingsDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLegalProceedingsDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r271", "r306", "r342", "r344", "r464", "r465", "r466", "r467", "r468", "r469", "r488", "r521", "r523", "r535", "r536" ], "lang": { "en-us": { "role": { "label": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r271", "r306", "r342", "r344", "r464", "r465", "r466", "r467", "r468", "r469", "r488", "r521", "r523", "r535", "r536" ], "lang": { "en-us": { "role": { "label": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r186", "r330", "r331", "r490", "r520", "r522" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r186", "r330", "r331", "r490", "r520", "r522" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r271", "r306", "r332", "r342", "r344", "r464", "r465", "r466", "r467", "r468", "r469", "r488", "r521", "r523", "r535", "r536" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r271", "r306", "r332", "r342", "r344", "r464", "r465", "r466", "r467", "r468", "r469", "r488", "r521", "r523", "r535", "r536" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r58", "r59", "r112", "r113", "r272", "r307" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDebtDetails", "http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails", "http://www.aclaristx.com/role/DisclosureStockholdersEquityOtherOfferingsAndAtmFacilityDetails" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r191", "r454" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLegalProceedingsDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLegalProceedingsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r46", "r457" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r18", "r33", "r192", "r193" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, Net, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.aclaristx.com/role/DisclosureAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureAccruedExpensesDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r44", "r237" ], "calculation": { "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r36", "r64", "r66", "r67", "r511", "r528", "r529" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r63", "r67", "r74", "r75", "r76", "r116", "r117", "r118", "r420", "r524", "r525", "r551" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r34", "r383", "r457" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid In Capital", "verboseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r116", "r117", "r118", "r380", "r381", "r382", "r426" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r345", "r347", "r386", "r387" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r320", "r327" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "terseLabel": "Offering costs netted against proceeds" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r347", "r376", "r385" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share-based Compensation Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r97", "r222", "r229" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsFutureAmortizationExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Potential common shares excluded from the calculation of diluted net loss per share attributable to common stockholders" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureNetLossPerShareAntiDilutionDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureNetLossPerShareAntiDilutionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureNetLossPerShareAntiDilutionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureNetLossPerShareAntiDilutionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r202", "r333" ], "lang": { "en-us": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset-backed securities" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r108", "r167", "r174", "r181", "r208", "r253", "r254", "r255", "r257", "r258", "r259", "r260", "r262", "r264", "r266", "r267", "r415", "r421", "r437", "r455", "r457", "r493", "r509" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r19", "r20", "r56", "r108", "r208", "r253", "r254", "r255", "r257", "r258", "r259", "r260", "r262", "r264", "r266", "r267", "r415", "r421", "r437", "r455", "r457" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r429" ], "calculation": { "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets measured at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r200" ], "calculation": { "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gain" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r201" ], "calculation": { "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross Unrealized Loss" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r198", "r215" ], "calculation": { "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale Debt Securities, Amortized Cost Basis", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Available-for-sale Securities [Abstract]", "terseLabel": "Marketable securities:" } } }, "localname": "AvailableForSaleSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r195", "r199", "r215", "r498" ], "calculation": { "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 }, "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Marketable securities", "terseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails", "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r197", "r215" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Short-term marketable securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "auth_ref": [ "r197", "r215" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Marketable Securities, Noncurrent", "terseLabel": "Marketable securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r348", "r378" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsCompensationDetails", "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails", "http://www.aclaristx.com/role/DisclosureStockBasedAwardsRsusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r341", "r343" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r341", "r343", "r404", "r405" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r96", "r408" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Revaluation of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails", "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r406", "r407" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r100", "r101", "r102" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Additions to property and equipment included in accounts payable" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r17", "r42", "r99" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r42" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash, Cash Equivalents, and Short-term Investments", "terseLabel": "Cash, cash equivalents and marketable securities" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureOrganizationAndNatureOfBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r94", "r99", "r103" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r94", "r438" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Initial exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Common stock warrants" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDebtDetails", "http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r409", "r410", "r412" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Agreements Related to Intellectual Property" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualProperty" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]", "terseLabel": "Agreements Related to Intellectual Property" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r52", "r251", "r499", "r515" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitment and Contingencies", "terseLabel": "Commitments and contingencies (Note 16)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Legal Proceedings" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r248", "r249", "r250", "r252", "r531" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Legal Proceedings" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLegalProceedings" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsFairValueDisclosure": { "auth_ref": [ "r30" ], "calculation": { "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of arrangements with third parties, including, but not limited to, operating lease arrangement and arrangement in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services.", "label": "Commitments, Fair Value Disclosure", "terseLabel": "Contingent consideration" } } }, "localname": "CommitmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r116", "r117", "r426" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)", "verboseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "verboseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "periodEndLabel": "Balance at end of period (in shares)", "periodStartLabel": "Balance at beginning of period (in shares)", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r32", "r320" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r32", "r457" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.00001 par value; 100,000,000 shares authorized at June 30, 2022 and December 31, 2021; 66,667,580 and 61,228,446 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r70", "r72", "r73", "r80", "r502", "r518" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r333", "r340", "r530" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate debt securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r172", "r173", "r174", "r175", "r177", "r183", "r185" ], "lang": { "en-us": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate and Other" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r85", "r108", "r208", "r253", "r254", "r255", "r258", "r259", "r260", "r262", "r264", "r266", "r267", "r437" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of revenue." } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r84" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r104", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r285", "r292", "r293", "r295", "r300" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r26", "r27", "r28", "r107", "r114", "r268", "r269", "r270", "r271", "r272", "r273", "r275", "r281", "r282", "r283", "r284", "r286", "r287", "r288", "r289", "r290", "r291", "r296", "r297", "r298", "r299", "r448", "r494", "r496", "r508" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r50", "r107", "r114", "r268", "r269", "r270", "r271", "r272", "r273", "r275", "r281", "r282", "r283", "r284", "r286", "r287", "r288", "r289", "r290", "r291", "r296", "r297", "r298", "r299", "r448" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r50", "r107", "r114", "r268", "r269", "r270", "r271", "r272", "r273", "r275", "r281", "r282", "r283", "r284", "r286", "r287", "r288", "r289", "r290", "r291", "r294", "r296", "r297", "r298", "r299", "r321", "r324", "r325", "r326", "r446", "r447", "r448", "r449", "r507" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table Text Block]", "terseLabel": "Schedule of the fair value of available for sale marketable securities" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r390", "r391" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Tax Liabilities, Net, Noncurrent", "terseLabel": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r97", "r235" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r97", "r162" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "verboseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r388" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "Stock-Based Awards" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwards" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Awards" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discontinued Operations." } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent": { "auth_ref": [ "r1", "r2", "r10", "r234", "r240" ], "calculation": { "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current", "terseLabel": "Accrued expenses" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r16", "r244" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "Discontinued Operations" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDiscontinuedOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "auth_ref": [ "r27", "r29", "r495", "r510" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.", "label": "Dividends Payable", "terseLabel": "Dividend declared" } } }, "localname": "DividendsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Loss per Share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r81", "r121", "r122", "r123", "r124", "r125", "r129", "r131", "r133", "r134", "r135", "r139", "r140", "r427", "r428", "r503", "r519" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share, basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureNetLossPerShareDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r81", "r121", "r122", "r123", "r124", "r125", "r131", "r133", "r134", "r135", "r139", "r140", "r427", "r428", "r503", "r519" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share, diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureNetLossPerShareDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r136", "r137", "r138", "r141" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureNetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.aclaristx.com/role/DisclosureAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Employee compensation expenses" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]", "terseLabel": "Stock-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average recognition period unrecognized stock-based compensation cost (in years)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r377" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options", "terseLabel": "Unrecognized stock-based compensation expense, RSUs" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r377" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options", "terseLabel": "Unrecognized stock-based compensation expense, options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r74", "r75", "r76", "r116", "r117", "r118", "r120", "r126", "r128", "r142", "r209", "r320", "r327", "r380", "r381", "r382", "r396", "r397", "r426", "r439", "r440", "r441", "r442", "r443", "r445", "r524", "r525", "r526", "r551" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Assets and Liabilities Measured at Fair Value" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r429", "r430", "r431", "r435" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r283", "r296", "r297", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r430", "r461", "r462", "r463" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r429", "r430", "r432", "r433", "r436" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Assets and Liabilities" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value of Financial Assets and Liabilities" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r283", "r333", "r334", "r339", "r340", "r430", "r461" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r283", "r296", "r297", "r333", "r334", "r339", "r340", "r430", "r462" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r283", "r296", "r297", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r430", "r463" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net", "terseLabel": "Transfers into or out of Level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r283", "r296", "r297", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r461", "r462", "r463" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r434", "r436" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": { "auth_ref": [ "r109", "r392" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current and deferred federal income tax expense (benefit) attributable to income (loss) from continuing operations.", "label": "Federal Income Tax Expense (Benefit), Continuing Operations", "terseLabel": "Federal income tax benefit" } } }, "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r202", "r203", "r205", "r206", "r207", "r210", "r211", "r212", "r213", "r214", "r216", "r217", "r218", "r219", "r294", "r318", "r425", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r543", "r544", "r545", "r546", "r547", "r548", "r549" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r228" ], "calculation": { "http://www.aclaristx.com/role/DisclosureLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated Amortization", "verboseLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetails", "http://www.aclaristx.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r230" ], "calculation": { "http://www.aclaristx.com/role/DisclosureIntangibleAssetsFutureAmortizationExpensesDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsFutureAmortizationExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.aclaristx.com/role/DisclosureIntangibleAssetsFutureAmortizationExpensesDetails": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsFutureAmortizationExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.", "label": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]", "terseLabel": "Schedule of estimated future amortization expenses" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r230" ], "calculation": { "http://www.aclaristx.com/role/DisclosureIntangibleAssetsFutureAmortizationExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsFutureAmortizationExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r230" ], "calculation": { "http://www.aclaristx.com/role/DisclosureIntangibleAssetsFutureAmortizationExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsFutureAmortizationExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r230" ], "calculation": { "http://www.aclaristx.com/role/DisclosureIntangibleAssetsFutureAmortizationExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsFutureAmortizationExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r223", "r225", "r228", "r232", "r491", "r492" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]", "terseLabel": "Future amortization expenses" } } }, "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsFutureAmortizationExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r228", "r492" ], "calculation": { "http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetail": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Cost" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r223", "r227" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r228", "r491" ], "calculation": { "http://www.aclaristx.com/role/DisclosureIntangibleAssetsFutureAmortizationExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Total" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsFutureAmortizationExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net [Abstract]", "terseLabel": "Definite-lived intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [ "r491" ], "lang": { "en-us": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Remaining life" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FixedIncomeSecuritiesMember": { "auth_ref": [ "r333", "r340" ], "lang": { "en-us": { "role": { "documentation": "Investment that provides a return in the form of fixed periodic payments and eventual return of principal at maturity.", "label": "Commercial paper" } } }, "localname": "FixedIncomeSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r86" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In-process research and development" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r239", "r245" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r110", "r393", "r394", "r395", "r398", "r400", "r401", "r402", "r403" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r96" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r96" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r96" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r96" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r224", "r231" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r231" ], "calculation": { "http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetail": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Gross cost" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]", "terseLabel": "Indefinite-lived intangible assets" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r224", "r231" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "calculation": { "http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "totalLabel": "Gross cost" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwillAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets, Gross (Excluding Goodwill) [Abstract]", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwillAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r221", "r226" ], "calculation": { "http://www.aclaristx.com/role/DisclosureLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets", "totalLabel": "Other assets" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeasesDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntersegmentEliminationMember": { "auth_ref": [ "r159", "r172", "r173", "r174", "r175", "r177", "r179", "r183" ], "lang": { "en-us": { "role": { "documentation": "Eliminating entries used in operating segment consolidation.", "label": "Intersegment Eliminations" } } }, "localname": "IntersegmentEliminationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r452" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r453" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Schedule of supplemental balance sheet information related to operating leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r47", "r108", "r175", "r208", "r253", "r254", "r255", "r258", "r259", "r260", "r262", "r264", "r266", "r267", "r416", "r421", "r422", "r437", "r455", "r456" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r39", "r108", "r208", "r437", "r457", "r497", "r513" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r49", "r108", "r208", "r253", "r254", "r255", "r258", "r259", "r260", "r262", "r264", "r266", "r267", "r416", "r421", "r422", "r437", "r455", "r456", "r457" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r429" ], "calculation": { "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "totalLabel": "Total liabilities measured at fair value" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r1", "r2", "r10", "r12", "r15", "r234", "r240" ], "calculation": { "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current", "terseLabel": "Discontinued operations", "totalLabel": "Discontinued operations - current liabilities" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r28", "r496", "r508" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Loan borrowed" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyAccrualCarryingValueCurrent": { "auth_ref": [ "r251" ], "calculation": { "http://www.aclaristx.com/role/DisclosureAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer.", "label": "Loss Contingency, Accrual, Current", "terseLabel": "Litigation settlements (see Note 16)", "verboseLabel": "Accrual for estimated financial obligation" } } }, "localname": "LossContingencyAccrualCarryingValueCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureAccruedExpensesDetails", "http://www.aclaristx.com/role/DisclosureLegalProceedingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyNumberOfDefendants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of defendants named in a legal action.", "label": "Loss Contingency, Number of Defendants", "terseLabel": "Number of defendants" } } }, "localname": "LossContingencyNumberOfDefendants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLegalProceedingsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "auth_ref": [ "r83" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in marketable security.", "label": "Marketable Securities, Unrealized Gain (Loss)", "terseLabel": "Unrealized gain / loss on marketable securities" } } }, "localname": "MarketableSecuritiesUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r145", "r153" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Organization and Nature of Business" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureOrganizationAndNatureOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r94" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r94" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r94", "r95", "r98" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r15", "r68", "r71", "r76", "r78", "r98", "r108", "r119", "r121", "r122", "r123", "r124", "r127", "r128", "r132", "r167", "r173", "r177", "r180", "r183", "r208", "r253", "r254", "r255", "r258", "r259", "r260", "r262", "r264", "r266", "r267", "r428", "r437", "r500", "r516" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureNetLossPerShareDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]", "terseLabel": "Basic and diluted net loss per share attributable to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetRentableArea": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net rentable area for properties owned.", "label": "Net Rentable Area", "verboseLabel": "Area leased, sublease agreement" } } }, "localname": "NetRentableArea", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeasesDetails" ], "xbrltype": "areaItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r155" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingCostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Costs and Expenses [Abstract]", "verboseLabel": "Costs and expenses:" } } }, "localname": "OperatingCostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r167", "r173", "r177", "r180", "r183" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Loss from operations", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r450" ], "calculation": { "http://www.aclaristx.com/role/DisclosureLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "Total operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r450" ], "calculation": { "http://www.aclaristx.com/role/DisclosureLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeasesDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r450" ], "calculation": { "http://www.aclaristx.com/role/DisclosureLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Other liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r451" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]", "terseLabel": "Financial position" } } }, "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeasesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Nature of Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r21", "r22", "r23", "r48" ], "calculation": { "http://www.aclaristx.com/role/DisclosureAccruedExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r45" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Commitments [Line Items]" } } }, "localname": "OtherCommitmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLegalProceedingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about obligations resulting from other commitments.", "label": "Other Commitments [Table]" } } }, "localname": "OtherCommitmentsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLegalProceedingsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r413", "r414", "r419" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r60" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r69", "r72", "r74", "r75", "r77", "r79", "r320", "r439", "r444", "r445", "r501", "r517" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Total other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r61", "r64" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax", "terseLabel": "Unrealized loss on marketable securities, net of tax of $0" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": { "auth_ref": [ "r62", "r65" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Tax", "verboseLabel": "Unrealized loss on marketable securities, tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherFiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r228" ], "calculation": { "http://www.aclaristx.com/role/DisclosureLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of finite-lived intangible assets classified as other.", "label": "Other Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross cost" } } }, "localname": "OtherFiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other intangible assets" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r51" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "terseLabel": "Other liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r87" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "verboseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Expenses" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r92" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "verboseLabel": "Payments of stock offering costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails", "http://www.aclaristx.com/role/DisclosureStockholdersEquityOtherOfferingsAndAtmFacilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r90" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedLabel": "Payments of employee withholding taxes related to restricted stock unit award vesting" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r196" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r88" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r348", "r378" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r31", "r304" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r31" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r31", "r304" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r31" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r31", "r457" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued or outstanding at June 30, 2022 and December 31, 2021" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r19", "r40", "r41" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r89" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "netLabel": "Proceeds from common stock", "terseLabel": "Aggregate gross proceeds" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails", "http://www.aclaristx.com/role/DisclosureStockholdersEquityOtherOfferingsAndAtmFacilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds from sales and maturities of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r89", "r379" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of employee stock options and the issuance of stock" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r15", "r68", "r71", "r76", "r93", "r108", "r119", "r127", "r128", "r167", "r173", "r177", "r180", "r183", "r208", "r253", "r254", "r255", "r258", "r259", "r260", "r262", "r264", "r266", "r267", "r413", "r417", "r418", "r423", "r424", "r428", "r437", "r504" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r44", "r238" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeasesDetails", "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r244", "r532", "r533", "r534" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r43", "r236" ], "calculation": { "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r24", "r25", "r238", "r457", "r506", "r514" ], "calculation": { "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r24", "r238" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r24", "r236" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureLeasesDetails", "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "auth_ref": [ "r91" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Repayments of Long-term Lines of Credit", "terseLabel": "Loan repaid" } } }, "localname": "RepaymentsOfLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r389", "r489", "r537" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted stock unit awards" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureNetLossPerShareAntiDilutionDetails", "http://www.aclaristx.com/role/DisclosureStockBasedAwardsCompensationDetails", "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails", "http://www.aclaristx.com/role/DisclosureStockBasedAwardsRsusDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r35", "r327", "r383", "r457", "r512", "r527", "r529" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureOrganizationAndNatureOfBusinessDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r116", "r117", "r118", "r120", "r126", "r128", "r209", "r380", "r381", "r382", "r396", "r397", "r426", "r524", "r526" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r158", "r159", "r172", "r178", "r179", "r186", "r187", "r189", "r329", "r330", "r490" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue, Net", "terseLabel": "Total revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails", "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_RoyaltyMember": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Money for usage-based right to asset.", "label": "Royalty" } } }, "localname": "RoyaltyMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "verboseLabel": "Proceeds from issuance of common stock, net of issuance costs" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityOtherOfferingsAndAtmFacilityDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureAccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureNetLossPerShareAntiDilutionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Potential common shares excluded from the calculation of diluted net loss per share attributable to common stockholders" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Available-for-sale Securities [Line Items]", "terseLabel": "Fair value of the Company's available for sale marketable securities" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r411" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r2", "r4", "r5", "r6", "r7", "r8", "r9", "r11", "r13", "r14", "r15", "r242", "r243" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Schedule of discontinued operations" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureDiscontinuedOperationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Basic and diluted net loss per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r347", "r375", "r385" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r347", "r375", "r385" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r429", "r430" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of assets and liabilities measured at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r44", "r238" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r167", "r170", "r176", "r220" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r167", "r170", "r176", "r220" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Summary of results of operations by segment" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r348", "r378" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails", "http://www.aclaristx.com/role/DisclosureStockBasedAwardsRsusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r352", "r364", "r367" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]", "terseLabel": "Summary of stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Assumptions used to determine fair value of stock options granted" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Summary of restricted stock units activity" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r53", "r105", "r143", "r144", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r309", "r313", "r318", "r321", "r322", "r323", "r324", "r325", "r326", "r327" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r154", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r172", "r173", "r174", "r175", "r177", "r178", "r179", "r180", "r181", "r183", "r189", "r246", "r247", "r520" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Information" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r154", "r156", "r157", "r167", "r171", "r177", "r181", "r182", "r183", "r184", "r186", "r188", "r189", "r190" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r96" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Compensation", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value, forfeited and cancelled (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsRsusDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value, granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsRsusDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "terseLabel": "Number of shares outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted average grant date fair value, ending balance (in dollars per share)", "periodStartLabel": "Weighted average grant date fair value, beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsRsusDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "RSU, Weighted Average Grant Date Fair Value Per Unit" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsRsusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsRsusDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value, vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsRsusDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "terseLabel": "Stock Option Valuation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Stock-based awards" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails", "http://www.aclaristx.com/role/DisclosureStockBasedAwardsRsusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations", "negatedLabel": "Forfeited and cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsRsusDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsRsusDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r353", "r355" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Units outstanding, end of period", "periodStartLabel": "Units outstanding, beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsRsusDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]", "terseLabel": "RSU, Number of Units" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsRsusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Additional shares available" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available for grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r366" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Forfeited and cancelled (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Number of Shares, Forfeited and cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Options granted (in shares)", "verboseLabel": "Number of Shares, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails", "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant-date fair value of stock options granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r378" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r354", "r378" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of Shares, ending balance", "periodStartLabel": "Number of Shares, beginning balance", "terseLabel": "Options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails", "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Options, Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, ending balance (in dollars per share)", "periodStartLabel": "Weighted Average Exercise Price, beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Options, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r369" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Options exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Number of Shares, Options exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Options exercisable (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r367" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Options vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Number of Shares, Options vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Options vested and expected to vest (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r346", "r351" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsCompensationDetails", "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails", "http://www.aclaristx.com/role/DisclosureStockBasedAwardsRsusDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Weighted Average Exercise Price, Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested", "terseLabel": "Aggregate intrinsic value of awards that vested during the period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsRsusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Term of award (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r371", "r384" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term, Options exercisable (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term, Options vested and expected to vest (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "terseLabel": "Common stock, sold", "verboseLabel": "Shares, issued" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails", "http://www.aclaristx.com/role/DisclosureStockholdersEquityOtherOfferingsAndAtmFacilityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "netLabel": "Common stock, price per share", "verboseLabel": "Shares issued, price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails", "http://www.aclaristx.com/role/DisclosureStockholdersEquityOtherOfferingsAndAtmFacilityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations": { "auth_ref": [ "r109", "r392", "r399" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of state and local current and deferred income tax expense (benefit) attributable to continuing operations.", "label": "State and Local Income Tax Expense (Benefit), Continuing Operations", "terseLabel": "State income tax benefit" } } }, "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r3", "r154", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r172", "r173", "r174", "r175", "r177", "r178", "r179", "r180", "r181", "r183", "r189", "r220", "r241", "r246", "r247", "r520" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r55", "r74", "r75", "r76", "r116", "r117", "r118", "r120", "r126", "r128", "r142", "r209", "r320", "r327", "r380", "r381", "r382", "r396", "r397", "r426", "r439", "r440", "r441", "r442", "r443", "r445", "r524", "r525", "r526", "r551" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r116", "r117", "r118", "r142", "r490" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r54", "r286", "r320", "r321", "r327" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Issuance of common stock in connection with exercise of stock options and warrants and vesting of restricted stock units (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityOtherOfferingsAndAtmFacilityDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r31", "r32", "r320", "r327" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "netLabel": "Common stock, sold", "verboseLabel": "Issuance of common stock, net of offering costs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityDetails", "http://www.aclaristx.com/role/DisclosureStockholdersEquityOtherOfferingsAndAtmFacilityDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r31", "r32", "r320", "r327", "r357" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Number of Shares, Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockBasedAwardsOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r55", "r320", "r327" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r31", "r32", "r320", "r327" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock, net of offering costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r32", "r37", "r38", "r108", "r194", "r208", "r437", "r457" ], "calculation": { "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' Equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r106", "r305", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r319", "r327", "r328" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityOtherOfferingsAndAtmFacilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityOtherOfferingsAndAtmFacilityDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureStockholdersEquityOtherOfferingsAndAtmFacilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r202", "r203", "r205", "r206", "r207", "r294", "r318", "r425", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r543", "r544", "r545", "r546", "r547", "r548", "r549" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r411" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureAgreementsRelatedToIntellectualPropertyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r111", "r333", "r505" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "U.S. government agency debt securities" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesByTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r146", "r147", "r148", "r149", "r150", "r151", "r152" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r130", "r135" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average common shares outstanding, diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureNetLossPerShareDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r129", "r135" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common shares outstanding, basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureNetLossPerShareDetails", "http://www.aclaristx.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.aclaristx.com/role/DisclosureNetLossPerShareDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r115": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r141": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r153": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r16": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8475-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r190": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r204": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r233": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2473-110228" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r244": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r252": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r328": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r388": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r403": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r412": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r453": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r538": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r539": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r541": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r542": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r543": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r544": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r545": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r546": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r547": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r548": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r549": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" } }, "version": "2.1" } ZIP 78 0001558370-22-011757-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-22-011757-xbrl.zip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�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end